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Abstract  
Three main xenobiotic transporters have been implicated in modulating breast cancer 
response to chemotherapy. These are Pgp (P-glycoprotein), MRP1 (multidrug 
resistance-associated protein 1), and BCRP (breast cancer resistance protein).  
 
My first aim was to investigate expression of these proteins before and after 
neoadjuvant chemotherapy (NAC) for breast cancer to determine whether their levels 
define response to NAC or subsequent survival. Immunohistochemistry was performed 
for Pgp, MRP1, and BCRP on paraffin embedded tissue representing matched pairs of 
core biopsy (pre-NAC) and resection specimens (post-NAC) from 39 breast cancer 
patients. Pgp and MRP1 were found to be significantly up-regulated after 
chemotherapy but levels did not relate to response or survival. High post-NAC BCRP 
expression independently predicted for poorer disease free survival (hazard ratio of 
4.04; p=0.013). 
 
Evidence within the literature suggested that MRP1 up-regulation after chemotherapy 
may be driven by activated Notch1. My second aim was to determine whether activated 
Notch1 expression correlated with MRP1 expression in the same patient samples. 
Further immunohistochemistry to determine activated Notch1 expression revealed a 
significant correlation between post-NAC activated Notch1 and MRP1 expression (rho 
coefficient 0.6; p=0.0008). The hypothesis that inhibition of Notch signaling enhances 
killing of breast cancer cells by chemotherapeutics was developed. MTT assays were 
performed after treatment of breast cancer cells with combinations of doxorubicin and 
the Notch inhibitor DAPT. Minor additive inhibition of survival/proliferation was seen in 
the combination treatment, failing to provide strong support for the hypothesis. 
 
The BCRP promoter has an oestrogen response element. My third aim was to 
investigate whether BCRP expression within breast tumours is regulated by oestrogen 
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and whether this impacts on cancer outcome. Immunohistochemistry was performed 
for BCRP in tumour samples from 51 patients receiving neoadjuvant endocrine therapy 
(NAET); matched core biopsy (pre-NAET) and resection specimens (post-NAET) were 
investigated. BCRP expression was significantly up-regulated after exposure to NAET 
(p<0.0001). High pre-NAET BCRP expression independently predicted for poorer DFS 
(hazard ratio of 17; p=0.014). Subsequent methylation analysis of cancer cell lines 
showed that the degree of methylation in the BCRP promoter region was potentially 
inversely correlated to the BCRP protein expression observed on immunoblotting. DNA 
was extracted from clinical sample and pyrosequencing analysis was performed. No 
such inverse correlation was observed in the clinical samples.   
 
My work demonstrates that analysis of tumour samples pre- and post-neoadjuvant 
therapies provides a powerful way of investigating therapy-dependent changes in 
expression of molecules of interest, and may be critical for determining the prognostic 
or predictive value of some markers. Given the relatively small sample size of the 
cohort examined, future higher powered studies are required to determine the 
prognostic significance of BCRP expression.   
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1.0 Introduction 
1.1 Breast cancer incidence and survival 
Breast cancer is the third commonest cause of death from cancer in United Kingdom 
with 11,762 deaths in 2011, which accounted for 7% of all deaths from cancer 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/mortality/uk-
breast-cancer-mortality-statistics). After lung cancer, it is the second most deadly 
cancer in women with a mortality rate in the same year of 24 deaths per 100,000 
women. Moreover, one in eight women will develop breast cancer during their lifetimes. 
The current 5-year survival estimate for patients diagnosed with breast cancer between 
2005 and 2009 is 85% (Office for National Statistics: 
http://www.ons.gov.uk/ons/rel/cancer-unit/breast-cancer-in-england/2010/sum-1.html), 
which is relatively high as compared to the other common solid cancers, such as colon 
cancer with a 5-year survival rate of 55%. However, despite this relatively successful 
treatment of breast cancer overall, some subtypes of breast cancer continue to give 
poorer outcomes. For example, triple negative breast cancer (see section 1.2) has an 
increased likelihood of distant recurrence and death within 5 years of diagnosis when 
compared to non-triple negative breast cancers (hazard ratio of 2.6 and 3.2; p<0.0001 
and p<0.001 respectively) (Dent et al., 2007).  
 
1.2 Breast cancer presentation and diagnosis 
Primary breast cancers typically either present as palpable lumps, usually initially 
identified by the patient themselves or by clinicians, or as impalpable lesions that were 
detected by mammographic screening. The diagnosis of breast cancer is made by 
microscopic examination of core biopsies taken from the breast lesion. Pathological 
assessment includes examination of the epithelial cell morphology in breast tissue. In 
normal breast tissue, terminal duct lobular units are seen surrounded by stroma. In 
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breast cancer, epithelial cells within ducts or lobules have a disorganised appearance 
and expand in a non-uniform manner. When cancer cells do not invade across the 
basement membrane and hence are confined within the ducts and lobules, they are 
termed ductal or lobular carcinoma in situ. When there is invasion of the surrounding 
tissue, they are termed invasive ductal or invasive lobular carcinoma. These diagnostic 
cores of are particular relevance to my work since I have used the material that was not 
required for diagnostic purposes extensively in this thesis. Having diagnosed cancer, 
histopathologists also use these diagnostic cores to classify the disease using various 
systems that guide subsequent treatment.  
 
Breast cancer classifications 
Breast cancers are classified according to histopathological subtypes, tumour grade, 
the international Tumour Node Metastasis (TNM) staging, and molecular subtype. 
Classification of breast cancer has particular importance as it is used to help define 
therapies and determine prognosis. 
 
The two commonest histopathological subtypes are invasive ductal and invasive 
lobular carcinomas. Li et al analysed the Surveillance, Epidemiology, and End Results 
(SEER) data from the National Cancer Institute from the United States. They 
determined that of 190,458 invasive breast cancer cases analysed, 72.8% were 
invasive ductal carcinomas, 7.6% were invasive lobular carcinomas, and 4.7% were 
invasive mixed ductal-lobular carcinomas (Li et al., 2003). The remaining 14.9% 
consists of numerous other rare histological breast cancer subtypes such as invasive 
tubular carcinoma, invasive medullary carcinoma, invasive papillary carcinoma, and 
invasive mucinous carcinoma. Depending on the morphology of breast cancer cells, 
they are assigned a grade of 1 to 3 according to the modified Bloom-Richardson 
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grading system, with higher grade tumours having worse prognoses. Higher grade 
tumours have more aggressive features with a lower degree of tubule formation, and 
higher degrees of mitotic activity and nuclear pleomorphism (Elston and Ellis, 1991). 
 
The extent of breast cancer in patients is staged according to the Tumour Node 
Metastasis (TNM) classification of the American Joint Committee on Cancer 
(http://www.cancerstaging.org/staging/)(Allen et al., 2002). Table 1.1 highlights the key 
components of the staging system which is confirmed post-operatively when 
pathological specimens are examined. 
 
T stages (tumour) T1 Tumour size ≤2cm 
 T2 Tumour size >2cm but ≤5cm   
 T3 Tumour size >5cm 
 T4 Tumour spread to the chest wall or breast skin 
envelope 
N stages (nodes) N0 No cancer cells in the axillary lymph nodes 
 N1 Metastases in 1 to 3 axillary lymph nodes 
 N2 Metastases in 4 to 9 axillary lymph nodes 
 N3 Metastases in ≥10 axillary lymph nodes or 
metastases in the ipsilateral supraclavicular lymph 
nodes 
M stages (metastases) M0 No distant metastases 
 M1 Presence of distant metastases 
  
Table 1.1: TNM staging for breast cancer 
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Breast cancers are also classified into molecular subtypes (Table 1.2) depending on 
the expression of oestrogen and progesterone receptor in the cell nucleus, as well as 
HER2 (human epidermal growth factor receptor 2) protein expression on the cell 
surface as well as gene amplification. 
 
Molecular subtype Receptor status 
Luminal A ER+ and/or PR+, HER2 - 
Luminal B ER+ and/or PR+, HER2+ 
Triple negative/basal-like ER-, PR-, and HER2- 
HER2 type ER-, PR-, and HER2+ 
     
Table 1.2: Breast cancer molecular subtypes 
 
Breast cancer classifications described so far are important in identifying subgroups of 
patients who have poorer prognosis. Patients with higher grade breast cancers, 
advanced TNM staging, and basal-like phenotypes have the worst prognosis. These 
patients have higher likelihood of tumour recurrence in the breast or the axilla, as well 
as other distant sites, which usually subsequently leads to death. 
 
1.3 The importance of systemic therapy  
Treatment of breast cancer is multi-modal with patients receiving combinations of 
surgery, radiotherapy, chemotherapy, endocrine therapy, and/or the targeted biological 
therapy Herceptin. The first two modalities are loco-regional therapies that treat the 
breast and the axillary lymph nodes. The latter modalities are systemic therapies which 
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in early breast cancer are administered to treat occult metastatic disease, with an aim 
of reducing the risks of tumour recurrences and prolong survival. 
 
Loco-regional therapies 
Surgery is indicated for patients without obvious evidence of distant metastasis, which 
applies to the majority of patients seen in the clinic, and is known as early operable 
breast cancer. Surgery consists of breast conserving surgery (BCS) or mastectomy of 
the breast, and sentinel node biopsies (SNB) or axillary nodal clearance (ANC) in the 
axilla. The aim of surgery is to resect the cancer with clear margins in order to minimise 
the likelihood of local tumour recurrence. In general, patients are offered BCS if the 
tumour size to breast volume ratio is small enough to achieve clear margins whilst 
minimising cosmetic distortion to the breast. BCS is applicable to the majority of 
patients who present with T1 tumours. The feasibility of BCS for T2 tumours depends 
on the patient’s breast volume, while the majority of patients with ≥T3 tumours will 
receive mastectomies. The SNB is performed to stage the axilla (i.e. to detect the 
presence or absence of tumour metastasis in the first draining axillary lymph nodes). 
The majority of patients who have evidence of metastatic cancer cells in the sentinel 
nodes subsequently undergo a second operation, ANC, to remove the remaining 
axillary lymph nodes with an aim of resecting further potentially involved lymph nodes.  
 
Radiotherapy is administered to patients after BCS to reduce survival of any potential 
residual cancer cells. It has been shown to reduce the rate of loco-regional tumour 
recurrence in the BCS setting, meaning that patients having BCS have a very similar 
disease free survival (DFS) as those having mastectomies. Poggi et al showed the 
estimated 20-year DFS rate for patients treated with mastectomies to be 67%, versus 
63% in patients treated with BCS and radiotherapy (p=0.64), at a median follow-up of 
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18.4 years (Poggi et al., 2003). Post-mastectomy radiotherapy is not always used, and 
is reserved for patients who present with large (T3 or 4) and/or substantially node 
positive (N2 or 3) disease (Dragun et al., 2012).  
 
Systemic therapies 
Chemotherapy is administered intravenously to patients who are at increased risk of 
having occult distant metastases and this is predicted by positive axillary lymph nodes 
(Rossi et al., 1981), grade 3 or T3 tumours, or those with triple negative breast cancer. 
This group of patients have the worst prognostic features, therefore aggressive 
treatment is indicated, and chemotherapy provides significant survival advantages 
(Goldhirsch et al., 2009). Chemotherapy agents limit proliferation of cancer cells and 
induce their apoptosis, but also have harmful effects on normal cells. The aim is to kill 
cancer cells, while minimising damage to normal tissues. Common chemotherapy 
agents that are in current clinical use include anthracyclines such as epirubicin (often 
given in combination with the alkylating agent cyclophosphamide), and taxanes such 
as docetaxel. Epirubicin intercalates with DNA, causing DNA damage and subsequent 
interference with DNA and RNA synthesis (Cersosimo and Hong, 1986). 
Cyclophosphamide is an alkylating agent which binds to DNA and results in the 
disruption of cell division (Awad and Stuve, 2009). By contrast, taxanes do not target 
the DNA directly. Microtubules are important in cell division and growth, and taxanes 
interact with tubulin units, resulting in mitotic problems and apoptosis (Cortes and 
Baselga, 2007). A significant survival gains from chemotherapy administration were 
demonstrated by the National Surgical Adjuvant Breast and Bowel Project (NSABP), 
which showed that chemotherapy achieved a 58% reduction in recurrence rate and a 
40% reduction in mortality rate when compared to surgery alone at 8 years of follow-up 
(Fisher et al., 2004a). However, chemotherapy can cause substantial side-effects such 
as febrile neutropenia, pulmonary embolism, congestive heart failure, and neuro-motor 
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and sensory toxicity (Smith et al., 2004). It would be advantageous if it was possible to 
improve the clinical utility of chemotherapy agents by enhancing the killing of cancer 
cells whilst reducing the drug side-effects.  
 
Endocrine therapy is offered to patients on the basis of positive expression of the 
oestrogen receptor (ER) within the nuclei of the tumour cells. Active ER signalling is a 
key driver of proliferation of breast epithelial cells (Tyson et al., 2011). ER can be 
activated by at least 2 defined pathways: the nuclear and non-nuclear pathways. In the 
former, oestrogen-bound ER activates transcription by binding to the oestrogen 
response element (ERE) of the target genes, including c-Myc and Survivin, leading to 
enhanced tumour cell proliferation (Welboren et al., 2007). In the latter, ER interacts 
with signalling molecules such as steroid receptor co-activator (SRC), and receptor 
tyrosine kinases (RTK) in the cytoplasm. This, in turn, activates downstream kinases 
that phosphorylate ER and other transcription factors to activate transcription (Giuliano 
et al., 2011), and promote tumour growth/survival. This mechanism of ER activation is 
independent of oestrogen but is dependent on EREs. ER protein expression is 
quantified by immunohistochemistry using the Allred scoring system (Allred et al., 
2012). The total score in whole numbers ranges from 0 to 8 (note: a score of 1 is not 
possible), with an intensity score ranging from 0 to 3 added to a score quantifying the 
proportion of tumours cells staining positively ranging from 0 to 5. A score of ≥3 out of 8 
is defined as being positive for ER expression from a clinical utility viewpoint. 
 
The aim of endocrine therapies is to interfere with the up-regulated ER signalling in ER 
positive tumours, to inhibit ER-dependent growth and survival. To achieve this, pre-
menopausal breast cancer patients receive tamoxifen, whereas post-menopausal 
breast cancer patients receive aromatase inhibitors such as anastrozole, letrozole, or 
exemestane. Tamoxifen binds to the oestrogen receptor and antagonises the action of 
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oestrogen by causing conformational changes to the receptor, which in turn inhibit the 
activation of transcription at EREs. A large trial in node negative, ER positive breast 
cancer patients demonstrated that tamoxifen treatment of at least 5 years resulted in 
significant improvement in outcome as compared to placebo in terms of DFS (hazard 
ratio, HR, 0.58) and overall survival, OS (HR of 0.8) at 15 years (Fisher et al., 2004b). 
Aromatase inhibitors target the enzyme aromatase, which is involved in the conversion 
of androgen to oestrogen, and hence inhibition of this enzyme results in the reduction 
of oestrogen level. Aromatase is not only specific to breast cancer cells, and is also 
present in ovary, liver, and muscle amongst other tissues. In post-menopausal women, 
ovarian oestrogen production decreases, and the aromatase activity in breast and 
adrenal tissues contributes significantly to oestrogen synthesis. Aromatase inhibitors 
cause a systemic reduction in oestrogen levels to exert the anti-tumourigenic effect 
(Bhatnagar, 2007). Aromatase inhibitors are superior compared to tamoxifen in terms 
of DFS in post-menopausal women with ER positive breast cancer (Cuzick et al., 
2010). 
 
HER2 overexpression stimulates tumour cell proliferation. Therefore, patients who 
have HER2 overexpression are treated with the monoclonal antibody Herceptin 
(trastuzumab) that reduces tumour cell proliferation. On binding of growth factor 
ligands, HER receptors (HER1 to HER4) form dimers with the same type of HER 
receptor (homodimers) or with other HER receptors (heterodimers). No known ligand 
exists for HER2 receptor on its own, but dimerisation of HER2 receptor with other HER 
receptors (HER1, HER3, or HER4) results in activation of intracellular signalling 
pathways involving MAPK, which stimulate tumour proliferation, and PI3K-Akt, which 
promotes tumour cell survival (Rubin and Yarden, 2001). Herceptin binds to the HER2 
receptor and prevents dimerisation and subsequent activation of the intracellular 
signalling pathways described (Roukos, 2011). A randomised clinical trial by Slamon et 
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al in patients with HER2 overexpression showed that the addition of Herceptin to 
chemotherapy resulted in a 20% reduction in relative risk of death at median follow-up 
of 30 months when compared to chemotherapy alone (Slamon et al., 2001). Herceptin 
is a relatively modern systemic therapy when compared to chemotherapy and 
endocrine therapy.   
  
1.4 The emergence of neoadjuvant systemic therapy 
Traditionally systemic therapies have been administered in the adjuvant setting (i.e. 
after surgery). Chemotherapy is administered as a combination of chemotherapy 
agents or as a monotherapy that consists of typically 4 to 8 cycles. Each cycle consists 
of chemotherapy administration for 5 consecutive days, followed by a rest period 
lasting 3 to 4 weeks, which allows patients to recover from the side-effects mentioned 
in the previous section. In contrast, patients usually receive endocrine therapy as oral 
medication for a total of 5 years. For patients who require both treatment modalities, 
chemotherapy is administered initially and endocrine therapy is commenced once the 
chemotherapy treatment is completed (Mariotto et al., 2002).  
 
Alternatively, patients who require chemotherapy or endocrine therapy can receive 
either treatment prior to surgery, as a neoadjuvant treatment. This has a number of 
potential benefits. One aim is to reduce the tumour size (i.e. down-stage) prior to 
surgery, which may enable BCS instead of mastectomy in patients who otherwise 
would have been obligate candidates for mastectomy. This benefits patients as it may 
allow less distressing surgery with consequent benefits to their psychological well-
being (Parker et al., 2007). There is no reduction in survival by a neoadjuvant approach 
(Mieog et al., 2007). Patients who would already be candidates for BCS, such as 
patients with T1 tumours, are not offered neoadjuvant systemic therapy (NST) since 
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there are no obvious surgical advantages. A further potential advantage of NST is that 
therapy regimens can be modified based on the response of primary tumours with an 
ultimate aim of improving response (Rigter et al., 2013). In the adjuvant setting this is of 
course not possible since the primary tumour has been resected, and any occult 
metastases (the actual targets of systemic therapies) cannot be monitored. It is hoped, 
although firm data are lacking, that such fine-tuning of therapy regimens would improve 
outcomes. Patients are monitored by using magnetic resonance imaging (MRI) or 
ultrasound scan (USS) in order to assess tumour responses to NST. Poor response 
observed leads to abandoning the neoadjuvant therapy, and proceeding with surgery.  
 
Substantial proportions of breast cancer patients receive neoadjuvant chemotherapy 
(NAC) compared to adjuvant chemotherapy, with a reported NAC administration of up 
to 31 to 39% in a range of institutions (Fisher et al., 2012, Kennedy et al., 2010). 
Patients treated with NAC have equivalent benefit in terms of overall survival and 
avoidance of loco-regional recurrence compared to those treated with adjuvant 
chemotherapy (Mieog et al., 2007). Patients undergo an initial breast core biopsy that 
establishes the diagnosis of breast cancer (see section 1.2 above). Those selected for 
NAC are then subjected to cycles of a chemotherapy regime that typically consists of 
epirubicin and cyclophosphamide at Leeds Teaching Hospital Trust (LTHT). However, 
NAC regimes are not standardised nationally. The tumour response to NAC is 
monitored using MRI during treatment and the regime can be switched, usually to a 
taxane-based therapy (Antolin et al., 2011, Walker et al., 2011, Rastogi et al., 2008), if 
the tumour fails to respond (i.e. there is no reduction in tumour size). Patients undergo 
a baseline MRI scan prior to commencing NAC, followed by an interval MRI scan to 
assess response after the second cycle of NAC. This is subsequently followed by a 
final MRI scan at completion of final NAC cycle. The decision to switch chemotherapy 
regimen occurs after the second cycle of NAC, and all patients receive at least six 
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cycles of NAC in total unless there is tumour progression. Based on the MRI 
assessment of tumour response (Table 1.3) (Therasse et al., 2000), patients 
subsequently undergo BCS or mastectomy.  
 
Classification of MRI response to NAC Definition 
Complete response Disappearance of all tumour lesions 
Partial response ≥30% reduction in tumour size 
Stable disease <30% reduction or <20% increase in tumour 
size 
Progressive disease ≥20% increase in tumour size 
 
Table 1.3: Response Evaluation Criteria in Solid Tumours (RECIST) classification of 
tumour response to NAC assessed by MRI 
 
Response to NAC can also be assessed post-operatively by measuring the residual 
pathological tumour size after surgery. A small proportion of patients achieve 
pathological complete response (pCR), where no tumour cells are identified after NAC 
on post-operative histopathology. These patients still require surgery, however, since 
an MRI scan alone is not sensitive enough to reliably predict this response, which is 
only evident after surgery by pathological examination. A recent meta-analysis showed 
that pCR was seen in 17.1% (Kong et al., 2011) of patients, and those who achieved 
pCR have a 5-year DFS rate of above 90%, as opposed to 50 to 70% in the non-pCR 
group (Tanei et al., 2011). However, definitions of pCR can be variable (Mailliez et al., 
2010) according to the classification systems used; the NSABP classification defines 
pCR as the absence of invasive tumour cells, whereas the Honkoop’s classification 
demands that there is also an absence of in situ tumour cells. Furthermore, there are 
no standardised laboratory protocols for processing post-NAC breast tissue samples, 
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such that there are substantial variations in the histopathological processing and 
examination of excised breast tissue at different centres. 
 
Similarly, neoadjuvant endocrine therapy (NAET) is used to attempt tumour down-
staging prior to surgery. Patients will typically receive NAET for 3 to 4 months prior to 
undergoing surgery (Colleoni and Montagna, 2012). However, NAET duration of up to 
12 months has been reported (Macaskill and Dixon, 2007). The endocrine therapy is 
also continued after surgery for a total duration of 5 years. The common side-effects of 
anti-oestrogenic therapy include hot flushes, arthralgia, and reduction in bone density. 
These side-effect profiles are potentially less severe than with NAC. The majority of 
patients who receive NAET are post-menopausal. This is in contrast to NAC where 
most patients are pre-menopausal, and are able to tolerate better the more severe 
side-effects of chemotherapy. Studies have shown no difference in tumour response 
rates between the aromatase inhibitors anastrozole, letrozole, and exemestane in the 
neoadjuvant setting (Ellis et al., 2011). Therefore, no particular aromatase inhibitor is 
preferentially used for NAET at LTHT. The monitoring of response to NAET treatment 
is assessed using USS as opposed to MRI, since there is no proven benefit in the use 
of MRI to monitor response in patients treated with NAET (Kaufmann et al., 2012). 
However, no consensus exists regarding the timing of USS during NAET, and 
response to NAET is more often assessed by a combination of clinical examination and 
USS (Smith et al., 2005). In the PROACT (Pre-Operative Arimidex Compared to 
Tamoxifen) trial, 262 ER positive breast cancer patients who were deemed to have 
inoperable breast cancer or scheduled for mastectomy were treated with 3 months of 
NAET. As a result, 15 patients (5.7%) were able to receive mastectomies that were 
originally deemed to have inoperable breast cancer. Furthermore, 98 patients (37.4%) 
who were originally scheduled for mastectomy achieved sufficient down-staging to 
enable breast conserving surgery (Cataliotti et al., 2006). Moreover, the IMPACT 
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(Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen) trial 
showed that of 124 patients who required mastectomy at baseline, a BCS rate of 44% 
was achieved with 3 months of neoadjuvant anastrozole (Smith et al., 2005). 
Compared to NAC, pCR is rarely seen with NAET (Chia et al., 2010), which probably 
relates to the anti-proliferative effect of the latter compared to the cytotoxic effect of the 
former. 
 
1.5 Predicting response to neoadjuvant systemic therapy 
The majority of patients treated with neoadjuvant systemic therapy do not achieve pCR 
and achieve partial responses. If this is insufficient to achieve tumour down-staging, 
patients are likely to require mastectomies and therefore the primary goal of the 
neoadjuvant systemic therapy is not achieved. These patients end up having delayed 
surgery with no benefit, and there are cost implications regarding MRI and USS 
monitoring of tumour response, which would have been unnecessary if these patients 
were treated with mastectomy followed by adjuvant systemic therapy. It would be of 
considerable benefit to be able to select accurately the patients who are likely to 
respond to neoadjuvant systemic therapies, and treat the remaining patients with 
surgery followed by adjuvant therapies. Clinico-pathological factors that are associated 
with improved response to NAC include invasive ductal carcinomas, ER negativity, high 
tumour grade, and increased Ki-67 expression (Kaufmann et al., 2012). Clinico-
pathological parameters that predict favourable response to NAET include positive 
progesterone receptor (PR) expression, lack of HER2 overexpression, and high ER 
expression (Macaskill and Dixon, 2007). However, relying on clinico-pathological 
parameters alone is inadequate in predicting response to NST in individual patients. 
For example, not all ER negative breast cancer patients respond to NAC in the same 
manner. Therefore, further research is required to identify more accurate predictive 
molecular markers. 
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There are studies emerging in which potential molecular predictive markers have been 
studied in the context of NAC. Using core biopsy tissues, one such study showed a 
positive correlation between thymosin beta 15 mRNA levels and pCR rates in patients 
with triple negative breast cancers, but not in luminal breast cancers (Darb-Esfahani et 
al., 2012). Wenners et al performed immunohistochemistry on tissue microarrays 
(TMA) constructed from core biopsy tissues, and showed that neutrophil gelatinase-
associated lipocalin (NGAL) expression was associated with improved pCR rate in a 
low-risk subset of patients with ER positive node-negative breast cancer (Wenners et 
al., 2012). Chen et al examined the expression of eleven candidate molecular markers 
using immunohistochemistry on core biopsy tissues. Multivariate analysis showed that 
the lack of β-tubulin III, bcl-2, and ERCC1 expression all independently predicted pCR 
in patients receiving taxane-based NAC (Chen et al., 2012b). Wang et al also 
performed immunohistochemistry on core biopsy tissues and showed that the lack of 
tau expression resulted in an improved response to taxane-based NAC (Wang et al., 
2013a). These studies show that significant correlations are only present in selected 
tumour subtypes, suggesting that tumour heterogeneity plays an important role.  
 
In the context of NAET, there are far fewer studies into predictive markers, with only Ki-
67 as a candidate. Paired biopsy samples in 158 patients were examined for a change 
in Ki-67 expression pre-NAET and after 2 weeks of NAET. At median follow-up of 37 
months, patients with high Ki-67 expression after two weeks of NAET had a lower DFS 
than those with lower Ki-67 (Hazard ratio of 1.95; p=0.004) (Dowsett et al., 2007). 
However, the baseline Ki-67 expression levels prior to NAET did not predict DFS. This 
study suggests that Ki-67 may be a marker of response to NAET.  
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Molecular 
markers 
Breast cancer 
molecular 
subtype 
Sample size mRNA or protein 
expression 
Positive/negative 
correlation  with 
pCR 
Thymosin beta 
15 
Basal 61 mRNA Positive 
NGAL Luminal 487 Protein Positive 
β-tubulin III, bcl-
2, and ERCC1 
All 91 Protein Negative 
Tau All 113 Protein Negative 
 
Table 1.4: Summary of studies investigating predictive molecular markers in breast 
cancer patients treated with NAC (Darb-Esfahani et al., 2012, Wenners et al., 2012, 
Chen et al., 2012b, Wang et al., 2013a). 
 
1.6 Mechanism of resistance to chemotherapy   
Studying predictive molecular markers can have importance in gaining further insight 
into the underlying mechanisms that are responsible for chemoresistance in breast 
cancer patients. The studied markers in Table 1.4 have been shown to have 
expression levels that correlated with tumour response to NAC in terms of pCR rate, 
and hence subsequent survival since patients who achieve pCR have improved 
survival. Therefore, their expression levels have clinical utility in predicting which 
patients respond more favourably to NAC and subsequent survival. Furthermore, 
examining the underlying mechanisms responsible for defining their expression levels 
may ultimately lead to therapies designed to improve sensitivity to chemotherapy, and 
result in improved response and survival.  
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The mechanisms of resistance to chemotherapy are highly complex and large numbers 
of molecules are involved. Different pathways involved in chemoresistance can be 
broadly classified into the alteration in protein expression affecting drug transport into 
the intracellular compartment (ABC transporters, LRP), modification in the expression 
and function of the molecules targeted by chemotherapeutics (DHFR, β-Tubulin, tau, 
MAP4), alterations in the DNA repair mechanism (Topoisomerase II, mismatch repair 
proteins), alterations in the enzyme affecting drug metabolism (cytochrome P450, GST, 
ALDH), and alteration in molecules responsible for the regulation of apoptosis 
(caspase-3, p27, p53, bcl-2, PTEN, and p27) (Rivera, 2010). 
 
The following molecules have been highlighted due to their importance in breast cancer 
chemotherapy resistance, although there is a wide literature and common themes are 
difficult to identify. One of the key mechanisms of chemoresistance is driven by ATP-
dependent drug efflux pumps, collectively termed ATP-binding cassette (ABC) 
transporters. Their substrates include the majority of chemotherapeutic agents 
currently in use, thereby the molecules potentially confer multidrug resistance (MDR). 
ABC transporters can reduce the intracellular concentration of chemotherapeutics, and 
therefore reduce their efficacy. These molecules are discussed in more detail in section 
1.8. p53 has an important role in regulation of apoptosis, cell cycle progression, and 
DNA repair. When compared to the wild-type p53, cells with mutant p53 show greater 
resistant to chemotherapeutics (Lai et al., 2012). This is attributed to the failure of cells 
to undergo apoptosis following treatment with chemotherapeutics. Breast cancer 1, 
early onset (BRCA1) is a tumour suppressor gene which is involved in regulation of 
transcription and DNA repair. Its overexpression can result in resistance to platinum-
based chemotherapeutics (Husain et al., 1998). DNA Topoisomerase II is an enzyme 
involved in DNA replication and repair. Anthracyclines exert their action by interfering 
with topoisomerase IIα (TOPOIIα). Studies have shown that TOPOIIα gene 
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amplification resulted in enhanced benefit from anthracyclines for breast cancer 
patients who were HER2-positive (Barrett-Lee, 2005). Therefore, reduction in 
topoisomerase II function results in resistance to anthracyclines. Taxanes target β-
tubulin which is involved in the formation of microtubules. Overexpression or mutations 
of β-tubulin has been shown to result in resistance to taxanes (Kamath et al., 2005).  
 
1.7 Mechanism of resistance to endocrine therapy   
Similarly, large numbers of molecules are involved in endocrine therapy resistance, 
and the mechanism of resistance can be broadly classified into the alteration of ER 
expression and its activity (ERα36, microRNAs, EGFR, HER2), alterations in the 
expression of ER co-repressors (NCoR) and co-activators (SRC3), change in the 
activity of transcriptional factors involved in mediating ER signalling in the non-nuclear 
pathway (AP-1, SP-1, NFκβ), alterations in receptor tyrosine kinase (RTK) signalling 
due to its cross-talk with ER (EGFR, HER2, PI3K, MAPK), and alterations in the 
expression of cell-cycle regulators (MYC, Cyclin E1, p21) (Giuliano et al., 2011). Some 
of the mechanisms involved in endocrine resistance are further highlighted below. 
 
Loss of ER expression can result in endocrine therapy resistance, and is in part 
controlled by post-transcriptional mechanisms. For example, ER mRNA stability can be 
affected by miR-206, and can result in the loss of ER expression (Adams et al., 2007). 
ER exerts its effect on gene expression by binding to a group of regulatory proteins to 
form the transcription initiation complex. High expression of such regulatory proteins, 
such as SRC3, is associated with tamoxifen resistance (Osborne et al., 2003). 
Increased activity of transcriptional factors, such as NFκB (Zhou et al., 2007), is also 
associated with resistance to endocrine therapy. Cross-talk between ER and RTK 
signalling can also result in endocrine therapy resistance. Specifically, ER causes up-
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regulation of RTK signalling, such as MAPK and PI3K/Akt, which in turn causes 
phosphorylation of ER and its co-regulatory proteins, resulting in the activation of ER in 
the presence of anti-oestrogens (Giuliano et al., 2011).  
 
1.8 The importance of ABC transporters 
1.8.1 Classification of ABC transporters and the distribution of their expression 
49 human ABC genes have been identified (Leonard et al., 2003), and there are 7 
subfamilies termed ABCA to ABCG. The following table adapted from Gottesman et al 
outlines the list of known ABC proteins according to each subfamily (Table 1.5). 
Subfamily Nomenclature Protein name Known tissue or cellular localization 
ABCA ABCA1 ABC1 Placenta, liver, lung, adrenal glands 
ABCA2 ABC2 Brain, monocytes 
ABCA3 ABC3 Apoptotic cells 
ABCA4 ABCR Retina 
ABCA7 KIAA0822 Brain 
ABCB ABCB1 Pgp Intestine, liver, kidney, placenta, blood-brain barrier 
ABCB2 and 3 TAP1 and 2 Endoplasmic reticulum membrane 
ABCB4 Pgp3 Liver 
ABCB7 and 8 ABC7 and M-
ABC1 
Mitochondrial membrane 
ABCB11 BSEP Liver 
ABCC ABCC1 MRP1 All tissues 
ABCC2 MRP2 Liver, kidney, intestine 
ABCC3 MRP3 Pancreas, kidney, intestine, liver, adrenal glands 
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ABCC4 MRP4 Prostate, testis, ovary, intestine, pancreas, lung 
ABCC5 MRP5 Most tissues 
ABCC6 MRP6 Liver, kidney 
ABCC7 CFTR Liver, pancreas, intestine, bronchial and sweat glands 
ABCC8 and 9 SUR1 and 2  Pancreas 
ABCD ABCD1 and 2 ALD/ALDL1 Peroxisomal membrane 
ABCD3 and 4 PXMP1 and 
PXMP1L 
Peroxisomal membrane 
ABCE/F ABCE1/ABCF1 OABP/ABC50 Unknown 
ABCG ABCG1 ABC8 Central nervous system 
ABCG2 BCRP Placenta, intestine, breast, liver 
 
Table 1.5: List of ABC transporters and their distributions of expression (Gottesman et 
al., 2002) 
 
1.8.2 Roles in normal physiology and multidrug resistance 
ABC transporters have normal physiological roles as well as roles in the multidrug 
resistance (MDR) phenotype. Table 1.5 shows that the majority of ABC transporters 
are expressed in vital organs responsible for excreting waste products of metabolism 
and potentially harmful chemicals. Their physiological function is to excrete xenobiotics 
and their metabolites, including phospholipids, ions, steroids, and amino acids. 
Therefore, the transporters have important roles in tissue defence, and prevent 
accumulation of potentially harmful compounds. They are present at the blood-brain 
barrier, luminal membranes of kidney, and the brush border membranes of intestinal 
cells amongst other locations (Klein et al., 1999b). For example, Pgp, MRP1/2/4, and 
BCRP provide protection to the brain at the blood-brain barrier. In the liver, Pgp, BSEP, 
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and MRP1-3 excrete xenobiotics into bile and blood stream. In the kidney, Pgp, 
MRP2/4, and BCRP excrete xenobiotics into urine. In the mammary gland of lactating 
animals, BCRP is involved in secretion of nutrients into milk (Huls et al., 2009).  
 
ABC transporter expression is also associated with MDR phenotype. This has been 
demonstrated experimentally repeatedly by growth of cell lines in medium containing a 
single specific chemotherapeutic agent thereby selecting for resistance; the resultant 
resistant cell lines typically show a MDR phenotype against multiple unrelated drugs, 
with deregulation of ABC transporters identified as being responsible. The wide range 
of relevant substrates of the most well studied ABC transporters are highlighted in 
Table 1.6 (Leonessa and Clarke, 2003, Chang, 2010, Doyle and Ross, 2003). This 
demonstrates that ABC transporters efflux most chemotherapeutics that are in current 
clinical use, and hence their basal expression in tumours or their change in expression 
on exposure to chemotherapy agents potentially has high clinical relevance. 
 
ABC transporter Examples of known substrates 
Pgp Anthracyclines, colchicine, cortisol, 
dexamethasone, diltiazem, methotrexate, 
mitoxantrone, nicardipine, taxanes, verapamil, 
vincristine.  
MRP1 Anthracyclines, cyclophosphamide, folic acid, 
methotrexate, vincristine.  
BCRP Anthracyclines, folic acid, methotrexate, 
mitoxantrone, sulphasalazine, topotecan.  
 
Table 1.6: Example of common substrates for ABC transporters 
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1.8.3 Molecular structure of ABC transporters 
ABC transporters are active pumps that efflux substrates against their concentration 
gradient. Their molecular structure consists of a nucleotide binding domain (NBD) in 
the cytoplasm and a transmembrane domain (TMD), composed of six transmembrane 
helices. Two or more TMDs are required to form an active ABC transporter. Two highly 
conserved peptide motifs within the NBD, Walker A and B, characterises the ABC 
transporters (Klein et al., 1999a), and are involved in the binding of ATP molecules. 
When a substrate binds to the transporters, ATP hydrolysis occurs, causing a 
conformational change at the cytosolic point of entry to the trans-membrane channel. 
This structural change moves the substrate through the protein channel and the 
plasma membrane, causing its export to the extracellular space. A further ATP 
hydrolysis at its binding site restores the protein to its original conformation, enabling it 
to bind to its substrate again (Sauna and Ambudkar, 2001). 
 
The vast majority of studies into the roles of these genes in MDR so far have focused 
on the 170 kDa ABC transporter P-glycoprotein (Pgp), the product of the ABCB1 
(MDR1) gene. It was discovered by selecting Chinese hamster ovarian cell lines with 
colchicine (Juliano and Ling, 1976), which then showed an MDR phenotype to a wide 
range of drugs. The gene encoding for Pgp, MDR1, was identified and cloned from the 
human KB carcinoma cell line (Ueda et al., 1986). The structure of Pgp consists of 12 
transmembrane helices, split into two TMDs that are linked by an intracellular ATP-
binding domain. Substrates of Pgp are highlighted in Table 1.6.  
 
Another well-studied ABC transporter is the 190 kDa Multidrug resistance-associated 
protein 1 (MRP1), the product of the ABCC1 gene. It was discovered by doxorubicin-
selection of drug resistant H69AR cells from the initially drug sensitive small cell lung 
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cancer cell line H69, and by subsequent cloning of the MRP1 cDNA (Cole et al., 1992). 
The selected cell line did not express Pgp, and both the mRNA and protein 
expressions of MRP1 was increased compared to the unselected parental cell line. 
MRP1, which has 17 transmembrane helices, shares less than 15% of amino acid 
identity compared to Pgp. Compared to Pgp, MRP1 has an additional TMD of 5 
transmembrane helices. It has similar substrate specificity to Pgp, including 
anthracyclines and methotrexates. It is worth noting that MRP1 does not efflux 
paclitaxel (Leonard et al., 2003).  
 
The 72 KDa BCRP is a less well-studied ABC transporter, especially in breast cancer. 
It is a product of the ABCG2 gene. BCRP was first identified in a human breast cancer 
cell line MCF7/AdrVp (Ni et al., 2010), a multidrug resistant cell line that does not 
express Pgp or MRP1. The cell line was developed by co-selecting the parental cell 
line in doxorubicin and verapamil, the latter being a Pgp inhibitor and therefore avoiding 
Pgp-mediated resistance (Leslie et al., 2005). Substrates of BCRP include doxorubicin, 
methotrexate, and mitoxantrone. Similar to MRP1, paclitaxel is not a substrate of 
BCRP (Leslie et al., 2005). In contrast to Pgp and MRP1, structurally BCRP consists of 
six transmembrane helices only, and an ATP-binding domain. To function as an active 
transporter, BCRP has to homodimerise. 
 
1.8.4 Regulation of Pgp, MRP1, and BCRP 
Patients with high ABC transporter expression might be expected to have poor 
responses to chemotherapy, and have lower survival rates. Therefore, manipulation of 
molecular mechanisms involved in the regulation of ABC transporter expression in 
cancer cells could potentially lead to improved efficacy of chemotherapy agents. 
Common regulation and cancer-specific deregulation mechanisms for ABC transporter 
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expression can be broadly classified into changes in genomic copy number, 
transcriptional regulation, and post-transcriptional regulation. Below I give specific 
examples in each of these categories for Pgp, MRP1 and BCRP (Nakanishi and Ross, 
2012, Kuo, 2009).  
 
Teeter et al selected Chinese hamster ovarian cells with increasing doses of vincristine 
to develop MDR. Cytogenetic analyses of the cell lines revealed MDR1 gene 
amplification as an underlying mechanism of chemoresistance (Teeter et al., 1986). 
Transcriptional regulation is defined by transcriptional factors. However, their binding to 
the target gene can be altered in cancer due to changes in DNA methylation and 
chromatin structure. Tada et al showed that in bladder cancer, MDR1 mRNA 
expression was up-regulated after exposure to chemotherapy. In this study, the 
frequency of patients with hyper-methylated MDR1 promoter region was reduced from 
50% to 17% after exposure to chemotherapy (Tada et al., 2000). Therefore, an inverse 
correlation was detected between the degree of methylation at the CpG (cytosine 
phosphate guanine) sites of the MDR1 promoter region and the mRNA levels. An 
example of post-transcriptional regulation is demonstrated by Randle et al. The 5’-
untranslated region (UTR) of the MDR1 mRNA contains considerable secondary 
structure, with double-stranded hair-pin loops. This sequence influenced the 
translational efficiency of transcripts and allowed regulation under cytotoxic stress 
(Randle et al., 2007).  
 
Yasui et al conducted cytogenetic analyses of parental cancer cell lines versus 
chemotherapy resistance cancer cell lines and determined that ABCC1 genomic copy 
number was amplified in the resistant cell lines compared to the parental cell lines 
(Yasui et al., 2004). Wild-type p53 is involved in the repression of transcription at the 
ABCC1 promoter sites, and the loss of p53 expression in colorectal cancer has been 
47 
 
shown to correlate with increased MRP1 expression (Fukushima et al., 1999). Borel et 
al examined ABCC1 mRNA expression amongst other ABC transporters in 
hepatocellular carcinoma compared to adjacent healthy liver. Higher mRNA levels were 
observed in the tumour tissue compared to healthy liver tissue. Furthermore, an 
inverse relationship was detected between microRNA expression (miR-199a/b and 
miR-296) and ABCC1 mRNA expression (Borel et al., 2012).  
 
Similarly to ABCB1 and ABCC1, comparative genomic hybridisation studies have 
shown ABCG2 genomic copy number amplifications in cancer cell lines treated with 
mitoxantrone and doxorubicin (Nakanishi and Ross, 2012). Oestrogen and its 
derivatives can act as either substrates or inhibitors (Staud and Pavek, 2005) for 
BCRP, which contains an oestrogen response element (ERE) in its promoter site. Ee et 
al showed that oestrogen enhanced BCRP mRNA expression in T47D cell lines (Ee et 
al., 2004), demonstrating transcriptional regulation of BCRP expression. In contrast, 
Imai et al showed that BCRP expression on western blot, but not at the mRNA level, 
was reduced with increasing levels of 17β-oestradiol in MCF7 cell lines, and the 
authors inferred that BCRP expression was regulated post-transcriptionally (Imai et al., 
2005).  
 
1.8.5 ABC transporter directed therapies 
The efflux activity of xenobiotic transporters can be inhibited by various targeted drugs 
(e.g. valspodar, biricodar, and tariquidar). However, they are not currently in routine 
clinical use, and have mostly been evaluated in phase II and III trials (Modok et al., 
2006). Their lack of advance in the clinical setting may be due to the fact that the 
transporters have a wide range of physiological roles and hence the inhibitors may 
cause non-specific toxicity. Verapamil, a Pgp inhibitor, was first used in clinical trials in 
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1980s, but had unacceptable levels of side-effects, including cardiotoxicity and 
myelotoxicity (Ozols et al., 1987, Mross et al., 1993). This was followed by valspodar, a 
second generation Pgp inhibitor, which had a reduced side-effect profile. However, 
phase III clinical trials using valspodar in ovarian or peritoneal cancer have not been 
encouraging. 762 patients with advanced ovarian or primary peritoneal cancer were 
treated with carboplatin and paclitaxel with or without valspodar in a phase III clinical 
trial. The result showed no significant improvement in time to disease progression or 
overall survival from the addition of valspodar. Furthermore, central and peripheral 
nervous system and gastrointestinal toxicities were more frequently seen in patients 
treated with valspodar (Lhomme et al., 2008). An MRP1 inhibitor, Sulindac, has been 
evaluated in phase I clinical trial in combination with epirubicin (O'Connor et al., 2007). 
However, as yet no further phase II or III trials have been reported. As shown in Table 
1.6, there is a considerable overlap in substrate specificities between the ABC 
transporters. Therefore, a limitation of these approaches may be that inhibition of a 
single transporter may not result in effective clinical response as it is possible, or even 
probable, that inhibition of a single transporter may lead to increased compensatory 
substrate efflux by the other transporters. However, further research is required to 
study the potential interaction and molecular cross-talk between the transporters. Apart 
from Pgp, MRP1, and BCRP, there are numerous other less well-studied ABC 
transporters (Table 1.5). It is possible that these other transporters also have key roles 
in chemoresistance. 
 
1.8.6 ABC transporter expression in cancer 
Pgp and MRP1 expression has been detected using immunohistochemistry, qPCR, 
and flow cytometry in a range of tumours including breast cancer, myeloma, lung 
cancer, ovarian cancer, and leukaemia (Leonard et al., 2003). Of note, in acute myeloid 
leukaemia Pgp expression is up-regulated in patients who suffer from disease relapse 
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(Han et al., 2000). Other studies have shown that the intrinsic expression levels of ABC 
transporters correlate with clinico-pathological parameters that are associated with 
poor patient outcome. For example, MRP1 expression in untreated hepatocellular 
carcinoma correlates with tumour grade, size, and the degree of microvascular 
invasion (Fletcher et al., 2010). Similarly a study by Weinstein et al found that Pgp 
expression in colon cancer correlated with vessel wall invasion and lymph node 
metastasis (Weinstein et al., 1991). 
 
In breast cancer, the majority of published studies have focused on the expression of 
Pgp since it was the first of the three to be discovered (Leonessa and Clarke, 2003). 
Many previous studies have focused on measuring expression levels prior to adjuvant 
(post-surgery) chemotherapy. A meta-analysis (Trock et al., 1997), including 21 
immunohistochemical studies, showed that Pgp expression was seen in 48.5% of 
breast tumours. However, the incidence ranges widely from 0 to 80% (Leonard et al., 
2003). This may reflect the differences in quantification of expression, heterogeneity 
between the patient cohorts, or the differences in the specificity of antibodies used. 
Indeed, antibodies JSB-1, C494, and C219, which have been used for “Pgp” detection, 
have been reported to have cross-reactivity with proteins other than Pgp (Trock et al., 
1997).  
 
Studies examining Pgp expression in normal breast tissues have shown variable 
results. Van der Valk et al used three antibodies (JSB-1, C219, and MRK16) for 
immunohistochemistry and showed that Pgp expression was weak and confined to the 
breast epithelial cells (van der Valk et al., 1990). Ro et al showed that Pgp expression 
was present in the adjacent normal or hyperplastic tissue in 67% of the 40 breast 
cancer specimens examined by immunohistochemistry using C219 antibody (Ro et al., 
1990). However, Pgp expression was undetectable in the normal breast tissue samples 
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with immunoblots using the same antibody, compared to the breast cancer tissue 
samples (Sanfilippo et al., 1991) where Pgp expression was detected in 10 out of 34 
cases. Such studies examining MRP1 and BCRP expression in normal breast tissues 
are limited. Linn et al (Linn et al., 1997) showed that MRP1 expression was observed in 
the normal breast epithelium as well as the malignant cells using 
immunohistochemistry. 
  
Regarding comparisons to clinico-pathological parameters, there are no studies that 
show clear correlations between Pgp expression and tumour grade or stage. Pooled 
analysis from 4 studies suggests a correlation between Pgp expression and tumour 
stage (Leonessa and Clarke, 2003), with Pgp expression observed in 23% of T1 
tumours, compared to 42% of T4 tumours. This correlation needs to be interpreted with 
caution due to the heterogeneity in study design and patient cohort in each study. Data 
from pooled studies (n=5) showed that MRP1 expression was observed in 49% of the 
cases using immunohistochemistry in untreated breast cancer patients. Similarly to 
Pgp, studies examining MRP1 expression did not detect correlations with tumour 
stage, grade, or ER status (Leonessa and Clarke, 2003). 
 
In terms of predicting survival, studies by Vargas-Roig et al (Vargas-Roig et al., 1999) 
and Honkoop et al (Honkoop et al., 1998) both show that Pgp expression detected by 
immunohistochemistry did not predict disease free survival (DFS) or overall survival 
(OS) in breast cancer, where patients in both cohorts received doxorubicin. The 
Austrian Breast and Colorectal Cancer Study Group carried out a large study (n=516) 
investigating the role of MRP1 in breast cancer (Filipits et al., 2005). Using 
immunohistochemistry, they determined that MRP1 expression independently 
predicted for poor DFS. BCRP expression has been studied using 
immunohistochemistry in lung (Kim et al., 2009) and pancreatic cancer (Lee et al., 
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2012). These studies have shown BCRP expression to be associated with poor DFS. A 
limited number of studies have used tissues from patients treated with NAC to study 
xenobiotic transporter expression in breast cancer. It is of clear interest to examine 
their expression in the context of NAC, which has become a key treatment modality in 
breast cancer. In patients treated with adjuvant chemotherapy, only the intrinsic initial 
expression of the xenobiotic transporters can be determined since the tumour has been 
resected, and no further tumour tissue is available post-adjuvant chemotherapy unless 
patients develop tumour recurrences. NAC treatment protocols enable examination of 
the effect of chemotherapy in modulating xenobiotic transporter expression, and 
whether these expression levels correlate with patient outcome. 
 
1.8.7 Introduction summary 
Breast cancer is a relatively common disease, and NST is an important treatment 
modality. ABC molecules potentially impact on response to NST, and further 
investigation of how they impact on response, and how NST impacts on their 
expression is warranted.  
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2.0 Hypothesis and Aims  
My hypothesis is that expression of xenobiotic transporters impacts on neoadjuvant 
systemic therapy response in breast cancer. 
 
1. The primary aim of the project was to investigate whether expression of Pgp, 
MRP1, and BCRP either pre- or post-NAC correlates with treatment outcome.  
 
2. The secondary aim was to examine whether Notch1 activity impacts on MRP1 
expression, and thereby on response to chemotherapy. 
 
3. The tertiary aim was to examine whether NAET modulates BCRP expression, 
and whether epigenetic mechanisms are involved.  
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3.0 Materials and methods 
3.1 Cohort selection 
Ethical approval was obtained from Leeds (East) Research Ethics Committee 
(reference 06/Q1206/180).  
 
Cohort 1 – Neoadjuvant chemotherapy 
136 breast cancer patients treated with NAC at Leeds Teaching Hospitals NHS Trust 
(LTHT) from 2005 to 2009 were identified using the LTHT computer database, Patient 
Pathway Manager (PPM). Patients to be studied further were subject to careful cohort 
selection in order to limit tumour heterogeneity. Relevant data on patient and tumour 
characteristics were collected. Strict inclusion criteria for the study included patients 
who had a minimum of 3 year clinical follow-up after NAC, post-operative radiotherapy, 
grade 2 or 3 invasive ductal carcinoma (IDC) on core biopsy specimen, and NAC 
regimen consisting of anthracyclines +/- taxanes. Exclusion criteria included 
inflammatory breast carcinoma, invasive lobular carcinoma (ILC), and those who 
received adjuvant chemotherapy as well as NAC. This identified a cohort of 45 
patients. Relevant clinical data are outlined in table 3.1. Disease free survival (DFS) 
was defined as survival free of local or distant disease post-surgery. 21 patients were 
diagnosed with axillary metastasis and nodal tissues were available in 15 cases. In 
2/15 cases the final pathology diagnosis was micrometastasis, where tumour size was 
less than 2mm. This was deemed insufficient for immunohistochemistry, and hence 13 
matching patient lymph node blocks were available for immunohistochemical analysis 
of tumour cells.  
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Characteristic Categories No. of patients (%) 
n=45 
Age <45 21 (47) 
>45 24 (53) 
Grade (pre-NAC) 2 15 (33.3) 
3 30 (66.7) 
Stage (pre-NAC) T2 26 (57.8) 
T3 16 (35.6) 
T4 3 (6.6) 
Stage (post-NAC) T0 6  (13.3) 
T1 14 (31.1) 
T2 17 (37.8) 
T3 6  (13.3) 
T4 2  (4.5) 
Tumour size change Increase 8 (17.8) 
Decrease 31 (68.9) 
pCR 6 (13.3) 
MRI response Minimal 9  (20) 
Partial 30 (66.7) 
Complete 6  (13.3) 
NAC regimen epirubicin + 
cyclophosphamide (EC) 
13 (28.9) 
EC + taxanes   32 (71.1) 
Lymphovascular invasion Positive 17 (37.8) 
Axillary metastasis Positive 21 (46.7) 
Estrogen receptor Positive 26 (57.8) 
Her2 Positive 9 (20) 
Surgery breast conserving 17 (37.8) 
Mastectomy 28 (62.2) 
Follow up median: 4.5 years  
(range 3-8.8 years) 
 
Recurrence  17 (37.8) 
Death  10 (22.2) 
 
Table 3.1: Clinico-pathological characteristics of the NAC cohort (note: a relatively high 
number of patients suffered from recurrences, reflecting the aggressive nature of 
disease presentation in this cohort) 
 
Cohort 2 – Neoadjuvant endocrine therapy 
144 breast cancer patients treated with NAET at LTHT from 2005 to 2013 were 
identified using the LTHT computer database, Patient Pathway Manager (PPM). 
Patients who were part of the POETIC or NEO-EXCEL clinical trials were excluded 
from further consideration. In the former trial the length of duration of NAET was only 2 
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weeks (Dowsett et al., 2011), and in the latter trial NAET was combined with celecoxib. 
Therefore, 86 patients were available for further cohort selection. Inclusion criteria for 
the study included NAET duration of 1 month to 1 year, IDC or ILC, Allred score for ER 
expression of 7 or 8, no change in NAET regime, and lack of HER2 overexpression. 
This identified a cohort of 51 patients. Relevant clinical data are outlined in Table 3.2. 
Patients were mostly post-menopausal and this is reflected by administration of 
aromatase inhibitors in the majority. Most patients presented with lower grade and 
stage tumours, reflected by the lower recurrence rates.  
Characteristic Categories No. of patients (%) 
n=51 
Age Median: 67 years old 
(range 40-95 years old) 
 
Histological type IDC 38 (74.5) 
ILC 7 (13.7) 
IDC/ILC 7 (13.7) 
Grade  1 15 (29.4) 
2 30 (58.8) 
3 6 (11.8) 
Stage (pre-NAET) T1         17 (33.3) 
T2 26 (51) 
T3 5 (9.8) 
T4 3 (5.9) 
Stage (post-NAET) T1 19 (37.3) 
T2 25 (49) 
T3 7 (13.7) 
Tumour size change Increase or no change           22 (43.1) 
Decrease  29 (56.9) 
Lymphovascular invasion                Positive           11 (21.6) 
Receptor status (4/8 as 
cut-off for positive 
expression)  
ER 51 (100) 
   PR  37 (78.7) 
NAET duration Median: 90 days 
(range 30-362 days) 
 
NAET regimen Anastrozole 24 (47.1) 
Letrozole 20 (39.2) 
Tamoxifen 7 (13.7) 
Axillary metastasis Positive 21 (41.2) 
Surgery breast conserving 22 (43.1) 
Mastectomy 29 (56.9) 
Adjuvant chemotherapy  6 (11.8) 
Recurrence Median follow-up 7 (13.7) 
 
Table 3.2: Clinico-pathological characteristics of the NAET cohort  
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3.2 Haematoxylin & Eosin staining and step sectioning 
Archival formalin-fixed paraffin-embedded (FFPE) matching breast core biopsy and 
resection blocks were obtained for the selected patients. Single core biopsy (pre-
NAC/NAET) blocks were available, compared to the numerous resection blocks (post-
NAC/NAET). A review of histopathology reports was required to identify appropriate 
resection blocks that contained tumour. To ensure the resection block contained 
tumour cells, haematoxylin & Eosin (H&E) staining was performed on the selected 
blocks.  
 
Blocks were sectioned at depths of 5µm with a microtome, and sections were placed 
onto single SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany). Slides 
were then air-dried, and incubated at 37oC. Sections were dewaxed in xylene, and 
rehydrated with graded ethanol. They were then stained in Mayer’s haematoxylin, 
Scotts substitute, and eosin. Following this, sections were dehydrated in ethanol and 
xylene, and mounted in DPX (Fluka, Gillingham, UK). The stained slides were then 
examined under a microscope to detect the presence of tumour cells. The slides were 
also examined by a pathologist (Dr Eldo Verghese, EV, Leeds Institutes of Molecular 
Medicine, University of Leeds and Department of Histopathology, LTHT) to confirm the 
findings.  
 
In addition, 8 patients receiving NAC were reported to have achieved pCR in the 
pathology reports. In order to confirm the absence of tumour tissue in these cases, a 
single resection block was selected per patient. These blocks had evidence of fibrosis, 
or the presence of a guide wire tip, and hence corresponded to the original tumour 
location prior to NAC. Step-sectioning was performed at intervals of 100µm and four 
consecutive sections of 5µm thickness were placed onto the SuperFrost Plus slides, 
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and immunohistochemistry (Section 3.4) was performed at each level (Table 3.3) with 
the monoclonal mouse anti-human cytokeratin AE1/3 antibody (M 3515; Dako, 
Glostrup, Denmark). This revealed residual tumour cells in 2 out of 8 cases (Appendix 
3, Fig S1). Therefore, the final cohort of patients for whom pre- and post-NAC tumour 
tissue was available was increased to 39/45 cases. 
 
3.3 Antibody selection 
Many monoclonal antibodies are available for Pgp, including; C219, JSB1, MRK16, 
UIC2, and 4E3 (Beck et al., 1996). Fewer monoclonal antibodies are available for 
MRP1 (QCRL1, QCRL3, and MRPr1), and BCRP (BXP21 and BXP34). UIC2 was 
chosen to detect Pgp expression as it has been widely used for immunohistochemistry 
on breast tissue (Mechetner et al., 1998, Hegewisch-Becker et al., 1998, Tsukamoto et 
al., 1997), and has also been validated by the presence of a single band at 170kDa 
(Mechetner and Roninson, 1992) in western blot experiments. Similarly, the QCRL1 
monoclonal antibody was chosen for MRP1 as it had been used on breast cancer 
tissues (Filipits et al., 1996), and was validated by a specific western blot at 190kDa on 
breast cancer cell lines (Morrow et al., 2006). In the aforementioned study, MRP1 
staining was mostly observed in tumour cells, with occasional weak staining in some 
stromal cells. Both membranous and cytoplasmic staining patterns were observed. For 
BCRP, BXP21 showed a range of positive staining in a variety of human tumours 
including FFPE breast tissue (Diestra et al., 2002). Both homogeneous and 
heterogeneous staining intensity were observed that was mostly tumour-specific, but 
some staining was observed in the endothelial cells. The staining patterns were mixed 
membranous and cytoplasmic. Western blot experiments using BXP21 on breast 
cancer cell lines showed a presence of a specific band at 72kDa (Morrow et al., 2006). 
Therefore, BXP21 monoclonal antibody was chosen (Table 3.3). Anti-activated Notch1 
antibody detects only the active, cleaved intracellular domain of Notch1 (Notch intra-
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cellular domain, “NICD”). It has been used on breast tissue for immunohistochemistry 
(Efstratiadis et al., 2007), and on western blots with breast cancer cell lines (Hao et al., 
2010). Strong nuclear staining was observed in breast cancer cells with this antibody, 
but normal ductal epithelial cells stained negative or weakly positive. 
 
Antigen Antibody Type Code and 
manufacturer 
Pgp UIC2 Mouse monoclonal 
IgG2a anti-human  
sc-73354, Santa 
Cruz Biotech., 
Santa Cruz, USA 
MRP1 QCRL1 Mouse monoclonal 
IgG1 anti-human 
sc-18835, Santa 
Cruz Biotech., 
Santa Cruz, USA 
BCRP BXP21 Mouse monoclonal 
IgG2a anti-human 
ab3380, Abcam, 
Cambridge, UK 
Notch1 NICD Anti-activated 
Notch1 antibody 
Rabbit polyclonal 
IgG anti-human 
ab8925, Abcam, 
Cambridge, UK 
Cytokeratin AE1/3 Mouse monoclonal 
IgG1 anti-human 
M3515, Dako, 
Glostrup, Denmark 
 
Table 3.3: Selected antibodies for immunohistochemistry   
 
3.4 Immunohistochemistry 
The protocol below describes my generic immunohistochemistry method; modifications 
made for use of specific individual antibodies are noted in section 3.5, and Table 3.4. 
FFPE breast tissue blocks were sectioned at depths of 5µm with a microtome, and the 
sections were placed onto SuperFrost Plus slides (Menzel-Glaser, Braunschweig, 
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Germany). Slides were then air-dried, and incubated at 37oC for 16 hours. Sections 
were dewaxed with xylene and rehydrated with graded ethanol. This was followed by a 
5 minute wash with water. The sections were then immersed in 10mM citric acid buffer 
(pH 6.0), and epitope retrieval was performed by heat using a 900W microwave or 
pressure cooker (10 min). Sections were then immersed in 0.3% H2O2 (10 min) to block 
endogenous peroxidase activity. Slides were rinsed in Tris-buffered saline (TBS), and 
mounted on Sequenza racks (Thermo Scientific, USA). Non-specific binding activity for 
primary antibodies was blocked, when required, using 100µl of casein solution 
(SP5020; Vector Labs, Burlingame, USA) diluted 10-fold (20 min) in TBS or antibody 
diluent reagent solution (Invitrogen, USA). Otherwise 100µl of antibody diluent reagent 
solution was added, and then 100µl of the primary antibody diluted in the same diluent 
was added for either 1 hour at room temperature or 16 hours at 4oC. Slides were then 
rinsed twice with TBS-tween (TBS-T), followed by a single wash with TBS. 1.25ml of 
10% v/v Tween-20 was added to 1 litre of TBS solution to form TBS-T (Appendix 
Section 1). Each wash lasted 5 minutes. Slides were incubated in a horseradish 
peroxidase (HRP) conjugated polymer secondary antibody (Dako, Glostrup, Denmark) 
for 30 minutes. The slides were then re-washed with TBS-T and TBS as before, and 
then 100µl of diaminobenzidine (DAB) was added to each slide for exactly 10 minutes, 
followed by a wash in water for 5 minutes. The slides were stained with haematoxylin 
for one minute, followed by a one minute wash in water. This was followed by a wash 
in Scott’s tap water (refer to Appendix Section 1 for recipe) for one minute, and a 
subsequent one minute wash in water. The slides were dehydrated with graded ethanol 
and xylene, and mounted in DPX (Fluka, Gillingham, UK). The recipe list for all the 
reagents used for immunohistochemistry and other experiments are listed in the 
appendix section 1.  
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3.5 Antibody optimisation and cohort staining 
Conditions for use of the antibodies in immunohistochemistry with breast cancer tissue 
were optimised using a tissue microarray (TMA) of 30 cores of randomly selected and 
fully anonymised breast carcinomas, normal breast tissue, and placenta tissues. The 
presence of placenta tissue was particularly important since this tissue is known to 
express the xenobiotic transporters highly (as corroborated by reviewing 
immunohistochemistry results compiled on the human protein atlas project 
http://www.proteinatlas.org) and therefore this tissue acted as a positive control. 
Negative controls were performed by omitting the primary antibody, which produced no 
staining in the TMA cores. Optimised staining of TMA tissues for each antibody is 
shown in Appendix section 3, Figure S2. Variables were method of antigen retrieval, 
antibody concentration, length of incubation and method of blocking (Table 3.4). 
Conditions were chosen for xenobiotic transporters that allowed a range of tumour-
specific cytoplasmic and membranous staining intensities in different cores with 
minimal staining in fibroblast or normal breast cells. For Notch1 NICD, conditions were 
chosen that allowed a nuclear-specific staining in tumour cells. Optimisation slides 
were reviewed by breast histopathologist EV.  
Antigen Antibody Optimised primary 
antibody 
concentration 
Optimised antigen 
retrieval methods 
Additional 
blocking 
steps 
Antibody 
incubation 
period 
Pgp UIC2 1/2000 No retrieval 10% 
casein  
1 hour 
MRP1 QCRL1 1/50 Microwave None 1 hour 
BCRP BXP21 1/50 No retrieval None 16 hours 
Notch1 
NICD 
Anti-activated 
Notch1 antibody 
1/100 Microwave 10% 
casein 
1 hour 
Cytokeratin AE1/3 1/50 Pressure cooker None 1 hour 
 
Table 3.4: Conditions for use of antibodies for immunohistochemistry 
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Core (pre-NAC/NAET) and resection (post-NAC/NAET) tissues for the whole cohort 
were sectioned at depths of 5µm. To enable direct comparison of the staining pattern in 
these matched tissues, the core and resection tissues were placed on the same slide 
(Fig 3.1). This methodology is unique in the literature for the proteins of interest, and 
potentially reduces experimental variation.   
 
Figure 3.1: Image of core (bottom) and resection (top) tissues placed on the same 
slide 
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3.6 Scoring protocol for xenobiotic transporters 
Stained sections were digitally scanned using Scanscope XT (Aperio®) at 20x 
magnification and were observed using ImageScope (Aperio®). Staining was scored 
initially manually by two independent scorers (BK and Dr Bethany Williams (BW), a 
histopathologist; Department of Histopathology, LTHT) in order to demonstrate that 
staining could be reproducibly assessed. Scoring was then performed using a semi-
automated procedure, which was validated against the initial manual scores. First, 
weighted histoscores (van Nes et al., 2012) [0 to 300 = (1 x % of tumour cells weakly 
stained) + (2 x % moderately stained) + (3 x % strongly stained)] were determined 
independently by BK and BW on a randomly selected tumour field containing at least 
100 tumour cells on each of a total of 54 slides with an equal distribution between the 
core and resection tissues, and between the three antibodies (Appendix Section 2, 
Table S1). Inter-observer intraclass correlation coefficient (ICC) was then calculated, 
resulting in an ICC of 0.87 between the two independent observers. Imagescope 
(Aperio®) software was then used to mark the identical tumour regions digitally (Fig 
3.2). The positive brown pixel count algorithm 
(http://tmalab.jhmi.edu/aperiou/userguides/Positive_Pixel.pdf) was then applied to 
these regions. Three intensity ranges for each pixel were defined (counts of <100 
defined as weakly positive, 100 to <175 as moderate, and >=175 as strong). Pixels not 
counted as brown were defined as negative. These values were used to generate 
automated histoscores: (1 x % weakly positive pixels within epithelial region) + (2 x % 
moderate) + (3 x % strong). ICCs were calculated for BK versus Imagescope (0.83), 
and for BW versus Imagescope (0.82). These values were deemed to be satisfactory to 
validate the use of Imagescope to perform semi-automated scoring protocol for the 
entire cohort. Then, BK manually marked all epithelial tumour cell regions of the cores 
and resections and Imagescope was used to generate semi-automated histoscores.  
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Figure 3.2: An example of manual versus automated scoring. Imagescope was used to 
mark out the tumour region (inside green boundary) and to generate an automated 
score within this region. For manual scoring of the same region: individual dots within 
the marked regions show examples of manual cell counting with different colours 
representing the different bands of staining intensity: on the left the staining was 
negative and hence the dots are marked in red colour predominantly, whereas on the 
right the staining was strong and dots are marked in black colour predominantly. The 
blue and green dots represent weaker staining observed within the marked region.  
  
3.7 Scoring protocol for Notch1 NICD 
Notch1 NICD nuclear staining was scored using the Allred method (Mohammed et al., 
2012, Allred et al., 2012). This generates a total score in whole numbers ranging from 0 
to 8 (note: a score of 1 is not possible), with an intensity score ranging from 0 to 3 
added to a score quantifying the proportion of tumours cells staining positively ranging 
from 0 to 5. Two independent observers (BK and BW) performed the scoring manually 
(Appendix Section 2, Table S2). Weighted Kappa co-efficients (k) were determined to 
compare the degree of agreement between the two observers. This resulted in a 
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k=0.78 for the core specimens, and a k=0.9 for the resection specimens. This resulted 
in an overall k=0.89 (n=58). The average of the two scores was used as the final score 
to indicate the degree of Notch1 NICD expression. 
 
3.8 Cell culture 
MCF7, HB2, and T47D cells were obtained from Dr Thomas Hughes (Leeds Institutes 
of Molecular Medicine, University of Leeds), and were routinely maintained in D-MEM, 
GlutaMAXTM I, 4500mg/L D-Glucose, 110mg/L Sodium Pyruvate (31966; Invitrogen) 
with 10% fetal calf serum (Sigma-Aldrich, USA). Cell line identities were confirmed by 
Short Tandem Repeat DNA profiling (Leeds Genomic Service). Cell lines were tested 
for mycoplasma at the start of the project and at every 6 months intervals (MycoAlert 
Mycoplasma detection assay, Lonza, Basal, Switzerland), which showed that the cell 
lines were consistently negative for mycoplasma. Cells were grown routinely in 75 cm2 
tissue culture flasks (430641; Corning life sciences) at 370C in humidified 5% carbon 
dioxide/air. No antibiotics were used routinely. The cells were passaged approximately 
every 72 hours when almost fully confluent. The media was removed from the flask, 
and the cells were washed with 10ml of Dulbecco’s phosphate-buffered saline (DPBS) 
(14190-094; Invitrogen) prior to dissociation with 2.5ml of trypsin (0.05% v/v) for 5 
minutes at 37oC. The detached cells were suspended by adding 7.5ml of fresh culture 
medium to inactivate the trypsin, and centrifuged at 400g for 5 minutes. The resulting 
pellet was re-suspended in 10ml of fresh culture medium, and 1ml of the resulting 
solution was added to 14ml of fresh culture medium in a new flask.  
 
H929 and HL60 cell lines were obtained from Dr Elizabeth Valleley (Leeds Institutes of 
Molecular Medicine, University of Leeds), and were routinely maintained in RPMI 1640, 
GlutaMAXTM I (61870-010; Invitrogen) with 10% fetal calf serum. Cells were grown 
routinely in 75 cm2 tissue culture flasks at 370C in humidified 5% carbon dioxide/air. 
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Since these cells are maintained in suspension culture, passaging was performed 
approximately every 5 days by adding 1ml of suspended cells to 14ml of fresh culture 
medium. 
 
3.9 Growth/proliferation assays for response to drugs 
MTT assays were used to assess proliferation/survival of cultures after treatment with 
various drug combinations. Assays were performed using 48 well cell culture multiwell 
plates (677180; Greiner Bio-one). Each well was seeded with the appropriate number 
of MCF7 or T47D cells diluted in 250µl of culture medium. Appropriate numbers were 
determined to enable log phase growth with the culture nearing confluence at either 3 
or 5 days (10,000 and 7,500 seeding cell numbers respectively for MCF7 cells) 
(Appendix Section 3, Fig S3). For the 5 day experiment, 10,000 cells were seeded for 
T47D cells (Appendix Section 3, Fig S4). A haemocytometer was used to count viable 
cells that appeared refractile, as opposed to dead cells which that stained blue and 
non-refractile; the chambers were loaded by mixing 5µl of cells suspended in medium 
with 5µl of 0.1% trypan blue (T8154; Sigma-Aldrich). Viable cell concentrations were 
determined using the formula below, taking account of the 50% dilution. 
 
Concentration (number of cells/ml) = {(number of cells counted in 1mm x 1mm grid) x 
10,000} x 2  
                                           
Cell counting was performed in four 1mm x 1mm haemocytometer squares on each 
occasion and the final concentration was taken from the mean. Cells were incubated in 
the same conditions as described in the previous section to allow them to adhere and 
after 24 hours dose-response experiments were performed with up to 1µM 
concentration of doxorubicin hydrochloride (BPE2516-1; Fisher scientific) alone and up 
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to 10µM concentration of DAPT (sc-201315; Santa cruz) alone. Each experimental 
condition was performed for three wells to generate triplicate values. Negative controls 
included wells without doxorubicin or DAPT but with the same volume of DMSO. Cells 
were then incubated at 37oC for a further 48 hours or 96 hours before the MTT assay 
was performed. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
solution (M2128; Sigma-Aldrich) was diluted in DPBS to a working concentration of 
5mg/ml. The media in each well was replaced with 50µl of the MTT solution, and 
incubated in the dark for 3 hours at 37oC. The MTT solution was then replaced with 
250µl of propan-1ol, and 100µl of the resulting solution was transferred onto a well of a 
96 well plate. The optical density was measured using a microplate reader at 570nm 
(Opsys MRTM Dynex technologies Ltd, UK), where the optical density readings from 
wells containing medium only was subtracted. The resulting IC (inhibitory 
concentration) 10, 25, and 50 doses of doxorubicin were determined for MCF7 and 
T47D cell lines. The cell lines were also treated with DAPT alone to examine its effect 
on cell growth/survival at lower doses of up to 10uM. Finally, MCF7 and T47D cells 
were incubated with or without the three IC doses of doxorubicin and with increasing 
doses of DAPT (range; 1nM to 100uM) for 2 or 4 days. 
 
3.10 Western blots 
3.10.1 Protein extraction and quantification 
Proteins were extracted from adherent cultures in 25cm2 tissue culture flasks (430639; 
Corning life sciences). Medium was removed, and cells were washed twice with DPBS. 
Once the DPBS was removed, 200µl of RIPA buffer (see Appendix Section 1 for 
recipe) with protease inhibitors (G6521; Promega) was added to each flask. Cell 
scraping was performed immediately, and the lysis buffer/cell mix was placed on ice for 
15 minutes. The resulting mixture was then centrifuged at 14,000g for 10 minutes at 
4oC to separate the cell debris from protein. The supernatant was then transferred to a 
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new microcentrifuge tube for assessment of protein concentration using the Bio-Rad 
DCTM protein assay (500-0116; Bio-Rad). This assay uses the principle that differential 
colour change of a dye is proportional to protein concentration. Bovine serum albumin 
(BSA) was serially diluted in PBS to create a range of concentrations (2mg/ml to 
0.125mg/ml) to generate a standard curve. The corresponding concentration of each 
lysate was extrapolated from this curve. 5µl of the lysate sample was added per well of 
a 96 well plate to 25µl of reagent A, followed by the addition of 200µl of reagent B. 
Absorbance was measured after 15 minutes using a Dynex OpSys MRTM microplate 
photometric reader (Dynex, Chantilly, VA) at 630nM. 
 
3.10.2 Gel electrophoresis and immunoblotting 
The lysate volume required for either 20µg or 35µg protein loading was determined for 
each sample. 5:1 mixture of NuPage® LDS 4x sample buffer (NP0007; Invitrogen) and 
2- β mercaptoethanol (Sigma-Aldrich) was prepared. This mixture was combined with 
the lysate and with additional RIPA buffer as appropriate to standardise the volumes of 
the samples. Samples were denatured at 105oC for 5 minutes and transferred to ice for 
5 minutes. The samples were then centrifuged at 8000g for 30 seconds, re-suspended 
and placed on ice. 
  
NuPage® Novex 4-12% Bis-Tris 1.0mm x 10 well gels (NP0321BOX; Life 
Technologies) were used for electrophoresis. Gels were slotted into XCell SureLockTM 
Mini-cell electrophoresis system (Invitrogen, Carlsbad, CA), which was filled with a 1x 
NuPage® MOPS SDS running buffer (NP0001; Invitrogen). Samples were loaded into 
the wells along with a Precision Plus ProteinTM Dual Color Standards (161-0374; Bio-
Rad). Electrophoresis was performed at 180V for 1 hour. Polyvinylidene fluoride 
(PVDF) membrane (88518; Thermo Scientific) was cut to match the size of the gel, and 
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activated in methanol for 30 seconds. This was rinsed for 5 minutes in running water 
thrice and soaked in 1X NuPage® transfer buffer (NP0006-1; Invitrogen). The pre-cast 
gel was removed and placed onto the activated membrane, flanked by Mini Trans-blot 
filter papers (170-3932EDU; Bio-Rad) and sponges soaked in transfer buffer. The 
resulting sandwich was loaded into the XCell II Blot Module (Invitrogen, Carlsbad, CA), 
and slotted into the mini-electrophoresis system filled with the transfer buffer. The outer 
chamber was filled with de-ionised water, and protein transfer was performed at 30V 
for 90 minutes. The PVDF membrane was removed from the system and Ponceau-S 
was used to confirm the success of protein transfer. Blocking of non-specific antibody 
binding was achieved by incubating the membrane with 1% or 5% milk powder solution 
dissolved in TBST for 1 hour. Following a 5 minutes wash with TBST, primary antibody 
incubation was performed for 16 hours at 4oC. This was performed by submerging the 
membrane in a Corning® 50ml centrifuge tube (430828; Corning®) containing the 
primary antibody, which was diluted in 1% milk powder solution dissolved in TBST. 
Three 10 minutes wash in TBST was performed, followed by HRP conjugated polymer 
secondary antibody incubation (Dako, Glostrup, Denmark) at room temperature for 1 
hour at concentration of 1/2000. Following further three 10 minute washes in TBST, 
chemiluminescence detection was performed using the SuperSignal® West Pico Trial 
kit (34079; Thermo Scientific) or the West Femto Trial kit (34094; Thermo Scientific). 
The images were acquired using a Bio-Rad Gel Doc Imaging system and Image LabTM 
software (version 4.0.1).        
 
3.10.3 Antibody optimisation for western blots  
For western blots, the following monoclonal antibodies were used; C219 for Pgp, 
MRPr1 for MRP1, and BXP21 for BCRP. Variables for optimisation were denaturing 
versus non-denaturing protocol, primary antibody concentration, quantity of protein 
loading, and method of blocking (Table 3.5). Antibody optimisation was attempted 
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using UIC2 and QCRL1 monoclonal antibodies for Pgp and MRP1 respectively. This 
proved to be unsuccessful and hence different antibodies to those used for 
immunohistochemistry were used for immunoblotting. The following table describes the 
optimised conditions for immunoblotting, where beta actin was used as a loading 
control. 
 
Antigen Antibody Concentration Denature Protein 
load 
Block 
Pgp C219 (Mouse 
mAb, 517310, 
Calbiochem) 
1/100 overnight No heating 35µg 1% milk 
MRP1 MRPr1 (Rat mAb, 
ab3368, Abcam) 
1/100 overnight No heating 35µg 1% milk 
BCRP BXP21 (Mouse 
mAb, ab3380, 
Abcam) 
1/250 overnight Heating 20µg 1% milk 
Notch1 Anti-activated 
Notch1 antibody 
(Rabbit pAb, 
ab8925, Abcam) 
1/2000 overnight Heating 20µg 5% milk 
Beta actin Anti-β-actin 
antibody (mouse 
mAb, A5441, 
Sigma-Aldrich) 
1/100,000 1 hour Heating 20µg 5% milk 
 
Table 3.5: Conditions for use of antibodies for western blot 
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3.11 DNA extraction 
3.11.1 DNA extraction from cell lines 
Cells were harvested using trypsin (adherent cells) or centrifugation (suspension cells). 
The cells were centrifuged for 10 minutes at 10oC (290g). The supernatant was 
discarded, and the pellet was re-suspended in 10ml of DPBS and washed twice. The 
resulting pellet was re-suspended in 10ml of DNA buffer (see Appendix Section 1) and 
centrifuged for 10 minutes. After removing the supernatant, the pellet was re-
suspended in 3ml of DNA buffer with 125µl of proteinase K (10mg/ml) and 400µl of 
10% SDS. The resulting solution was incubated for 16 hours at 45oC. 3.6ml of phenol, 
chloroform, and isoamyl alcohol was subsequently added and mixed thoroughly by 
vortexing, and the resulting mixture was centrifuged for 10 minutes at 10oC (1811g). 
The supernatant was transferred into a new tube, and 3.6ml of chloroform/isoamyl 
alcohol was added and mixed thoroughly. The resulting mixture was again centrifuged, 
and 3ml of the supernatant was added to 300µl of 3M sodium acetate (pH 5.2) and 9ml 
of 2-propanol to enable DNA precipitation. The resulting precipitate was washed in 
70% ethanol, and the remaining dry precipitate was dissolved in 500µl of nuclease free 
water (P119E; Promega).  
 
3.11.2 DNA extraction from formalin-fixed paraffin-embedded breast tissue 
blocks 
Macrodissection of FFPE tissues were performed to isolate tumour-rich regions with an 
active effort to limit stromal contamination. From the NAET cohort, 46 biopsy tissues 
were available, compared to 51 resection tissues. The tumour-rich regions were 
identified and marked on the stained sections after extensive training from breast 
pathologist EV. Guided by this, macrodissection was performed on adjacent sections of 
10µm thickness using a sterile surgical scalpel blade number 11 (0503; Swann-Morton 
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Ltd). The resulting tissue was collected in 1.5ml microcentrifuge tubes (Eppendorf, 
Hamburg, Germany). For the larger resection tissues, 3 sections of 10µm were 
dissected. For the smaller biopsy tissues, 5 sections of 10µm were dissected. DNA 
extraction was performed using the QIAamp® DNA FFPE tissue kit (56404; Qiagen) 
and the manufacturer’s protocols. In brief, paraffin was removed from material using 
xylene and ethanol. Material was resuspended and digested with Proteinase K and 
then incubated at 90oC in order to reverse the formalin cross-linking partially. The 
resulting DNA was then bound to silica-based membranes, and washed before elution. 
A Nanodrop spectrophotometer (Nanodrop® Technologies) was used to quantify the 
amount of DNA in the resulting solution for the cell line samples as well as the FFPE 
samples (µg/µl). The DNA concentration in the biopsy tissues ranged 6.1 to 139.1 
ng/µl, compared to 9 to 958.1 ng/µl in the resection tissues (Appendix Section 2, Table 
S3). This was in comparison to DNA concentrations of 58.2 ng/µl in H929, 138.1ng/µl 
in MCF7, 193.6ng/µl in HL60, and 392.3ng/µl in HB2 cell lines.  
 
3.12 Bisulphite conversion of extracted DNA 
Bisulphite conversion of the extracted DNA was performed using the Epitect® bisulfite 
kit (59104; Qiagen) and the manufacturer’s protocols. For bisulphite conversion of 
extracted DNA from FFPE tissue, 500ng of DNA was used where there was sufficient 
sample volume (n=71), otherwise the entire sample volume was used for bisulphite 
conversion (n=26). The latter strategy was mainly required for the core tissues (21/26 
cases). There was sufficient sample volume to convert 500ng of DNA extracted from 
cell lines. In brief, DNA solutions containing 500ng of extracted DNA were added to 
“DNA protect” buffer, which prevents DNA fragmentation during the bisulphite 
treatment. The resulting solution was added to the bisulphite mix in ABgene low profile 
PCR tube strips (AB-0776; ThermoScientific). Bisulphite-mediated conversion of 
unmethylated cytosines was carried out using a Bio-Rad PTC-220 DNA engine Dyad™ 
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Peltier thermal cycler. The thermal cycling program outlined below (Table 3.6) 
denatures DNA and facilitates sulfonation and cytosine deamination. 
   
The converted single-stranded DNAs were bound to membranes of EpiTect spin 
columns, were desulfonated on the membranes, and were eluted in 20µl of nuclease 
free water. In the case of DNA from FFPE tissue, carrier RNA was added after the 
thermal cycling incubation in order to enhance binding of DNA to EpiTect spin-column 
membranes. 
 
Step  Time Temperature 
 
Denaturation 1 5 minutes 95
o
C 
Incubation 1  25 minutes  60
o
C 
Denaturation 2 5 minutes 95
o
C 
Incubation 2 85 minutes  60
o
C 
Denaturation 3 5 minutes 95
o
C 
Incubation 3 175 minutes  60
o
C 
Hold Indefinite 20
o
C 
 
Table 3.6: Thermal cycler condition for bisulphite conversion of extracted DNA 
   
3.13 Amplification of target DNA after bisulphite conversion 
Two sets of primers were used targeting specific regions of the BCRP (ABCG2) 
promoter, as described in previous studies in myeloma (Turner et al., 2006) and 
pancreatic cancer cell lines (Chen et al., 2012a). The primers from the former study 
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have been designated as Turner et al and the latter primers designated as Chen et al 
(Table 3.7). 
 
Turner et al ABCG2 forward 5’-GGATAATATTAGGTAAGGTTGAGTAA-3’ 
Turner et al ABCG2 reverse 5’-TCAAAATAACTCCCTCCAAACAAAAC-3’ 
Chen et al ABCG2 forward 5’-AATGAGYGTTTGGTGATTTT-3’ 
Chen et al ABCG2 reverse 5’-ATTTCCCCAAATCRAAATTC-3’ 
        
Table 3.7: Primers for BCRP promoter regions 
 
5µl out of total of 20µl of the bisulphite-modified DNA was added to a mixture (35µl) 
containing 8µl GoTaq flexi buffer (M890A; Promega), 4µl of 10mM dNTPs (U151; 
Promega), 0.5µl each of the 100µM forward and reverse primers (Sigma-Aldrich), 0.5µl 
of GoTaq Hot Start polymerase (M500B; Promega), 2µl of 25M MgCl2 (A351H; 
Promega), and 19.5µl of nuclease free water. The following thermal cycling program 
was used for amplification (Table 3.8). Gradient PCR was performed for each set of 
primers to determine optimal annealing temperature (54.7oC to 61.4oC) for PCR: 56oC 
for the Turner et al primer and 55oC for the Chen et al primer (Appendix Section 3, Figs 
S5 and S6). These conditions were used for subsequent PCR on all cell lines which 
confirmed the optimal conditions (Appendix Section 3, Fig S7). 
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1 Denaturation 95
o
C 3 minutes 
2 Denaturation 95
o
C 30 seconds 
3 Annealing  56
o
C for the Turner et al primer and 
55
o
C for the Chen et al primer  
30 seconds 
4 Extension 72
o
C 30 seconds 
5 Repeat Step 2 to 4 were repeated 34 times  
6 Extension 72
o
C 45 seconds 
7 Hold 10
o
C Indefinitely 
 
Table 3.8: PCR thermal cycler conditions used to amplify BCRP promoter region 
sequences 
 
10µl of the PCR product was subsequently analysed by gel electrophoresis to confirm 
the amplification of the correct sized product. 1% agarose / TAE gels, containing 
ethidium bromide, were cast in gel trays containing 20 well combs and allowed to set at 
room temperature (30 min). Gels were submerged in an electrophoresis system (Sub-
cell GT cell®; Bio-Rad) filled with TAE buffer. Each sample was mixed with 6x Loading 
Dye (#R 0611; Fermentas), and loaded into the wells. The first well was reserved for 
the DNA ladder (#SM1331; Fermentas), which contains markers ranging from 75 to 
20,000 base pairs. DNA was visualised using the Bio-Rad Gel Doc Imaging system, 
and Image LabTM software.                                                                                                                                 
 
3.14 Molecular cloning and sequence analysis of promoter products 
The remaining 30µl of the PCR product was separated from residual primers by gel 
electrophoresis and purified from the gel using a Zymoclean™ gel DNA recovery kit 
and the manufacturer’s protocol (D4001; Zymo Research). Gel electrophoresis was 
performed as stated in the previous section with the exception of using 10µl of 
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GelGreenTM nucleic acid gel stain (41005; Biotium) instead of ethidium bromide. 
Minimal ultraviolet light exposure enabled visualisation of the DNA fragments, which 
were excised from gel with sterile surgical scalpel blades and transferred into 1.5ml 
microcentrifuge tubes. Agarose dissolving buffer was used to ensure full dissolution of 
the gel. The resulting solutions were placed into spin columns to enable DNA binding to 
membrane, and elution of the purified DNA was achieved after washing with 70% 
ethanol. The resulting DNA was used for both direct Sanger sequencing and molecular 
cloning followed by sequencing. The resulting sequences were aligned to a reference 
bisulphite-converted sequence (Fig 3.3).   
 
5’AATGAGCGTTTGGTGATTTTCGTAGTTAATTATTTTGGTTTATTTCGTTCGATTTC
GGAGGCGGGAGTGTTTGGTTTGTTTTTGCGTGTTACGGTAGGGTGATTTTAGTTT
CGAGGGAGGGCGGTGGTATTAGTTTTGTTGGCGGTTTAGCGCGGTAGGATACGT
GTGCGTTTTTAGTCGGGTCGTAGGGCGTTTATCGCGGTTCGGTAGTCGGGGTTAC
GTTTTATTTTCGTTCGCGAATTTCGATTTGGGGAAAT3’ 
 
Figure 3.3: Bisulphite-converted reference sequence for the Chen et al amplicon. The 
resulting amplicon contains 257 base pairs and 27 CpG sites which are highlighted in 
green, assuming all CpG sites are methylated. The primer sequences are underlined.  
 
Molecular cloning was performed using the TA Cloning® kit with pCR™2.1 vector 
(K2020-40; Invitrogen) and the manufacturer’s protocol. Ligation reactions consisted of 
PCR product (sufficient to achieve 1:1 vector:insert ratio), ligation buffer, pCR™2.1 
vector, and DNA ligase in a total volume of 10µl and were incubated at 14oC for 16 
hours. MAX Efficiency® DH10B™ competent E. Coli cells (18297-010; Invitrogen) were 
transformed by the addition of ligated DNA, heat shocking the cells for 45 seconds at 
43oC, and subsequent addition of the S.O.C. medium. The resulting mixture was 
incubated at 37oC for 1 hour and spread onto the Lysogeny Broth (LB) agar plates 
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containing ampicillin for 16 hour incubation at 37oC. Colonies were screened by colony 
PCR. M13 forward (5´-GTAAAACGACGGCCAG-3´) and reverse (5´-
CAGGAAACAGCTATGAC-3´) primers were used to enable amplification of insert. 20µl 
reactions contained 4µl of GoTaq flexi buffer, 2µl of 10mM dNTPs, 0.25µl of the 
forward and reverse 100µM M13 primer, 0.25µl of GoTaq Hot Start polymerase, 1µl of 
25M MgCl2, and 9.75µl of nuclease free water. Each colony was harvested using a fine 
pipette tip, dipped into the PCR reaction, and subsequently dipped into a 15ml 
centrifuge tube (430790; Corning®) containing 5ml of ampicillin-treated LB solution. 
The following thermal cycling program was used for colony PCR (Table 3.9). 
 
1 Denaturation 98oC 3 minutes 
2 Denaturation 94oC 30 seconds 
3 Annealing  60oC 30 seconds 
4 Extension 72oC 30 seconds 
5 Repeat Step 2 to 4 were repeated 29 
times 
 
6 Extension 72oC 10 minutes 
7 Hold 10oC Indefinitely 
 
Table 3.9: Thermal cycler conditions used for colony PCR 
 
Gel electrophoresis was performed as stated in section 3.13. The PCR products were 
visualised, and colonies selected that showed product sizes representative of plasmids 
containing an appropriate plasmid insert (Appendix Section 3, Figs S8 to S11). The 5ml 
cultures of these specific colonies were incubated at 37oC for 16 hours in a shaker. 
Minipreps were performed using the Qiagen plasmid buffer set. Bacterial cultures were 
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centrifuged and the supernatant discarded. Bacteria were re-suspended in P1 re-
suspension buffer (1047015; Qiagen) and lysed by the addition of P2 lysis buffer 
(1014935; Qiagen). Cell debris was precipitated by addition of P3 neutralisation buffer 
(1014958; Qiagen). The resulting mixture was centrifuged, and the DNA in the 
supernatant was precipitated by addition of propan-2-ol. The DNA was pelleted and the 
pellet washed in 70% ethanol and then re-suspended in 50µl of nuclease free water. 
The resulting DNA was diluted to 500ng/µl for Sanger sequencing (Source BioScience 
plc, Nottingham, United Kingdom). The resulting sequences from individual clones 
were successfully aligned to the reference sequence using ApE software (v2.0.32; 
copyright © 2003-2009 by M. Wayne Davis). Methylation analysis was performed using 
CpGviewer software (http://dna.leeds.ac.uk/cpgviewer/) (Carr et al., 2007) designed by 
Dr Ian Carr (Leeds Institutes of Molecular Medicine, University of Leeds) and checked 
manually. 
 
3.15 Pyrosequencing  
In pyrosequencing (Doyle et al., 2011), nucleotide incorporation during the synthesis of 
a complementary strand results in the release of pyrophosphate, which subsequently 
generates ATP. This provides the energy for the luciferase-mediated conversion of 
luciferin to oxyluciferin. This chemical reaction generates visible light, where the degree 
of luminescence is proportional to the number of incorporated nucleotides. The four 
nucleotides are added sequentially to enable base calling and provides quantitative 
analysis of each CpG sites. Pyrosequencing can perform direct sequencing of 
bisulphite-modified DNA and examine multiple CpG sites. Hence, it is ideal for 
examining methylation status of clinical samples and has been used extensively using 
FFPE tissues (van Bemmel et al., 2012, Christians et al., 2012, Tuononen et al., 2012, 
Baba et al., 2010). PyroMark CpG assay was used to examine 5 CpG sites (Fig 3.4) 
within the Chen et al amplicon (PM00111321; Hs_ABCG2_01_PM PyroMark CPG 
78 
 
assay, Qiagen). This assay was performed by Dr Philip Chambers (Leeds Cancer 
Research UK Centre, Genomics Facility) to determine if pyrosequencing analysis 
mirrored the methylation analysis from the cloned sequences.  
 
5’AATGAGCGTTTGGTGATTTTCGTAGTTAATTATTTTGGTTTATTTCGTTCGATTTC
GGAGGCGGGAGTGTTTGGTTTGTTTTTGCGTGTTACGGTAGGGTGATTTTAGTTT
CGAGGGAGGGCGGTGGTATTAGTTTTGTTGGCGGTTTAGCGCGGTAGGATACGT
GTGCGTTTTTAGTCGGGTCGTAGGGCGTTTATCGCGGTTCGGTAGTCGGGGTTAC
GTTTTATTTTCGTTCGCGAATTTCGATTTGGGGAAAT3’ 
 
Figure 3.4: Bisulphite-converted reference sequence for the Chen et al amplicon 
highlighting the sites examined for pyrosequencing. The resulting amplicon contains 
257 base pairs and 27 CpG sites which are highlighted in green, assuming all CpG 
sites are methylated. The primer sequences are underlined. The five CpG sites 
examined by pyrosequencing are highlighted in red. 
 
This approach resulted in successful methylation analysis for the cell line samples 
which mirrored the cloned sequences, but not for the FFPE samples (Appendix Section 
3, Figs S12 and S13), perhaps reflecting the amplicon size of 228 base pairs. 
Therefore, alternative primer sets were designed using PyroMark Assay Design SW 
2.0 (Qiagen) by Dr Philip Chambers (Leeds Cancer Research UK Centre, Genomics 
Facility) (Fig 3.5) with an aim to design primers with an amplicon size of less than 150 
base pairs (Patterson et al., 2011). This resulted in 2 assays which examined 2 CpG 
sites each. The designed assays resulted in amplicons of 62 and 144 base pairs. 
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Figure 3.5: Two sets of primers designed for pyrosequencing assay. The 257 base 
pair sequence is the amplicon of the Chen et al primers. The CpG sites are highlighted 
in green. The 5 CpG sites previously examined using the PyroMark assay is 
highlighted in red. Two sets of primers were designed to amplify a 62 (top row of 
sequences) and 144 (bottom row of sequences) base pair products analysing two CpG 
sites each (highlighted in bold and double underlined). The 4 CpG sites have been 
labelled as position 165 and 172 on the top row of sequences, and as position 236 and 
250 on the bottom row of sequences. The cloned sequences were examined to ensure 
that 4 CpG sites selected were representative of the whole region. 
 
3.16 Statistical analysis 
Statistical analyses were performed using SPSS v16.0 (SPSS, Chicago, USA), 
GraphPad Prism v6.0 (GraphPad, California, USA), and MedCalc v12.4.0 (MedCalc 
software, Ostend, Belgium).  
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4.0. Neoadjuvant chemotherapy induces expression levels of 
Breast Cancer Resistance Protein that predict disease-free 
survival in breast cancer 
 
4.1. Abstract 
My aim in this chapter was to investigate tumour expression of Pgp, MRP1, and BCRP 
before and after neoadjuvant chemotherapy (NAC) to determine whether levels define 
response to NAC or subsequent survival. The NAC regime consisted of anthracyclines 
with or without taxanes. Paraffin embedded tissue was collected representing matched 
pairs of core biopsy (pre-NAC) and resection specimens (post-NAC) from 45 patients 
with invasive ductal carcinomas, and expression of the three markers was examined 
using immunohistochemistry. A computer-aided scoring protocol was developed and 
validated against 2 independent observers (intra-class correlation coefficients 0.83 and 
0.82). Pgp and MRP1 expressions were significantly up-regulated after exposure to 
NAC (p=0.0024 and p<0.0001; Wilcoxon signed-rank test). BCRP expression showed 
more variation in response: cases showed either down- (41%) or up-regulation (59%) 
after NAC, but no overall significant difference was observed. Pre- or post-NAC 
expression of Pgp, MRP1 or BCRP did not correlate with clinical (MRI-determined) 
response to NAC. Pre-NAC expression of all three markers, and post-NAC expression 
of Pgp and MRP1 did not correlate with disease free survival. However, high post-NAC 
BCRP expression independently predicted for poorer disease free survival (hazard 
ratio of 4.04; 95% confidence interval 1.3-12.2; p=0.013). Therefore, NAC-induced 
BCRP expression has potential value in predicting survival in breast cancer patients 
treated with NAC, whilst Pgp and MRP1 expressions have little predictive value.   
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4.2. Introduction 
Given the known function of the xenobiotic transporters, it is reasonable to expect that 
high expression of them within tumour cells may contribute to relative chemotherapy 
resistance, which may be reflected in poor responses to therapy. In the context of NAC, 
both pre- and post-NAC expression levels can be assessed, as tissue from both pre-
treatment biopsies and post-treatment resections would potentially be available. Either 
of these measures, or the change in expression levels during treatment, may be 
informative in terms of predicting response to treatment or subsequent survival. Given 
the overlap in substrate specificities of the xenobiotic transporters, analyses of the 
relative expressions of multiple xenobiotic transporters is likely to be more informative 
than individual analyses. In this study, I aimed to determine whether Pgp, MRP1, or 
BCRP expression pre-NAC or post-NAC has a predictive role, whether their expression 
is altered by NAC, and whether any change in expression during treatment has clinical 
relevance. Together, these proteins can efflux more than 80% of chemotherapeutic 
agents that are currently in use (Kuo, 2007). 
 
Only six studies, involving a total of 176 patients, have utilised tissues from patients 
treated with NAC to study the relevance of xenobiotic transporter protein expression in 
breast cancer (Leonessa and Clarke, 2003). However, most of these 
immunohistochemistry studies have focused on Pgp expression only, and examined 
whether Pgp expression is induced by NAC. Combined analyses of these studies show 
that Pgp expression was detected pre-NAC by immunohistochemistry in 42.9% of 
patients, compared to 63.9% post-NAC, suggesting an NAC-dependent increase in 
expression. For example, 36.8% of the cases where Pgp expression was initially 
negative were positive following NAC (Leonessa and Clarke, 2003). This suggests that 
Pgp could potentially contribute to acquired chemotherapy resistance. Since then, 
further studies have examined combined expression of xenobiotic transporters in 
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breast cancer patients treated with NAC. A notable study by Rudas et al showed that 
Pgp and MRP1 expression were both significantly up-regulated after exposure to NAC 
(Rudas et al., 2003), and the absence of pre-NAC MRP1 expression predicted for 
longer DFS. However, the cohort used for this study was heterogeneous, including 
both patients with ductal carcinomas and those with lobular carcinomas. This is 
important since published data suggest that lobular carcinomas respond poorly to NAC, 
and that the breast conserving surgery rate in this group is not increased after NAC 
(Boughey et al., 2009), therefore the results in Rudas et al may combine differential 
responses in the ductal and lobular groups. Tanei et al found BCRP expression, but not 
Pgp expression, was up-regulated after exposure to NAC (Tanei et al., 2011). No 
correlation to clinicopathological parameters were detected for Pgp or BCRP 
expression. The NAC regimes in the Tanei et al study involved 12 cycles of paclitaxel, 
followed by 4 cycles of fluouracil, epirubicin, and cyclophosphamide and therefore 
comparisons to typical current NAC regimen of 6 cycles only are difficult. No previous 
studies have examined Pgp, MRP1, and BCRP together in breast cancer patients 
treated with NAC. More importantly, previous studies were not designed to limit tumour 
heterogeneity in terms of cohort selection.  
 
Breast cancer recurrences are typically distant metastases and it is these that are 
responsible for subsequent cancer-related deaths (Redig and McAllister, 2013). If 
expression levels of xenobiotic transporters within the primary tumour reflect survival, it 
can be assumed that this is because these levels also reflect the levels in metastatic 
deposits. Occult distant metastatic cells are not available to test this assumption, since 
metastases are by definition sub-clinical in these patients with primary cancers, and 
even in patients with metastatic recurrences samples are typically not available since 
distant metastases of breast cancers are seldom biopsied or resected. However, the 
resected axillary lymph nodes at the time of surgery can potentially be examined, which 
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may reflect the xenobiotic transporter expression in metastatic deposits. This approach 
has been used previously to examine Pgp and MRP1 expression, but not BCRP 
expression, in the axillary lymph nodes of breast cancer patients (Zochbauer-Muller et 
al., 2001). Pgp and MRP1 expression was determined by immunohistochemistry using 
a cohort of 32 patients. The authors determined that Pgp expression was lower in the 
lymph nodes compared to the corresponding primary tumours, but MRP1 expression 
was higher in the lymph nodes compared to the corresponding primary tumours. 
However, patients were not treated with NAC. Lymph node tissue sampling pre-NAC is 
frequently performed by fine needle aspiration yielding cytological material rather than 
the histopathological material available after core biopsies or surgical resections. As a 
result, no lymph node tissue samples were available for analysis pre-NAC. This study 
will examine whether xenobiotic transporter expression in the lymph nodes post-NAC 
reflect the equivalent expression in the matching primary tumour sample post-NAC.  
 
4.3 Results 
 
4.3.1 Expression of Pgp and MRP1 were significantly up-regulated after NAC, but 
BCRP expression responded more variably 
I aimed to determine expression levels of Pgp, MRP1, and BCRP both pre- and post-
treatment in the tumours of a cohort of breast cancer patients treated with NAC. A 
cohort of 39 patients was assembled who had matching pre-NAC core biopsy tissues 
and post-NAC resection tissues, and a further 6 patients with pre-NAC core biopsy 
tissues but no matched post-NAC tumour material as these individuals had complete 
pathological responses (Table 3.1). Protein expression was determined using 
immunohistochemistry and quantified using semi-automated histoscores. As described 
in the methods (Section 3.6), quantification of expression was initially performed 
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manually, and then digitally using the validated semi-automated scoring protocol. This 
enabled determination of protein expression for the 45 core tissues and 39 matched 
resections for Pgp, MRP1, and BCRP (full data set: Table S4). The three proteins 
mainly displayed cytoplasmic/membrane staining pattern that was specific to epithelial 
cells, with some accentuation of cell nuclei. Representative staining patterns are 
illustrated in Figure 4.1 and quantified staining levels are shown in Figure 4.2.  
 
 
 
Figure 4.1a: Representative immunohistochemistry images for Pgp and MRP1 (x20 
magnification) in matched pre-NAC (left) and post-NAC (right) breast cancer samples. 
In both cases, very little/no staining is visible in the core tissues (pre-NAC), as opposed 
to positive staining in the resection tissues (post-NAC). These images represent the 
significant up-regulation in Pgp and MRP1 expression after exposure to NAC (Kim et 
al., 2013).  
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                   Pre-NAC       Post-NAC               
Figure 4.1b: Representative immunohistochemistry images for BCRP (x20 
magnification) in matched pre-NAC (left) and post-NAC (right) breast cancer samples 
from two individuals (top and bottom). Different individuals showed weak (top) or strong 
(bottom) staining pre-NAC. The top image shows up-regulation in BCRP expression 
post-NAC, whereas the bottom image shows down-regulation in BCRP expression 
(Kim et al., 2013). 
 
Pre-NAC expression was variable for Pgp (histoscores range: <0.1-161.7) and BCRP 
(histoscores range: 0.2-143.5), compared to MRP1 expression, which was very low in 
almost all core biopsy samples (histoscores range: <0.1-35.4). Post-NAC expression 
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was variable for all three proteins; Pgp (histoscores range: 0.2-171.4), MRP1 
(histoscores range: 0.2-202.9), and BCRP (histoscores range: 4.3-161.3).  
Pgp and MRP1 expressions were frequently up-regulated post-NAC (Figures 4.1a and 
4.2a), but changes in BCRP expression were more variable (Figures 4.1b and 4.2a), 
showing frequent up-regulation or down-regulation. Up-regulation was observed in 
29/39 cases for Pgp (74%), 36/39 cases for MRP1 (92%), and 23/39 cases for BCRP 
(59%) (Figure 4.2a). Significant up-regulation was observed for Pgp and MRP1 
(Wilcoxon signed-rank tests: Pgp, p=0.0024; MRP1, p<0.0001) (Figure 4.2b). The up-
regulation seen in for MRP1 was particularly striking, with very low expression seen in 
the core tissues in almost all the cases. However, a significant up- or down-regulation 
was not observed for BCRP (Fig 4.2b).  
 
  
Figure 4.2a: Pgp and MRP1 were up-regulated whilst BCRP responded variably (red: 
up-regulation, blue: down-regulation). Matched pre-NAC and post-NAC breast cancer 
samples were stained using immunohistochemistry for Pgp, MRP1 and BCRP. 
Expression within tumour cells was quantified as histoscores of 0 – 300. Expression 
levels in matched samples are linked by lines coloured red or blue so as to indicate an 
increase or decrease in expression respectively.  
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Figure 4.2b: Pgp and MRP1, but not BCRP, were significantly up-regulated by NAC. 
Pre- and post-NAC expressions of Pgp, MRP1, and BCRP are shown as median 
histoscore values with interquartile range; n=39 (pre-NAC samples lacking matched 
post-NAC samples were excluded). Statistically significant up-regulation was observed 
for Pgp and MRP1 (p=0.0024 and p<0.0001 respectively; Wilcoxon signed-rank tests). 
No statistically significant up-regulation was observed for BCRP (p=0.18; Wilcoxon 
signed-rank test).   
 
4.3.2 Post-NAC expression of Pgp, MRP1, and BCRP in the axillary lymph nodes 
reflects expression of the primary tumours post-NAC 
If post-NAC expression levels of these transporters in the primary tumours were to be 
of relevance for cancer outcomes in terms of likelihood of metastatic recurrences and 
therefore disease-specific survival, this would suggest that primary tumour expression 
could be representative of expression in metastatic cells. In order to test this 
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hypothesis, I aimed to compare the expression of Pgp, MRP1, and BCRP in tumour 
cells in the axillary lymph nodes, when available, to the corresponding primary breast 
cancer tissue expression post-NAC. 13 lymph node blocks were identified, and 
immunohistochemistry was performed for the three proteins using same experimental 
conditions as for the primary breast cancer tissues. As previously, the semi-automated 
scoring protocol was used to quantify expression. Representative staining patterns are 
shown in Figure 4.3, demonstrating epithelial-specific staining pattern that is mainly 
cytoplasmic/membraneous. 
 
       Pgp   MRP1                      BCRP 
   
 
Figure 4.3: Pgp, MRP1, and BCRP expression in axillary lymph nodes. Post-NAC 
axillary lymph node tissues were stained using the same immunohistochemistry 
protocol as per primary tumour. The images show positive staining in tumour cells with 
weak or no staining in the surrounding stroma.   
 
Post-NAC expression in the axillary lymph nodes for the 13 patients were highly 
variable for Pgp (histoscores range: 21.6-108.7), MRP1 (histoscores range: 0.5-167.1), 
and BCRP (histoscores range: 3.6-105.7). This variability was similar to that seen in 
post-NAC in the primary tumours of the same 13 patients; Pgp (histoscores range: 
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10.1-168.7), MRP1 (histoscores range: 0.9-197.5), and BCRP (histoscores range: 4.3-
119.9). There were no statistically significant differences between the lymph node 
expression and the primary tumour expression post-NAC (Fig 4.4) (Mann-Whitney test: 
Pgp, p=0.57; MRP1, p=0.75; BCRP, p=0.26). This suggests that post-NAC primary 
tumour xenobiotic transporter expression is potentially reflective of that in metastatic 
deposits. However, no statistically significant correlation was found when post-NAC 
primary tumour expressions were compared to the matching lymph node expressions 
for Pgp, MRP1, and BCRP using Spearman’s rho analyses (Fig 4.5; Pgp, rho=0.007, 
p=0.99; MRP1, rho=0.13, p=0.68; BCRP, rho=0, p>0.99). 
 
P g p  (p = 0 .5 7 )
P o s t A x i l la
0
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1 0 0
 
M R P 1   (p = 0 .7 5 )
P o s t A x i l la
0
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1 0 0
P o s t A x i l la
0
5 0
1 0 0
B C R P  (p = 0 .2 6 )
 
Figure 4.4: Comparison of xenobiotic transporter expression in the axillary lymph 
nodes and the corresponding primary tumour post-NAC (median histoscore values with 
interquartile range). There were no statistically significant differences between the 
lymph node expression and the primary tumour expression post-NAC (Mann-Whitney 
test: Pgp, p=0.57; MRP1, p=0.75; BCRP, p=0.26).  
90 
 
0 5 0 1 0 0 1 5 0 2 0 0
0
5 0
1 0 0
1 5 0
2 0 0
P g p  (rh o = 0 .0 0 7 ;  p = 0 .9 9 )
P o s t
A
x
i
l
l
a
 
0 5 0 1 0 0 1 5 0 2 0 0
0
5 0
1 0 0
1 5 0
2 0 0
M R P 1  (rh o = 0 .1 3 ;  p = 0 .6 8 )
P o s t
A
x
i
l
l
a
0 5 0 1 0 0 1 5 0 2 0 0
0
5 0
1 0 0
1 5 0
2 0 0
B C R P  (rh o = 0 ;  p > 0 .9 9 )
P o s t
A
x
i
l
l
a
 
Figure 4.5: Correlation of post-NAC lymph node expression with corresponding post-
NAC primary tumour expression. Protein expressions quantified by histoscores are 
shown on the y (post-NAC axilla) and x axis (matched post-NAC primary tumour) for 
Pgp, MRP1, and BCRP. No significant correlations were seen, which also remained the 
case when all three markers were examined together. 
 
4.3.3 Analyses of correlations between expression of Pgp, MRP1, and BCRP  
Next, I wished to examine whether expression levels of Pgp, MRP1 or BCRP either 
pre- or post-NAC, or the changes in expression of these markers between pre- and 
post-NAC, were related to each other. This would potentially reveal evidence of co-
regulation of these transporters. To compare the change in protein expression after 
exposure to NAC, pre-NAC expression was subtracted from matching post-NAC 
expression and positive values were assigned as up-regulation, whereas negative 
values were assigned as down-regulation.  
 
I analysed these relationships using Spearman’s rho analyses (Table 4.1). The pre- 
and post-NAC levels showed some significant correlations to the changes in 
expression levels of the same proteins, as would be expected since these values are 
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directly related. In addition, for Pgp the post-NAC level positively correlated with the 
pre-NAC level, suggesting that post-NAC expression depends to some extent on the 
initial level. The changes in expression levels of the proteins were not related to each 
other, providing no evidence of co-regulation or mutually exclusive induction. 
Interestingly a significant and moderately strong negative correlation was seen 
between the pre-NAC Pgp expression and the change in BCRP expression (rho 
coefficient -0.5; p=0.01), as well as the post-NAC BCRP expression (rho coefficient -
0.34; p=0.03).  
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 Pgp pre 
n=45 
Pgp post  
n=39 
Pgp 
∆ 
n=39 
MRP1 
pre  
n=45 
MRP1 
post  
n=39 
MRP1 
∆ 
n=39 
BCRP 
pre 
n=45 
BCRP 
post  
n=39 
BCRP 
∆ 
n=39 
Pgp pre 
n=45 
-         
Pgp 
post 
n=39 
0.44 
(0.005) 
-        
Pgp 
 ∆ 
n=39 
-0.15 
(0.36) 
0.75 
(<0.01) 
-       
MRP1 
pre 
n=45 
0.09 
(0.56) 
0.07 
(0.67) 
0.11 
(0.5) 
-      
MRP1 
post 
n=39 
-0.11 
(0.51) 
-0.29 
(0.078) 
-0.15 
(0.37) 
-0.2 
(0.23) 
-     
MRP1 
∆ 
n=39 
-0.12 
(0.47) 
-0.28 
(0.079) 
-0.28 
(0.08) 
-0.25 
(0.13) 
0.99 
(<0.01) 
-    
BCRP 
pre 
n=45 
0.27 
(0.071) 
0.07 
(0.69) 
-0.13 
(0.43) 
0.24 
(0.11) 
-0.03 
(0.88) 
-0.05 
(0.78) 
-   
BCRP 
post 
n=39 
-0.34 
(0.032) 
-0.16 
(0.35) 
0.05 
(0.75) 
-0.17 
(0.29) 
0.14 
(0.40) 
0.14 
(0.39) 
-0.12 
(0.46) 
-  
BCRP 
∆ 
n=39 
-0.5 
(0.01) 
-0.15 
(0.37) 
0.16 
(0.32) 
-0.15 
(0.36) 
0.12 
(0.48) 
0.13 
(0.42) 
-0.77 
(<0.01) 
0.63 
(<0.01) 
- 
 
Table 4.1: Spearman’s correlation coefficients demonstrating relationships between 
expression pre-NAC or post-NAC, or change in expression (∆) for Pgp, MRP1 and 
BCRP (p values are denoted in brackets). 
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4.3.4 Do pre-NAC Pgp, MRP1, and BCRP expression levels predict complete 
pathological response? 
Next, I examined whether pre-NAC expression levels predicted whether patients would 
achieve pCR. There were 6 patients with pCRs leaving 39 in the non-pCR group. There 
were no significant differences in the MRP1 and BCRP expression levels between the 
pCR group versus the non-pCR group (pCR vs non-pCR, MRP1: medians 0.1 vs 0.4, 
p=0.4; BCRP: medians 6.35 vs 19.5, p=0.43). However, for Pgp, the expression level in 
the pCR group (median score 45.7) was significantly higher compared to the non-pCR 
group (median score 8.3, Mann-Whitney U test: p=0.013) (see discussion below for 
comments on this surprising finding). 
 
4.3.5 Correlation of xenobiotic transporter expression with clinico-pathological 
parameters 
My next aim was to analyse potential correlations between pre- and post-NAC 
xenobiotic transporter expression levels as well as the change in expression levels, 
and the clinico-pathological parameters (outlined in Table 3.1) using Spearman’s rho 
analyses (Table 4.2). Due to the large number of parameters being tested, a more strict 
threshold of p<0.01 was used to indicate statistical significance (Cleophas and 
Zwinderman, 2006). This is a more pragmatic approach to reduce the risk of type I 
error, which is the risk of parameters achieving significance of commonly stated p value 
of less than 0.05 by chance due to the large number of parameters being tested. This 
approach of using a lower p value has been adopted in a number of studies (Kim et al., 
2013, Morenos et al., 2014). An alternative approach would have been to adopt 
Bonferroni correction, which has potential limitations. For example, it is a stringent test 
with a conservative approach which has potential to overcorrect for type I error and 
thereby potentially lead to type II error (Pocock, 1997).  
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No significant correlations were observed for MRP1 and BCRP expression against the 
clinico-pathological parameters. Similar findings were observed for post-NAC Pgp 
expression, as well as the change in Pgp expression. However, a positive and weakly 
strong correlation between the pre-NAC Pgp expression and patient age (rho 
coefficient 0.41; p=0.005) was detected. Correlation coefficient values of 0.2, 0.5, and 
0.8 were defined as cut-off values for categorising the strength of correlation as weak, 
moderate, and strong respectively (Zou et al., 2003).  
 
 Pgp 
pre 
 
Pgp 
post  
Pgp 
∆  
 
MRP1 
pre  
MRP1 
post  
MRP1 
∆  
 
BCRP 
pre  
BCRP 
post  
BCRP 
∆  
 
Age at diagnosis 0.41 
(0.005) 
0.31 
(0.057) 
0.04 
(0.81) 
0.1 
(0.5) 
-0.13 
(0.45) 
-0.13 
(0.44) 
0.08 
(0.62) 
-0.18 
(0.25) 
-0.33 
(0.04) 
          
Tumour factors 
determined pre-
NAC: 
         
Grade 0.19 
(0.21) 
-0.16 
(0.33) 
-0.3 
(0.06) 
0.16 
(0.28) 
-0.02 
(0.91) 
0.01 
(0.95) 
-0.09 
(0.54) 
0.04 
(0.81) 
0.04 
(0.82) 
T Stage 0.06 
   (0.69) 
-0.09 
(0.57) 
-0.13 
(0.42) 
-0.14 
(0.36) 
0.29 
(0.07) 
0.27 
(0.1) 
-0.26 
(0.08) 
-0.16 
(0.34) 
0.04 
(0.82) 
ER status -0.08 
(0.6) 
-0.17 
(0.29) 
-0.12 
(0.48) 
0.24 
(0.11) 
0.13 
(0.43) 
0.11 
(0.5) 
0.18 
(0.23) 
-0.07 
(0.7) 
-0.06 
(0.74) 
Her2 status -0.03 
(0.85) 
0.21 
(0.19) 
0.33 
(0.04) 
-0.18 
(0.23) 
0.01 
(0.97) 
0.01 
(0.94) 
0.01 
(0.96) 
-0.02 
(0.91) 
0.03 
(0.86) 
          
Tumour factors 
determined post-
NAC: 
         
T stage -0.36 
(0.017) 
-0.15 
(0.38) 
0.04 
(0.83) 
0.22 
(0.15) 
0.14 
(0.39) 
0.1 
(0.55) 
0.14 
(0.38) 
0.05 
(0.79) 
0.05 
(0.78) 
Lymphovascular 
invasion 
-0.35 
(0.41) 
-0.1 
(0.53) 
0.04 
(0.8) 
0.04 
(0.79) 
0.23 
(0.15) 
0.24 
(0.14) 
0.17 
(0.26) 
-0.38 
(0.02) 
-0.23 
(0.16) 
Axillary 
metastasis 
-0.07 
(0.66) 
0.19 
(0.24) 
0.3 
(0.07) 
0.38 
(0.011) 
-0.1 
(0.53) 
-0.11 
(0.49) 
0.36 
(0.02) 
-0.08 
(0.62) 
-0.26 
(0.11) 
 
Table 4.2: Spearman’s correlation coefficients demonstrating relationships between 
expression pre-NAC or post-NAC, or change in expression (∆) for Pgp, MRP1 and 
BCRP with clinico-pathological parameters (p values are denoted in brackets). 
 
Expression levels and the change in expression levels were then examined against the 
response to NAC. The latter was defined in three separate ways: the change in tumour 
stage after NAC (TNM staging; see Section 1.2), qualitative response as assessed by 
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MRI scan, and as a quantitative change in tumour size derived from comparison of 
resection pathology to pre-NAC MRI scans (Table 4.3). No significant correlations were 
observed at the threshold of p<0.01.  
 
 Pgp 
pre 
 
Pgp 
post  
Pgp 
∆  
 
MRP1 
pre  
MRP1 
post  
MRP
1 ∆  
 
BCR
P 
pre  
BCR
P 
post  
BCRP 
∆  
 
∆ T 
stage 
-0.25 
(0.1) 
-0.08 
(0.63) 
0.11 
(0.52) 
0.19 
(0.22) 
0.09 
(0.57) 
0.06 
(0.72) 
0.1 
(0.53) 
0.15 
(0.38) 
0.07 
(0.69) 
MRI 
response 
0.2 
(0.19) 
0.07 
(0.69) 
0.004 
(0.98) 
-0.28 
(0.06) 
0.04 
(0.8) 
0.08 
(0.62) 
0.03 
(0.85) 
-0.09 
(0.61) 
-0.2 
(0.23) 
∆ in 
tumour 
size  
-0.25 
(0.1) 
-0.16 
(0.34) 
-0.02 
(0.92) 
-0.003 
(0.98) 
0.15 
(0.37) 
0.16 
(0.32) 
0.17 
(0.28) 
0.37 
(0.02) 
0.21 
(0.21) 
 
 
Table 4.3: Spearman’s correlation coefficients demonstrating relationships between 
expression pre-NAC or post-NAC, or change in expression (∆) for Pgp, MRP1 and 
BCRP with tumour response (p values are denoted in brackets). 
 
4.3.6 Disease free survival analysis of xenobiotic transporter expression 
Next, expression levels and change in expression levels of the transporters were 
analysed for correlations with disease free survival (DFS), defined as survival post-
surgery, using Kaplan-Meier survival analyses. Receiver Operating Characteristic 
(ROC) curve analysis was performed to dichotomise expression into high and low 
groups for both pre- and post-NAC levels. This was performed by comparing the 
presence or absence of disease recurrence against protein expression as quantified by 
histoscores. This generated a ROC curve with sensitivity value on the y-axis and one 
minus specificity value on the x-axis for each histoscore value. From this curve, the cut-
off providing the highest combined sensitivity and specificity for prediction of DFS was 
selected (Fig 4.6). For the change in expression, we dichotomised into groups with up-
regulation after NAC or with down-regulation.  
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Figure 4.6: ROC curve analysis for Pgp, MRP1, and BCRP; for pre-NAC histoscores, 
the respective cut-offs were 55 for Pgp, 4 for MRP1, and 1 for BCRP. For post-NAC 
histoscores, the respective cut-offs were 90 for Pgp, 21 for MRP1, and 47 for BCRP. 
 
There was no significant relationship between the DFS and the pre-NAC expression 
levels for any of the three transporters (Fig 4.7). Similarly, no significant relationship 
was observed between DFS and the change in expression levels (Fig 4.8). It is worth 
noting that down-regulation was a rare event for MRP1, occurring in only three patients 
none of whom suffered from recurrences, therefore this particular analysis is limited by 
the small numbers in this group.  
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Figure 4.7: Kaplan-Meier survival analyses for pre-NAC xenobiotic transporter 
expression versus disease free survival. 
 
 
Figure 4.8: Kaplan-Meier survival analyses for the change in xenobiotic transporter 
expression versus disease free survival. 
 
For post-NAC Pgp and MRP1 expression levels, no significant relationship was seen 
for DFS (Fig 4.9). For BCRP however, post-NAC expression was significantly 
correlated with DFS (Log rank: p=0.007). Patients with high BCRP expression had 5-
year survival of 40%, compared to 80% for those with low BCRP expression (Fig 4.9). 
Multivariate Cox regression analysis was performed taking into account post-NAC 
BCRP expression and the pathological factors typically regarded as having prognostic 
impact, including tumour grade, receptor status, axillary metastasis, tumour stage, and 
lymphovascular invasion. This showed that only BCRP expression post-NAC 
independently predicted DFS, with high expression giving a hazard ratio of 4.04 (95% 
confidence interval, 1.3-12.2; p=0.013).  
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Figure 4.9: Kaplan-Meier survival analyses for post-NAC xenobiotic transporter 
expression versus disease free survival. No significant correlation was detected for Pgp 
and MRP1. However, high BCRP expression post-NAC significantly predicted for 
poorer disease free survival. 
 
4.4 Discussion 
Methodology 
This is the first published study to examine Pgp, MRP1, and BCRP expression using 
immunohistochemistry in the context of breast cancer patients treated with NAC (Kim 
et al., 2013). Immunohistochemistry was used since protein expression is more likely to 
reflect the function and efflux activity of the transporters than analysis of transcript 
levels. Also, immunohistochemistry provides microanatomical details and hence 
tumour epithelium can be readily distinguished and examined specifically. However, 
subjectivity in quantifying protein expression can be a problem in interpreting results. 
Another potential method would have been to examine mRNA levels of Pgp, MRP1, 
and BCRP in clinical samples using RT-PCR. Although this would have potentially 
provided a more quantitative measure of expression, quantity and quality of nucleic 
acids extracted from FFPE tissues can be variable. Moreover, unless tumour cells are 
isolated by macrodissection or laser capture microscopy, results from RT-PCR need to 
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be interpreted with caution due to potential contamination by non-tumour cells. Burger 
et al examined mRNA levels of MDR1 (Pgp), MRP1, and BCRP using fresh frozen 
tumour resection tissues from 59 patients, where 30/59 went onto receive adjuvant 
chemotherapy. The authors found that MDR1 mRNA levels were inversely correlated 
with tumour response and progression free survival, but not MRP1 or BCRP mRNA 
levels. No active effort was made to isolate tumour cells in this study, and the survival 
analysis did not include Cox regression analysis performed in our study (Burger et al., 
2003). A further study by Faneyte et al examined MRP1 mRNA expression in tissue 
samples of 30 breast cancer patients treated with NAC. However, the tissue availability 
was limited in their study with 23 samples available after neoadjuvant chemotherapy, 
and only 3 patients had matching pre- and post-NAC tissue samples available for 
analysis. They found that MRP1 mRNA expression did not correlate with clinico-
pathological parameters or patient survival (Faneyte et al., 2004). Furthermore, as 
eluded in section 1.8.4, post-transcriptional regulation, amongst other complex 
mechanisms, may play an important role in regulation of ABC transporters and hence 
mRNA levels may not reflect functional activity.  
 
To overcome the potential issues in subjective quantification of protein expression in 
immunohistochemistry, we have used a novel method of placing core tissues on the 
same slide as the resection tissues, thereby limiting potential inter-experimental 
variation. Furthermore, we quantified protein expression using the objective computer-
aided scoring protocol, which is being increasingly used in other studies (Mohammed 
et al., 2012) with the potential advantages of reproducibility and increased objectivity. 
Our scoring protocol also enabled quantification of protein expression as a continuous 
variable, and hence enabled more precise comparison of change in expression after 
exposure to NAC, as well as selection of appropriate cut-offs for survival analysis. This 
is in comparison to change in protein expression simply quantified as positive/negative 
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as adopted in another NAC study (Tanei et al., 2011). As eluded to in section 1.5, 
previous studies regarding potential predictive markers to NAC have shown that 
significant correlations are only present in selected tumour subtypes, suggesting that 
tumour heterogeneity plays an important role. Therefore, unlike previous studies 
mentioned in section 4.1, we have made an active effort to limit tumour heterogeneity 
during the patient cohort selection.  
 
Marker expression levels 
My results show that Pgp and MRP1 are up-regulated after exposure to NAC. These 
findings are in keeping with previously published studies (Rudas et al., 2003, Chung et 
al., 1997). Interestingly we found that MRP1 expression was uniformly low pre-NAC, 
which is in contrast to study by Rudas et al in which pre-NAC MRP1 expression was 
detected in 62% of their study cohort. Up-regulation of MRP1 expression occurred in 
92% of our cohort, compared to 57% in their cohort. The differences in finding may be 
due to the difference in the cohort characteristics or in experimental protocol, such as 
the monoclonal antibody used to detect MRP1 expression. Tanei et al found that BCRP 
expression was significantly increased after NAC with positive BCRP expression seen 
in 15/72 patients pre-NAC, compared to 26/72 patients post-NAC. However, the 
limitation of this study in terms of quantifying change in expression as positive/negative 
rather than as a continuous variable highlights the limitations of their study. BCRP 
expression was rather variable in our study with up-regulation observed in 59%, 
compared to the respective values of 74% for Pgp and 92% for MRP1.  
 
This study showed that Pgp, MRP1, and BCRP expression in the axillary lymph nodes 
post-NAC was not significantly different to that of primary breast cancer post-NAC. 
However, no correlation in expression pattern was found for all three transporters, 
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perhaps reflecting the fact that only 13 lymph node tissues were examined. Our finding 
is different to the previously mentioned study in section 4.1 where Pgp and MRP1 
expressions in the lymph nodes differed significantly from those of the corresponding 
primary tumours (Zochbauer-Muller et al., 2001). As our study examined lymph node 
expression post-NAC, as opposed to untreated in Zochbauer-Muller et al, it is difficult 
to compare the results and further studies with larger cohort sizes are required. 
  
We have also found that in tumours with low pre-NAC Pgp expression, there is a 
greater increase in the BCRP expression after NAC. One possible explanation is that 
high Pgp expression results in sufficient efflux of chemotherapeutic agents, and hence 
the stimulus for BCRP up-regulation is reduced. However, this is unlikely since MRP1 
up-regulation was observed in 92% of the cases, suggesting that the stimulus for up-
regulation remains. Alternatively, regulatory cross-talk between the two transporters 
may enable tumours with low Pgp expression to respond by compensatory up-
regulation of BCRP. A study by Bark et al supports this hypothesis of regulatory cross-
talk between Pgp and BCRP (Bark et al., 2008). Their study reported that Pgp down-
regulated the expression of BCRP in a doxorubicin-resistant lung cancer cell line.  
 
Interestingly for Pgp, pre-NAC expression level in the pCR group was significantly 
higher compared to the non-pCR group (Mann-Whitney U test: p=0.013). This is a 
paradoxical finding that requires further investigation, and may potentially be explained 
by single nucleotide polymorphism (SNP) in these patients attenuating the efflux 
activity of Pgp. George et al examined SNP 3435 C>T in exon 26 of the MDR1 gene in 
76 breast cancer patients treated with NAC. The authors found that patients with 
3435TT genotype with low Pgp expression had improved overall response to NAC than 
3435CC genotype with high Pgp expression. However, the difference was not 
significant (George et al., 2009). This study is further supported by meta-analysis by 
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Wang et al who showed association between the MDR1 C3435T polymorphism and 
risk of breast cancer based on 10 case-control studies involving 5282 breast cancer 
cases and 7703 controls. TT versus CC genotypes was associated with the most 
significant increased risk of breast cancer with an odds ratio of 1.45 (Wang et al., 
2013b). I do not have data concerning the genotypes of patients in my cohort. For 
MRP1 and BCRP, no statistically significant difference was detected between the pCR 
group and the non-pCR group. Therefore, these findings also suggest that pre-NAC 
xenobiotic transporter levels do not predict response to NAC, and that post-NAC 
expression may be more informative. This is reflected by the significance of the post-
NAC BCRP expression. 
 
Significance of expression in terms of survival 
Pre-NAC BCRP expression had no predictive value in terms of survival, and our study 
shows that BCRP expression levels vary widely after exposure to NAC. However, this 
variably induced-change is of potential relevance since high BCRP expression post-
NAC correlated with poor DFS. BCRP expression has also been shown to significantly 
correlate inversely with survival in patients with acute myeloid leukaemia (Damiani et 
al., 2006, Benderra et al., 2004, Benderra et al., 2005). Our study finding and the 
transferrable methodology of using objective computer-aided scoring protocol requires 
examination in a larger independent cohort for validation. Based on the Kaplan-Meier 
survival analysis of post-NAC BCRP expression versus disease free survival, post hoc 
power analysis was performed to examine whether the study cohort size was sufficient 
to identify this association. IBM SPSS SamplePower v3.0 (SPSS, Chicago, USA) was 
used for this analysis. Based on a two-tailed test with alpha value of 0.05, the cohort 
size of 39 patients resulted in a power value of 0.78. Further analysis showed that a 
cohort size of 44 patients would have achieved the commonly accepted power value of 
0.8.  
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Patients with high BCRP expression post-NAC may benefit from further adjuvant 
therapies to attempt to improve disease free survival. However, the adjuvant therapy 
may not be in the form of further chemotherapy as these patients will already have high 
BCRP expression level within any remaining tumour cells. Alternative approaches 
include investigation of mechanisms that regulate BCRP expression to potentially 
improve the efficacy of NAC, which is the focus of chapter 6.   
 
Pre-NAC MRP1 expression did not predict survival in this study, which is in contrast to 
the findings of the Rudas et al study (Rudas et al., 2003), which found that high pre-
NAC MRP1 expression predicted poor survival. However, the cohort used in this work 
included patients with lobular carcinoma, a different monoclonal primary antibody, and 
a scoring protocol which quantified expression in a discrete manner rather than our 
continuous data. In our study, MRP1 expression pre-NAC was uniformly low, and up-
regulation occurred in 92%, compared to 57% in their study. Investigating potential 
mechanism responsible for this striking up-regulation of MRP1 expression is the focus 
of the next chapter.  
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5.0 NAC up-regulates Notch1 and MRP1 expression, but Notch1 
inhibition does not potentiate chemotherapy efficacy 
 
5.1 Abstract 
My data in chapter 4 demonstrated that MRP1 expression was up-regulated in 36/39 
cases after NAC. Evidence within the literature suggested that MRP1 up-regulation 
may be driven by activated Notch1. Therefore, my first aim in this chapter was to 
determine whether activated Notch1 expression correlated with MRP1 expression. 
Activated Notch1 expression was determined in the same NAC cohort tissue samples 
as used in chapter 4 using immunohistochemistry. Similarly to MRP1, Notch1 
expression was significantly up-regulated after NAC (p=0.0003). Moreover, a 
significant correlation was observed between post-NAC Notch1 and MRP1 expression 
(rho coefficient 0.6; p=0.0008), suggesting that Notch may indeed drive MRP1 up-
regulation after NAC. The hypothesis that inhibition of Notch signaling, and therefore of 
MRP1 up-regulation, increases the sensitivity of breast cancer cells to 
chemotherapeutics was developed from these observations. This hypothesis was 
tested by assessing survival/proliferation of breast cancer cell lines using MTT assays 
after treatment with combinations of the chemotherapeutic doxorubicin and the Notch 
inhibitor DAPT. Minor additive effects on survival/proliferation were seen with 
combinations of doxorubicin and DAPT, but no synergistic effect was observed. Further 
investigation using immunoblotting revealed that under these conditions doxorubicin 
did significantly up-regulate MRP1 expression, but activated Notch1 expression was 
not significantly up-regulated. Immunohistochemistry findings from this study add 
further weight to the potential role of Notch1 in regulating MRP1 expression. However, 
further in vitro studies and alternative experimental strategies are required to determine 
whether abrogating Notch1 expression results in improved efficacy of chemotherapy.      
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5.2 Introduction 
In the previous chapter I showed that treatment of breast cancers with NAC was 
associated with dramatic up-regulation of MRP1 expression within the tumour cells. I 
was interested to investigate the molecular mechanisms potentially responsible for this 
up-regulation. A considerable body of work exists concerning the pathways that 
regulate MRP1 expression in normal physiology as well as in cancer (Bakos and 
Homolya, 2007, Haimeur et al., 2004).  
 
Regulation of MRP1 expression in normal physiology 
MRP1 has a role in protection against xenobiotics and endogenous toxic metabolites. 
Lorico et al used knock-out mice to investigate the physiological role of MRP1 (note, 
the authors refer to the murine gene as mrp). No physiological abnormalities were 
observed between mrp(+/+) and mrp(-/-) mice up to 4 months of age, perhaps 
indicating functional redundancy amongst the xenobiotic transporters. However, the 
mrp(-/-) mice displayed increased sensitivity to the chemotherapeutic agent etoposide, 
which resulted in greater bone marrow toxicity (Lorico et al., 1997). MRP1 is highly 
expressed in lung, testis, kidney, heart, and placenta (Bakos and Homolya, 2007). 
Pascolo et al showed that MRP1 expression increased with placental maturation, 
supporting the notion that MRP1 contributes to protection of the fetus from toxic 
compounds. They showed that MRP1 mRNA expression was increased four-fold in 
third compared to first trimester human placental tissue samples (Pascolo et al., 2003). 
Qian et al showed that high expression of MRP1 in Leydig cells of testis has potential 
roles in protecting testes from the feminising side effects of endogenous oestrogen 
conjugates. They used MRP1-transfected HeLa cells to show that conjugated 
oestrogen was efficiently transported by MRP1 (Qian et al., 2001).     
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Regulation of MRP1 expression in cancer 
As well as the aforementioned studies in section 1.8.4, the following studies elaborate 
further on regulation of MRP1 expression in cancer, providing evidence of 
transcriptional regulation. Under wild-type conditions, the p53 tumour suppressor 
protein represses transcription of MRP1. In cancer, mutant p53 loses the ability to 
repress MRP1 transcription, thereby resulting in up-regulation of MRP1 expression 
(Wang and Beck, 1998). A further transcriptional control is exerted by the oncogenic 
transcription factor c-jun, potentially via an AP-1 site within the MRP1 promoter. Cripe 
et al showed that transfection of a multidrug resistant leukaemic cell line, HL-60/ADR, 
with a vector to over-express dominant negative c-jun resulted in reduced MRP1 
expression and abrogation of MRP1-dependent efflux, and hence increased sensitivity 
to daunorubicin (Cripe et al., 2002).  
 
My work described in the previous chapter demonstrated that MRP1 expression was 
up-regulated by exposure to NAC in breast cancer tissue samples (Kim et al., 2013). 
Two further publications were of specific interest in the context of determining factors 
potentially responsible for NAC-dependent up-regulation of MRP1. First, a study in 
which a potential link between the transcription factor Notch1 and MRP1 was examined 
(Cho et al., 2011). The authors showed that MRP1 was a direct transcriptional target of 
Notch1 in the multi-drug resistant breast cancer cell line, MCF7/VP. They showed that 
down-regulation of Notch1 activity, using the gamma-secretase inhibitor DAPT, led to 
subsequent down-regulation of MRP1 expression as detected by western blots. 
Furthermore, transfection of MCF7/VP cells with a luciferase reporter allowing 
measurement of activity of the ABCC1 promoter (ABCC1 being the gene that codes for 
MRP1), showed that ABCC1 transcriptional activity was reduced by treatment with 
DAPT. Finally, siRNA-mediated knock down of MRP1 expression in Notch1-
overexpressing cells resulted in increased sensitivity to etoposide. Overall, this study 
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convincingly demonstrates a regulatory link between Notch1 and MRP1, and that 
targeting of Notch1 with DAPT or siRNA could be used to modulate MRP1 expression. 
The second relevant publication demonstrated that Notch1 activity was up-regulated by 
NAC in clinical breast cancers. Analysis of gene expression profiles of clinical breast 
cancer samples treated with NAC (Gonzalez-Angulo et al., 2012) revealed over-
expression of targets of Notch signalling. This study compared gene expression data of 
pre- and post-NAC tissues from 21 breast cancer patients. In non-basal-like subset of 
breast cancers, enriching of Notch signalling targets was observed in differentially 
expressed genes. Thus, from bioinformatics it was inferred that NAC may activate 
Notch signalling in the non-basal (mainly luminal) breast cancers. By combining the 
findings of these two highlighted studies, my hypothesis was that the up-regulation of 
MRP1 by NAC that I demonstrated in the previous chapter is mediated, at least in part, 
by Notch signalling. 
 
Notch proteins and Notch signalling 
Notch proteins are transmembrane receptors that interact with ligands of the delta or 
jagged families, which are mostly present on adjacent cells. Notch proteins are initially 
translated as precursor forms, which are then processed by an S1 cleavage in the 
Golgi network, resulting in the formation of the mature Notch proteins, which consist of 
extracellular, transmembrane, and cytoplasmic domains. Extra-cellular ligand binding 
to the Notch protein leads to further cleavage in two successive steps. The first 
proteolytic cleavage (S2) is performed at the extracellular domain by the 
metalloprotease ADAM17 (A Disintegrin And Metalloproteinase) and TACE (TNF-α 
converting enzyme). The second proteolytic cleavage (S3) is carried out by gamma 
secretase at the transmembrane domain, generating the free Notch intracellular 
domain (NICD) in the cytoplasm (Yin et al., 2010). The NICD is translocated to the cell 
nucleus, and acts as a transcription factor potentially regulating cell proliferation, 
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differentiation, and apoptosis through a large range of target genes. NICD binds to a 
transcriptional repressor CSL [CBF-1 (C-promoter binding factor 1), Suppressor of 
Hairless and Lag-1], which leads to the displacement of the co-repressor complex and 
recruitment of co-activators such as mastermind-like (MAML) and p300 to activate 
transcription of Notch target genes, including the Hes and Hey family genes. This in 
turn can lead to the regulation of transcriptional targets, cyclin D1 (involved in cell-cycle 
regulation), c-Myc (transcription factor), and HER2 (growth factor receptor) (Guo et al., 
2011).  
 
There are four Notch receptors; Notch1 to 4, which are encoded by separate genes. 
The Notch pathway can have oncogenic as well as tumour suppressive effects. For 
example, mouse models have demonstrated that Notch1 overexpression results in 
mammary gland tumours (Hu et al., 2006) and immunohistochemistry studies have 
shown that high Notch1 expression is associated with poorly-differentiated breast 
cancers (Li et al., 2010). Furthermore, Reedijk et al showed that high Notch1 mRNA 
expression was associated with poor overall survival in breast cancer patients (Reedijk 
et al., 2005); 5-year OS for patients with high Notch1 expression was 49% versus 64% 
for low Notch1 expression. In contrast, Parr et al examined Notch2 expression in 97 
breast cancer specimens using immunohistochemistry, and showed that high Notch2 
levels correlated with improved survival in breast cancer patients and well-differentiated 
tumours (Parr et al., 2004). 
 
Notch signalling and NAC – a potential therapeutic opportunity? 
My initial hypothesis was that Notch signalling contributes to the up-regulation of MRP1 
by NAC. Should this hypothesis be correct, my aim would then be to attempt to inhibit 
the chemotherapy-dependent up-regulation of MRP1 using inhibitors of Notch1 activity.  
I will test whether this might be used to increase the efficacy of chemotherapy, by 
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reducing MRP1-dependent chemotherapy resistance (Fig 5.1). A caveat to this 
therapeutic strategy is the fact that MRP1 expression did not demonstrate a significant 
relationship with patient survival in the work in the previous chapter, therefore MRP1-
dependent chemotherapy resistance may be relatively unimportant. However, high 
MRP1 expression consistently showed a trend to be associated with poor survival and 
MRP1 showed the most consistent NAC-dependent up-regulation, therefore interfering 
with this potential pathway of chemoresistance remains attractive. 
 
 
Figure 5.1: Proposed pathway for enhancing the efficacy of chemotherapy. The aim of 
NAC is to kill cancer cells but MRP1 has a role in protecting cancer cells by effluxing 
chemotherapeutics and hence reducing their efficacy. If up-regulation of MRP1 is 
mediated by Notch1 signalling, inhibition of Notch1 using DAPT would result in 
reduction of MRP1 levels in cancer cells, thereby improving the efficacy of NAC.  
 
Gamma-secretase inhibitors (GSI), such as DAPT (N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester), have been developed to inhibit conversion of 
mature full-length Notch to its active NICD form. Hallahan et al used DAPT to induce 
this Notch inhibition in medulloblastoma cell lines and mouse models. They found that 
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DAPT caused dose-dependent decreases in the number of viable cancer cells 
(Hallahan et al., 2004). Farnie et al cultured ductal carcinoma in situ (DCIS) cells to 
form mammospheres, and showed that mammosphere-forming efficiency, calculated 
by dividing the number of mammospheres formed by the original number of single cells 
seeded, was attenuated by DAPT (Farnie et al., 2007). Therefore, DAPT was chosen 
to inhibit Notch expression for my study. GSIs are currently being evaluated in phase I 
clinical trials as a monotherapy (Groth and Fortini, 2012). However, they have been 
shown to have significant side-effects including gastro-intestinal bleeding, and 
immunosuppression. Other approaches, such as combination therapies, may be useful 
to improve the efficacy of GSI, potentially allowing use at reduced doses or lengths of 
exposure thereby reducing side-effects. Osipo et al showed that inhibition of HER2 
function by Herceptin led to up-regulation of Notch1 activity in a panel of breast cancer 
cell lines. This up-regulation was attenuated by GSIs, and the combination of GSIs with 
Herceptin led to enhanced rates of apoptosis compared to GSIs alone in both 
Herceptin resistant and Herceptin sensitive cells (Osipo et al., 2008). Hence, ErbB2 
inhibition activates Notch1 and leads to increased sensitivity to GSI. Moreover, 
Nefedova et al showed that inhibition of Notch signalling enhanced sensitivity to 
chemotherapeutics in multiple myeloma cells (Nefedova et al., 2008). Combining 
doxorubicin with GSI led to a greater rate of apoptosis in a myeloma cell line, and also 
led to significant tumour size reduction in a mouse model, compared to each drug 
alone.  
 
Therefore, in this chapter I aimed to examine expression of activated (S3 cleaved) 
Notch1 in the same cohort as studied for MRP1 in the previous chapter and test the 
relationships between Notch 1 and MRP1, and between Notch1 and clinico-
pathological parameters including NAC response. Finally, I aimed to treat breast 
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cancer cells with combinations of chemotherapeutics and inhibitors of Notch function to 
test whether the drugs exhibit synergistic cancer cell killing.  
 
5.3 Results 
5.3.1 Activated Notch1 expression was up-regulated post-NAC and correlated 
with post-NAC MRP1 expression 
I aimed to determine the expression of activated Notch1 using immunohistochemistry 
in the same cohort of breast cancer patients treated with NAC as was used in Chapter 
4, and then compare activated Notch1 expression patterns to MRP1 expression. 
However, further biopsy core tissues was available for analysis of Notch1 NICD 
expression in only a subset of this initial cohort, and therefore the matched analysis 
was possible in pre- and post-NAC tissues from only 29 of the 39 original cases. The 
clinico-pathological characteristics of this reduced cohort are illustrated in Table 5.1. 
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Characteristic Categories No. of patients (%) 
n=29 
Age <45 12 (41.4) 
>45 17 (58.6) 
Grade (pre-NAC) 2 9 (31) 
3 20 (69) 
Stage (pre-NAC) T2 19 (65.5) 
T3 10 (34.5) 
Stage (post-NAC) T1 9  (31) 
T2 15 (51.7) 
T3 5 (17.3) 
Tumour size change Increase 6 (20.7) 
Decrease 23 (79.3) 
MRI response Minimal 9  (31) 
Partial 20 (69) 
NAC regimen Epirubicin + 
cyclophosphamide (EC) 
5 (17.2) 
EC + taxanes   24 (82.8) 
Lymphovascular invasion Positive 11 (37.9) 
Axillary metastasis Positive 15 (51.7) 
Oestrogen receptor Positive 17 (58.6) 
Her2 Positive 3 (10.3) 
Surgery breast conserving 11 (37.9%) 
Mastectomy 18 (62.1%)  
Follow up median: 4.2 years  
(range 3-5.7 years) 
 
Recurrence  11 (37.9) 
Death  5 (17.2) 
 
Table 5.1: The clinico-pathological characteristics of the patient cohort for which 
Notch1 NICD expression was examined 
 
Immunohistochemistry for Notch1 NICD was performed on these matched pre- and 
post-NAC samples, using core biopsy and resection samples mounted on the same 
slide as before. Staining was observed in the nucleus and cytoplasm in epithelial cells 
only, with strong accentuation of the cell nuclei. Representative staining patterns are 
illustrated in Figure 5.2. Active Notch1 NICD is functionally active in the nucleus, unlike 
MRP1, therefore in order to score this specific active compartment a different scoring 
protocol was required from the semi-automated method used for MRP1. Manual Allred 
scoring of nuclear expression was used to quantify Notch1 NICD expression, involving 
assessment of both staining intensity (from 0 to 3) and the proportion of cells staining 
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positively (classes enumerated as 0 to 5) (Tacca et al., 2007). Two independent 
scorers quantified expression and inter-scorer reproducibility was assessed as 
excellent (Kappa values 0.78 for core tissues and 0.9 for resection tissues; see section 
3.7); the mean value of the two scores (overall kappa value of 0.89) was taken as the 
final assessment.  
 
           
  Pre-NAC     Post-NAC 
Figure 5.2: Immunohistochemistry for Notch1 NICD (x20 magnification) shows no 
nuclear staining in the core tissues (pre-NAC), as opposed to positive nuclear staining 
in the resection tissues (post-NAC). These images represent the significant up-
regulation in Notch1 NICD expression after exposure to NAC.  
 
Pre-NAC and post-NAC Notch1 NICD expression ranged from 0-4 (out of maximum 
score of 8), and 0–8 respectively (Fig 5.3). Up-regulation of Notch1 NICD expression 
after exposure to NAC was seen in 23/29 cases (Figure 5.3a) and, overall, the up-
regulation was statistically significant (Figure 5.3b) (Wilcoxon signed-rank test: 
p=0.0003). 
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          5.3a       5.3b 
   
Figure 5.3a (left) and b (right): Notch1 NICD expression pre- and post-NAC (red: up-
regulation, blue: down-regulation or no change) is shown on Figure 5.3a. Up-regulation 
was observed in 23/29 cases (79.3%). Matched pre- and post-NAC breast cancer 
samples were stained using immunohistochemistry for Notch1 NICD. Expression within 
tumour cells was quantified as Allred score of 0 to 8. Expression levels in matched 
samples are linked by lines coloured red or blue so as to indicate an increase or 
decrease in expression respectively. Figure 5.3b illustrates pre- and post-NAC 
expressions of Notch1 NICD shown as median Allred score values with interquartile 
range; n=29. Statistically significant up-regulation was observed for Notch1 NICD 
(p=0.0003; Wilcoxon signed-rank test). 
 
The pre- and post-NAC Notch1 NICD expression was then analysed with the 
equivalent MRP1 expressions from the same samples using the Spearman’s rho 
analysis. No significant correlation was observed pre-NAC between Notch1 NICD and 
MRP1 expression (rho coefficient 0.33; p=0.08; Fig 5.4a), although it should be noted 
that MRP1 expression was generally extremely low pre-NAC and these expression 
levels may be subject to a substantial contribution of non-specific noise (Fig 5.4a). 
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However, a significant correlation was observed between post-NAC Notch1 NICD and 
MRP1 expression (rho coefficient 0.6; p=0.001; Fig 5.4b). Pre- and post-NAC Notch1 
NICD expressions were also compared to the equivalent Pgp and BCRP expressions. 
Notch1 NICD expression did not correlate with either Pgp or BCRP expression either 
pre- or post-NAC (pre-NAC Notch1 NICD and Pgp expression: rho -0.03, p=0.87; post-
NAC Notch1 NICD and Pgp expression: rho 0.04, p=0.82; pre-NAC Notch1 NICD and 
BCRP expression: rho 0.03, p=0.88; post-NAC Notch1 NICD and BCRP expression: 
rho -0.02, p=0.91). These findings demonstrated that Notch1 NICD levels correlate with 
MRP1 specifically, rather than xenobiotic transporters generally. 
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      5.4a (pre-NAC)             5.4b (post-NAC) 
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Figure 5.4a (left) and b (right): Scatter plots of Notch1 NICD expression versus 
MRP1 expression (n=29). Figure 5.4a illustrates pre-NAC Notch1 NICD expression 
plotted on the y-axis (Allred score of 0 to 8), and matching pre-NAC MRP1 expression 
plotted on the x-axis (histoscores). Due to low MRP1 expression pre-NAC, the x-axis is 
only shown up to histoscore of 40. No significant relationship was seen (Spearman’s 
rho coefficient 0.33, p=0.08). Figure 5.4b illustrates post-NAC Notch1 NICD expression 
plotted on the y-axis (Allred score of 0 to 8), and matching post-NAC MRP1 expression 
plotted on the x-axis (histoscores; 0 to 300). A positive and significant correlation was 
observed between post-NAC Notch1 NICD and MRP1 expression (Spearman’s rho 
coefficient 0.6; p=0.001). 
 
5.3.2. Correlation of Notch1 NICD expression with clinico-pathological 
parameters and disease free survival. 
My next aim was to examine pre- and post-NAC Notch1 NICD expression levels, as 
well as the change in expression of Notch1 NICD, against the clinico-pathological 
parameters (outlined in Table 5.1) using Spearman’s rho analyses (Table 5.2). As 
stated in the previous chapter, p<0.01 was used to indicate statistical significance. A 
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statistically significant negative correlation was seen between tumour grade and pre-
NAC Notch1 NICD expression level on univariate analysis, although this correlation 
was not significant after multivariate regression analysis. As previously (see Section 
4.2.5), the expression levels and the change in expression levels were then examined 
against the response to NAC. No significant correlations were observed.  
 
 Notch1 
pre 
 
Notch1
post  
Notch1 
∆  
 
Age at diagnosis 0.15 
(0.43) 
-0.003 
(0.99) 
0.097 
(0.62) 
    
Tumour factors 
determined pre-
NAC: 
   
Grade -0.5 
(0.006) 
-0.18 
(0.34) 
0.025 
(0.9) 
T Stage     0.25 
   (0.19) 
0.32 
(0.095) 
0.26 
(0.18) 
ER status -0.3 
(0.12) 
-0.089 
(0.65) 
0.083 
(0.67) 
Her2 status -0.08 
(0.68) 
0.14 
(0.46) 
0.17 
(0.37) 
    
Tumour factors 
determined post-
NAC: 
   
T stage 0.32 
(0.87) 
0.18 
(0.34) 
-0.044 
(0.82) 
Lymphovascular 
invasion 
0.32 
(0.09) 
0.17 
(0.38) 
0.048 
(0.8) 
Axillary 
metastasis 
0.4 
(0.032) 
0.075 
(0.7) 
-0.12 
(0.54) 
Tumour 
response 
   
∆ T stage 0.12 
(0.53) 
-0.088 
(0.65) 
0.14 
(0.46) 
MRI response 0.15 
(0.43) 
0.47 
(0.011) 
0.21 
(0.28) 
∆ in tumour size -0.14 
(0.46) 
-0.005 
(0.98) 
-0.16 
(0.41) 
 
Table 5.2: Spearman’s correlation coefficients demonstrating relationships between 
expression pre-NAC or post-NAC, or change in expression (∆) for Notch1 NICD with 
clinico-pathological parameters (p values are denoted in brackets) 
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Next, expression levels and change in expression levels of Notch1 NICD were 
compared against disease free survival, using Kaplan-Meier survival analyses. 
Receiver Operating Characteristic (ROC) curve analysis was performed to dichotomise 
expression as previously. No significant correlations were detected between Notch1 
NICD expressions pre- or post-NAC and disease free survival (Fig 5.5). To determine 
the change in Notch1 NICD expression, pre-NAC Notch1 NICD Allred score was 
subtracted from post-NAC Notch1 NICD Allred score. In 3 cases where the Allred score 
was 0 out 8 both pre- and post-NAC, these cases were excluded from the analysis. 
 
 
Figure 5.5: Kaplan-Meier survival analyses for Notch1 NICD expression versus 
disease free survival 
 
5.3.3. Comparison of Notch1 expression in different breast cancer subtypes 
The initial published report in which up-regulation of Notch signalling targets was 
demonstrated post-NAC found this to be true in non-basal-like breast cancers only 
(Gonzalez-Angulo et al., 2012). Therefore I aimed to compare the expression pattern of 
Notch1 NICD separately in basal-like and non-basal-like breast cancers in my cohort. 
This distinction was made by examining ER, PR, and HER2 status in each patient. 
Patients who had triple negative tumours (ER-, PR-, and HER2-) were categorised into 
a basal-like group (n=13). These who had ER+ and HER2- tumours were categorised 
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into luminal A-like group (n=13), and those with ER+ and HER2+ tumours into luminal 
B-like group (n=3). Luminal A and B-like groups were combined to form 16 luminal-like 
tumours. Notch1 NICD expression was not significantly different in luminal-like tumours 
as compared to basal-like tumours either pre- or post-NAC (Fig 5.6) (p=0.06 pre-NAC; 
p=0.66 post-NAC; Mann-Whitney test). Furthermore, Notch1 NICD expression was 
significantly up-regulated after NAC in both subtypes when analysed separately (Fig 
5.7) (p=0.02 luminal-like; p=0.001 basal-like; Wilcoxon signed-rank test). 
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Figure 5.6: No difference in Notch1 NICD expression was observed between the 
basal- and luminal-like tumours pre- and post-NAC (p=0.06 pre-NAC; p=0.66 post-
NAC; Mann-Whitney test). Notch1 NICD expression is shown on y-axis (Allred score 0 
to 8) with median expression displayed with interquartile range for basal-like (n=13) 
and luminal-like tumours (n=16).  
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Figure 5.7: Significant up-regulation of Notch1 NICD expression was seen in both 
basal-like and luminal tumours upon exposure to NAC (p=0.001 basal-like; p=0.02 
luminal-like; Wilcoxon signed-rank test). Notch1 NICD expression is shown on y-axis 
(Allred score 0 to 8) with median expression displayed with interquartile range for 
basal-like (n=13) and luminal-like tumours (n=16). 
 
5.3.4. Do Notch inhibitors enhance the efficacy of doxorubicin? 
Having determined that NAC exposure, including at least some component of 
anthracyclines, resulted in up-regulation of Notch1 NICD expression and MRP1 
expression in many clinical breast cancers I wished to examine whether this would be 
recapitulated in cell line models, and whether treatment with chemotherapy agents 
would lead to induction of Notch1 activity and MRP1 expression. In accordance with 
this, data produced by other investigators in our laboratory demonstrated that treatment 
of T47D cells, a luminal breast cancer cell line, with doxorubicin induced Notch1 
activation and MRP1 expression (Fig 5.8).  
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Figure 5.8: Doxorubicin induces MRP1 (left) and Notch1 NICD (right) expression in 
vitro. T47D cells were treated for 24h with 1µM doxorubicin or vehicle control. MRP1 
expression was quantified by Western blot (left). Data for Western blot are 
representative of at least 2 independent biological replicates. The figure is courtesy of 
Dr James Thorne (LIMM). ELISAs (right) were used to quantify levels of Notch1 NICD 
with data shown representing 2 independent biological replicates with technical 
duplicates (error bars show SEM). The figure is courtesy of Dr Sam Stephen (LIMM). 
 
Based on these findings, I aimed to determine whether treatment with DAPT, an 
inhibitor of Notch1 activation, would potentially sensitize cells to chemotherapy agents 
(see Figure 5.1) using MTT assays to determine cell survival/proliferation. First, I 
established suitable conditions for this assay, including doses of chemotherapy agent 
and length of treatment. I treated luminal breast cancer cell lines MCF7 and T47D in 
vitro with doses up to 1μM of doxorubicin, as a representative anthracycline 
chemotherapeutic, for up to 4 days and used MTT assays to measure relative 
growth/survival. Doxorubicin is an anthracycline that has similar clinical efficacy as 
epirubicin (Bontenbal et al., 1998), and has been used on MCF7 cell lines in other 
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studies (Zang et al., 2010). Addition of increasing concentrations of doxorubicin 
resulted in reduction of growth/proliferation of the luminal cancer cell lines in an 
exponential manner (Appendix Section 3, Fig S14). From the resulting dose-response 
curves, three inhibitory concentration (IC) values of doxorubicin were extrapolated for 
each cell line, and for MCF7 cells for treatment for both 2 and 4 days. The IC10, 25, 
and 50 values are shown in Table 5.3. 
 
 IC10 (nM) IC25 (nM) IC50 (nM) 
MCF7 (2 days) 10 25 70 
MCF7 (4 days) 4 10 30 
T47D (4 days) 10 25 60 
 
Table 5.3: Inhibitory concentration values of doxorubicin for MCF7 and T47D cell lines 
 
Next, I examined the influence of the inhibitor of Notch activation DAPT, using the 
same strategy, on MCF7 cell lines only. In contrast to doxorubicin, concentrations of up 
to 10μM DAPT had little influence on growth/proliferation of MCF7 cells after either 2 or 
4 days of treatment (Appendix Section 3, Fig S15).   
 
Finally, MCF7 cells were treated for either 2 or 4 days with doxorubicin, at either the 
IC10, IC25 or IC50 doses (Table 5.3), combined with an initial range of doses of DAPT 
from 1nM through to 1uM, and cell survival/proliferation was determined as before. 
Data are shown for the IC25 shown in Fig 5.9a, while for the IC10 and 50 doses these 
are included in the appendix (Appendix Section 3, Fig S16a). As expected, doxorubicin 
alone caused a reduction in cell numbers appropriate for the dose (i.e. approximately 
reductions of 10%, 25% or 50%). The inclusion of doses of DAPT caused some minor 
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additive effects although a clear dose dependency was not seen, and overall there was 
no evidence for synergy between doxorubicin and DAPT. Next, the assay was 
repeated using a range of higher doses of DAPT, 1µM to 100µM (Fig 5.9b and 
Appendix Section 3, S16b). In this case, some toxicity from the highest doses of DAPT 
was seen, but it remained the case that there was no evidence of a synergistic effect 
from the drugs. These assays were also repeated in T47D cells at either IC10, IC25, or 
IC50 doses (Table 5.3) combined with DAPT doses ranging from 1nM to 100µM. The 
results for the IC25 are shown in Fig 5.10, while the results for IC10 and 50 doses are 
shown in Appendix Section 3, Fig S17. As previously, some minor additive effects were 
seen when doxorubicin was added to DAPT, but no synergistic effect was seen 
between doxorubicin and DAPT.  
 
 
124 
 
 
Figure 5.9a: 2 and 4 day combination assay using MCF7 cell lines for the lower DAPT 
concentrations (1nM to 1µM). Y- axis shows optical density reading normalised to 
untreated. The first black bar denotes the controls (-) with no DAPT or doxorubicin, with 
remaining black bars showing increasing DAPT alone. The first green bar denotes the 
IC25 value (25nM and 10nM for 2 and 4 day assays respectively) without DAPT (-), 
with the remainder showing IC25 doxorubicin (DOX) with increasing DAPT.  
125 
 
  
    
Figure 5.9b: 2 and 4 day combination assay using MCF7 cell lines for the higher DAPT 
concentrations (1µM to 100µM). Y- axis shows optical density reading normalised to 
untreated. The first black bar denotes the controls (-) with no DAPT or doxorubicin, with 
remaining black bars showing increasing DAPT alone. The first green bar denotes the 
IC25 value (25nM and 10nM for 2 and 4 day assays respectively) without DAPT (-), 
with the remainder showing IC25 doxorubicin (DOX) with increasing DAPT.  
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Figure 5.10: 4 day combination assay using T47D cell lines (DAPT concentrations of 
1nM to 100µM). Y- axis shows optical density reading normalised to untreated. The first 
black bar denotes the controls (-) with no DAPT or doxorubicin, with remaining black 
bars showing increasing DAPT alone. The first green bar denotes the IC25 value 
(25nM) without DAPT (-), with the remainder showing IC25 doxorubicin (DOX) with 
increasing DAPT.  
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5.3.5. Notch1 NICD expression was not up-regulated in response to doxorubicin 
and DAPT did not inhibit Notch1 NICD or MRP1 expression at the doses used for 
survival assays 
Contrary to our proposed model, combined treatments with doxorubicin and DAPT did 
not demonstrate synergy in vitro. Therefore, I next performed Western blot analysis 
(see Section 3.10 for methods) to determine whether MRP1 expression and Notch1 
activation was changing as expected under the drug treatment conditions used, and 
also whether any changes in expression of the other xenobiotic transporters, Pgp and 
BCRP could be acting as confounding factors, since both are potentially able to efflux 
doxorubicin. Therefore, immunoblotting was performed to examine the protein 
expression for Notch1 NICD, MRP1, Pgp, and BCRP under essentially the same 
conditions used for the cell survival/proliferation analyses.  
 
MRP1 and Notch1 NICD expressions were examined on western blots using MCF7 cell 
lysate (Fig 5.11). Basal MRP1 expression was low, and up-regulation of MRP1 
expression was only observed at the lowest dose of doxorubicin treatment (IC10). In 
contrast, basal Notch1 NICD expression was considerable. Marginal up-regulation of 
Notch1 NICD expression was also observed at the lowest dose of doxorubicin 
treatment (IC10). Surprisingly, both MRP1 and Notch1 NICD expressions were down-
regulated with increasing doses (IC25 and IC50) of doxorubicin treatment. DAPT 
treatment on its own resulted in up-regulation of MRP1 expression. Similarly, 
combination therapy of doxorubicin and DAPT also resulted in up-regulation of MRP1 
expression. DAPT treatment on its own did not result in down-regulation of Notch1 
NICD expression as expected. The combination therapy of Notch1 and DAPT resulted 
in down-regulation of Notch1 NICD expression however. 
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Figure 5.11: Western blot to examine MRP1 and Notch1 NICD expression using MCF7 
cell lysates treated with doxorubicin +/- DAPT for 4 days. IC10 doxorubicin treatment 
led to up-regulation of MRP1 and Notch1 NICD expression. Note that basal Notch1 
NICD expression was considerable without any drug treatment (control). However, 
subsequent IC25 and IC50 doxorubicin treatment led to down-regulation of MRP1 and 
Notch1 NICD expression. DAPT treatment (100µM) with or without doxorubicin led to 
up-regulation of MRP1 expression. Treating the cells with DAPT did not result in down-
regulation of Notch1 NICD expression. However, the combination of doxorubicin and 
DAPT led to down-regulation of Notch1 NICD expression.   
 
The western blots for MRP1 and Notch1 NICD were repeated twice more using 
different protein lysates harvested at different biological time points but using the same 
treatment conditions described so far, as well as further combination treatments with 
DAPT for IC10 and IC25 doxorubicin doses. The resulting immunoblots (Fig 5.12) 
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showed that MRP1 expression was up-regulated in a dose dependent manner. 
However, DAPT with or without doxorubicin did not result in down-regulation of MRP1 
expression. Further MRP1 western blot was consistent with this finding (Appendix 
Section 3, Fig S18), and Notch1 NICD western blots reflected the findings on Figure 
5.11 (Appendix Section 3, Fig S19 and S20). These data provided little support for the 
role of Notch1 in regulation of MRP1 under these conditions, and provided no evidence 
that doxorubicin-dependent MRP1 up-regulation could be inhibited using DAPT. 
 
 
Figure 5.12: Western blot to examine MRP1 expression using MCF7 cell lysates 
treated with doxorubicin +/- DAPT for 4 days. Increasing doses of doxorubicin 
treatment led to up-regulation of MRP1 expression. DAPT treatment did not result in 
down-regulation of MRP1 expression however. Combination therapy of doxorubicin 
and DAPT did not cause significant down-regulation of MRP1 expression. 
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Finally, Pgp and BCRP expressions were also examined, to determine whether 
changes in expression of these pumps had potential to influence the effects on MRP1 
and Notch1 induced by doxorubicin and/or DAPT. Pgp expression was up-regulated by 
doxorubicin treatment, although not in a dose-dependent manner (Fig 5.13). 
Interestingly Pgp expression was significantly up-regulated by DAPT treatment, either 
with or without doxorubicin, raising the possibility that enhanced Pgp function could 
interfere with the effective intra-cellular doses of either DAPT or doxorubicin in this 
experiment. BCRP expression did not alter significantly with doxorubicin or DAPT 
treatment (Fig 5.13). 
 
 
 
Figure 5.13: Western blot to examine Pgp and BCRP expression using MCF7 cell 
lysates treated with doxorubicin +/- DAPT for 4 days. Doxorubicin treatment (IC10; 
4nM) up-regulated Pgp expression, but this up-regulation was not dose-dependent. 
DAPT treatment (100µM) with or without doxorubicin resulted in a significant up-
regulation of Pgp expression. Doxorubicin or DAPT treatment did not cause a 
significant change in BCRP expression. 
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5.3 Discussion 
This chapter contains data that can conveniently be divided up into clinical and tissue 
culture based analyses, and I will discuss these separately.  
 
Notch and MRP in clinical cancers 
The clinical findings demonstrate that Notch1 NICD expression and MRP1 expression 
were both significantly up-regulated after NAC in breast cancers. Furthermore, post-
NAC MRP1 expression correlated significantly with post-NAC Notch1 NICD 
expression. As far as I am aware, this is the first study to examine the change in 
Notch1 NICD expression after NAC setting using immunohistochemistry. My data add 
further weight to the gene expression study mentioned previously (Gonzalez-Angulo et 
al., 2012), in which it was inferred that Notch activity was up-regulated after NAC in 
luminal-like tumours by the changes in expression of Notch target genes. However, 
unlike the Gonzalez-Angulo et al study, I found Notch1 NICD expression to be up-
regulated by NAC in basal-like tumours as well as luminal-like tumours. Notch1 NICD 
expression or up-regulation did not significantly correlate with clinico-pathological 
parameters, response to NAC or subsequent survival on multivariate analyses, 
although it is clear that a cohort of only 29 patients is likely to be underpowered to 
detect these potential relationships. In contrast to my findings, some studies have 
revealed correlations between Notch1 expression and clinico-pathological features of 
tumours. For example, Wu et al examined total Notch1 expression in 44 patients 
diagnosed with cholangiocarcinoma using immunohistochemistry and found that 
Notch1 overexpression was more prevalent in patients with larger tumour size 
(p=0.021) (Wu et al., 2014b). Yao et al examined nuclear, cytoplasmic, and membrane 
Notch1 expression in 48 breast cancer patients. On multivariate analysis, high 
cytoplasmic Notch1 expression significantly correlated with nodal status (Yao et al., 
2011). However, the literature are conflicting since Zardawi et al found that total Notch1 
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expression in 228 patients with operable breast cancer did not correlate significantly 
with clinico-pathological parameters or patient survival (Zardawi et al., 2010). Further 
investigations should clarify the relevance of Notch1 expression in breast cancer. 
 
Notch and MRP1 in cell lines 
The significant correlation I found between post-NAC Notch1 NICD and MRP1 
expression supports the conclusions of the cell line-based study by Cho et al, in which 
MRP1 was found to be a direct transcriptional target of Notch1 (Cho et al., 2011) and 
allowed me to build the hypothesis that Notch-dependent up-regulation of MRP1 might 
be responsible for some degree of acquired chemotherapy resistance (see flow-chart 
Figure 5.1). I then proceeded to test this hypothesis using cell line models. Luminal 
breast cancer cell lines (MCF7 and T47D) were used in accordance with the findings 
from Gonzalez-Angulo et al study (Gonzalez-Angulo et al., 2012). Doxorubicin is an 
anthracycline that has similar clinical efficacy to epirubicin (Bontenbal et al., 1998), 
which is widely used in clinical practice. MRP1 does not efflux taxanes (Leonard et al., 
2003), and hence were not used for this study. GSIs have been widely used in clinical 
trials in colorectal cancer (Strosberg et al., 2012) and in other solid tumours including 
breast cancer (Tolcher et al., 2012), providing credibility for its use in our study to 
achieve Notch inhibition. DAPT was used in this study to achieve Notch inhibition in 
line with other aforementioned in vitro studies mentioned in section 5.1 (Cho et al., 
2011, Farnie et al., 2007, Hallahan et al., 2004).   
 
Three IC values of doxorubicin, IC10, 25 and 50, were chosen for use in combination 
with DAPT, itself at a wide range of potentially relevant conditions. Doxorubicin doses 
ranged from 4 to 70nM for MCF7 cell line, and 10 to 60nM for T47D cell line. These 
concentrations are comparable to concentration of doxorubicin detected by plasma 
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pharmacokinetic analysis by Chow et al. They showed that in 10 patients with solid 
tumours including breast cancer, the mean plasma end-of-infusion doxorubicin level 
was 83.8nM (range 59.1 to 106.9nM) (Chow et al., 2004). The physiological doses or 
plasma levels of DAPT in patients have not been well studied. However, concentration 
of 10mg/kg to 100mg/kg of DAPT has been used in mouse studies to achieve Notch 
inhibition (Lanz et al., 2003). The authors determined that these dosages resulted in 
plasma DAPT levels ranging from 140nM to 720nM. In our study, DAPT doses of 1nM 
to 1μM was initially used for the combination assay, which is comparable to the DAPT 
levels observed in the Lanz et al study. Furthermore, I also used higher DAPT doses of 
1μM to 100μM in accordance with the in vitro study by Cho et al (Cho et al., 2011). 
However, these higher doses may be potentially harmful in clinical setting. Despite this, 
the combination therapy of doxorubicin and DAPT in luminal cell lines did not potentiate 
the efficacy of chemotherapy with additive effects seen at best.  
 
Using western blots, I initially demonstrated activation of Notch1 NICD and MRP1 at 
only the lowest dose of doxorubicin (IC10). Further western blots at different biological 
time points showed that MRP1, but not Notch1 NICD, was up-regulated in a dose-
dependent manner in response to doxorubicin treatment. This suggests that MRP1 up-
regulation is not solely dependent on Notch. It is plausible that other regulators of 
MRP1 expression mentioned in section 1.8.4 and 5.1 may have a role in MRP1 up-
regulation in response to treatment with doxorubicin. For example, Cyclo-oxygenase 2 
(COX-2) activation can lead to up-regulation of MRP1 expression. Saikawa et al 
showed that COX-2 overexpression in colon cancer cell line, TR-5, led to up-regulation 
of ABCC1 mRNA level and chemoresistance to cisplatin. Treatment with Cox-2 
inhibitors subsequently enhanced chemosensitivity in this cell line (Saikawa et al., 
2004). MicroRNA may also have a role in regulation MRP1 expression; Borel et al 
detected an inverse relationship between microRNA expression (miR-199a/b and miR-
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296) and ABCC1 mRNA expression (Borel et al., 2012). Marginal up-regulation of 
Notch1 NICD after doxorubicin treatment was observed which was not dose-
dependent. This may potentially be explained by the difference in the cell density 
observed with varying dosage of doxorubicin treatment. For example, there is a greater 
density of viable cells after 4 days of IC10 treatment, compared to the IC50 treatment. 
Notch1 NICD is activated by extracellular ligands, and hence increased cell density 
may influence Notch1 NICD activation. This may also potentially explain the high basal 
Notch1 expression level in the control lysates.  
 
It is important to note that MCF7/VP subline was used in the Cho et al study (Cho et 
al., 2011), which is etoposide-resistant. This is in contrast to the non-resistant MCF7 
and T47D cell lines used in our study. An alternative approach may be to perform the 
combination assay on basal breast cancer cell lines, since the data from my 
immunohistochemistry study also showed up-regulation of Notch1 NICD expression in 
the basal-like breast cancers. This is in contrast to findings by Gonzalez-Angulo et al 
who found enriching of Notch signalling targets in non-basal-like breast cancers only 
(Gonzalez-Angulo et al., 2012). 
  
Most concerningly, I was unable to demonstrate that DAPT achieved significant Notch1 
NICD inhibition when cells were treated with DAPT alone. The western blot results 
showed that DAPT did not down-regulate Notch1 NICD or MRP1 expression in the 
MCF7 cell lysates. Cho et al showed that DAPT dosage of 50μM or greater was 
effective in achieving Notch1 NICD and MRP1 down-regulation. However, 100μM 
dosage of DAPT treatment in this study did not result in down-regulation of Notch1 
NICD or MRP1 expression. This is perhaps explained by the significant up-regulation of 
Pgp expression with DAPT treatment, suggesting that Pgp may efflux DAPT to 
attenuate its effect on Notch activity. A potential solution may be to add a Pgp inhibitor 
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to the combination assay or to use siRNA to inhibit Notch1 expression at the 
transcriptional level. Other alternative methods of achieving Notch1 inhibition involve 
the use of monoclonal antibody against the Notch ligand TACE, or inhibitors that 
interfere with the S2 cleavage (Yin et al., 2010). It is also important to note that GSIs do 
not solely inhibit Notch. They have a range of other substrates, including E-cadherin 
and Erb-B4, which are involved in cell adhesion and apoptosis (Lleo, 2008), and 
therefore off-target effects may have a confounding influence. 
 
Interestingly, subsequently to me completing my laboratory work, other researchers in 
my supervisor’s group have continued with this in vitro work. They demonstrated that 
doxorubicin does indeed induce Notch activation and MRP1 expression and function. 
They also demonstrated that this can be inhibited by DAPT, leading to enhanced 
doxorubicin-induced cell death. Critically, however, they were only able to demonstrate 
this using short term assays, where cells were treated with doxorubicin for up to 24 
hours, and by assessing induction of apoptosis in selected cell lines, rather than cell 
survival/proliferation. My data show that this combination treatment appears less 
promising in longer term assays and using cell survival as the end point, conditions that 
may potentially more accurately reflect chemotherapy in patients, where treatment lasts 
for many days and tumour cell survival is the most relevant measure of treatment 
failure or success.        
 
Summary 
The immunohistochemistry results from clinical tissue samples support previous in vitro 
studies that identified the significance of Notch signalling in regulating MRP1 
expression and thereby chemoresistance in breast cancer. The MTT assays and the 
western blot results show that further investigations are required in vitro before Notch 
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inhibitors can be utilised to potentially improve the efficacy of chemotherapy in clinical 
setting.  
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6.0 Neoadjuvant endocrine therapy up-regulates Breast Cancer 
Resistance Protein expression but only pre-treatment levels 
predict survival 
6.1 Abstract 
The BCRP promoter has an oestrogen response element, and there is evidence that 
BCRP expression is regulated by oestrogen, with reports of oestrogen leading to either 
transcriptional up-regulation or post-transcriptional down-regulation. However, the 
relevance of this in oestrogen-dependent cancers remains unclear. Therefore, my aim 
in this chapter was to investigate whether BCRP expression in breast tumours is 
regulated by oestrogen and whether this impacts on outcome. 51 breast cancer 
patients receiving neoadjuvant endocrine therapy (NAET) were identified, and BCRP 
expression was examined by immunohistochemistry using matched pairs of core 
biopsy (pre-NAET) and surgical specimens (post-NAET). BCRP expression was 
significantly up-regulated after exposure to NAET (p<0.0001; Wilcoxon signed-rank 
test), with up-regulation seen in 48/51 cases. Neither pre- nor post-NAET BCRP 
expression correlated with tumour response to NAET. However, high pre-NAET BCRP 
expression independently predicted for poorer disease free survival (hazard ratio of 
19.1; 95% confidence interval 1.05-348.2; p=0.046). Subsequent methylation 
sequencing analysis of cancer cell lines showed that the degree of methylation in the 
BCRP promoter region was inversely correlated to the protein expression of BCRP 
observed on immunoblotting. DNA was extracted from the paraffin embedded tissues 
used for immunohistochemistry and bisulphite-treated. Pyrosequencing was used to 
examine BCRP promoter methylation pattern. Comparison of protein expression and 
methylation levels in the clinical samples did not result in the significant negative 
correlation that was expected, and NAET did not consistently or significantly influence 
BCRP promoter methylation levels. The results from this chapter further highlight the 
significance of BCRP expression as a prognostic indicator. However, the significance 
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of DNA methylation in regulating BCRP protein expression requires further 
investigation.      
 
6.2 Introduction 
One of the main finding from Chapter 4 was that high BCRP expression post-NAC 
correlated with poor DFS. One hypothesis is that these induced high levels directly 
contributed to increased cancer cell survival. Therefore it would be of interest to 
investigate potential mechanisms responsible for defining these high BCRP expression 
levels, since modulation of these regulatory pathways could potentially be used to 
reduce BCRP expression and improve the efficacy of NAC.  A considerable body of 
data concerning mechanisms responsible for regulation of BCRP expression is 
available – and this is summarised below. Potential regulation by oestrogen and at the 
level of promoter methylation are of particular relevance as these are investigated in 
this chapter. 
 
Regulation of BCRP expression 
Broadly, the mechanisms involved in deregulation of BCRP expression can be 
classified into DNA changes (gene amplification / mutation), transcriptional changes 
(use of multiple transcriptional start sites / histone modification / methylation of CpG 
sites), and post-transcriptional regulation by miRNAs amongst other mechanisms 
(Nakanishi and Ross, 2012).  
 
The following studies elucidate the mechanisms involved in the regulation of BCRP 
expression mentioned above in order. Knutsen et al examined BCRP expression in 
breast cancer cell lines treated with chemotherapeutics. Using comparative genomic 
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and cDNA hybridisation, they determined that high BCRP expression was due to gene 
amplification (Knutsen et al., 2000). Imai et al examined ABCG2 SNPs in 59 human 
tumour cell lines. cDNA sequence analysis showed that C421A mutation which 
substitutes Lys for Gln-141 was found in the breast cancer cell line MDA-MB-231. 
G34A mutation that substitutes Met for Val-12 was found in the MCF-7 cell line. BCRP 
proteins with coding changes encoded by these SNP variants proved to be expressed 
at lower levels than wild-type BCRP in murine fibroblast PA317 cell lines (Imai et al., 
2002).  
 
BCRP expression can also be influenced by alternative promoter usage. Zong et al 
identified three novel leader exons at the 5’-UTR region of mouse ABCG2 mRNA. By 
using 5’-rapid amplification of cDNA ends (RACE), they showed that the three isoforms 
were differentially expressed from multiple promoters using different transcriptional 
start sites (Zong et al., 2006). Histone deacetylase inhibitors (HDIs) can increase 
chromatin acetylation, resulting in alteration of gene expression. Robey et al showed 
that treatment of kidney cancer cell lines with HDIs resulted in up-regulation of ABCG2 
mRNA expression (Robey et al., 2006).  
 
Pan et al examined the role of miR-328 in post-transcriptional regulation of ABCG2 in 
breast cancer cell lines. They showed that overexpression of BCRP protein was 
associated with reduction in miR-328 expression. Moreover, when breast cancer cells 
were transfected to over-express miR-328 BCRP protein expression was down-
regulated. Furthermore, inhibition of miR-328 using a selective antagomir resulted in 
up-regulation of BCRP protein expression (Pan et al., 2009).  
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The role of oestrogen in regulation of BCRP expression 
Interestingly, oestrogen and its derivatives can regulate BCRP expression. Ee et al 
discovered a putative oestrogen response element (ERE) in the BCRP promoter 
region. They also showed that ABCG2 mRNA expression was increased by the 
addition of 17β-oestradiol (E2) in the ER positive T47D and PA-1 breast cancer cell 
lines. This effect was reversed by the use of anti-oestrogen ICI 182,780. PA-1 cell lines 
were transfected with the BCRP promoter-luciferase reporter gene construct, along 
with an ERα expression vector. The subsequent luciferase assay showed that the 
promoter activity was enhanced in the presence of E2 (Ee et al., 2004). In contrast, 
Imai et al used western blots to show that BCRP protein expression was down-
regulated in response to oestrogen in MCF-7 and T47D cell lines, and this effect was 
reversed by tamoxifen. They concluded that oestrogen caused post-transcriptional 
down-regulation of BCRP expression (Imai et al., 2005). Zhang et al treated MCF-7 
cells with toremifene, an anti-oestrogen, and showed that both ABCG2 mRNA and 
protein expressions were decreased by increasing doses of toremifene (Zhang et al., 
2010). These studies show that oestrogen is likely to have a role in regulating BCRP 
expression. However, the study findings are conflicting as to whether oestrogen up-
regulates of down-regulates BCRP expression. Moreover, these experiments are 
based on cell line models, and currently there is no existing literature on how BCRP 
expressions in the breast tumours of patients are modulated by the changes in 
oestrogen levels. The question is potentially of substantial clinical importance since any 
increases in BCRP expression caused by anti-oestrogen therapies would potentially 
increase subsequent tumour cell therapy-resistance. 
 
The importance of methylation in regulating BCRP expression 
The human BCRP gene is located on chromosome 4 at 4q22. It spans over 66 kb, and 
consists of 16 exons and 15 introns. BCRP promoter region was identified as the 
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region from -300 to -50 relative to the transcription start site, whose nucleotide position 
was found 529 base pairs upstream of the junction between exon 1 and 2 (Nakanishi 
and Ross, 2012). Bailey-Dell et al used bacterial artificial chromosome sequencing and 
Proscan, a promoter identification program, to identify the putative promoter region for 
the ABCG2 gene. The functional importance of this putative promoter region was 
tested by luciferase reporter assay using MCF7 and human choriocarcinoma cell line 
known to have high endogenous BCRP expression. Transient transfection of these cell 
lines with series of deletion constructs, lacking segments of the putative promoter 
region, resulted in reduced transcriptional activity. This assay hence mapped the BCRP 
promoter region, which overlaps the adjacent CpG island (Bailey-Dell et al., 2001). 
CpG islands are regions with a high frequency of CpG sites. CpG sites are when a 
cytosine nucleotide occurs adjacent to guanine nucleotide (cytosine being 5 prime to 
the guanine nucleotide) in a linear fashion on the same strand (rather than the CG 
base pairing of cytosine and guanine between strands). The cytosine in CpG sites can 
be methylated to form 5-methylcytosine, which can lead to gene silencing in some 
cases, particularly within CpG islands. The methylated CpGs can prevent the binding of 
transcription factors, or recruit methyl-binding proteins which repress transcription.  
 
Methylation of CpG islands is maintained by DNA methyltransferases (DNMT), and 
may be inhibited by 5-aza-2'-deoxycytidine (5-aza-dC) or by siRNAs specific for 
DNMTs, leading to reactivation of gene expression (Jung et al., 2007). Methylation 
status can be experimentally assessed by bisulphite treatment of DNA, which converts 
unmethylated cytosine to uracil, but leaves methylated cytosine intact. PCR 
amplification of the modified DNA then replaces uracil with thymine. The resulting 
product can be sequenced and aligned against a reference sequence to examine the 
methylation status of individual CpG sites – methylated sites are read as cytosine while 
unmethylated sites are read as thymine.  
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There is growing evidence that the methylation status of CpG islands in the ABCG2 
promoter region has a crucial role in regulating BCRP expression. Turner et al 
performed bisulphite sequencing analysis on multiple myeloma cell lines and 
determined that degree of methylation at the ABCG2 promoter region was inversely 
correlated to the ABCG2 mRNA levels. H929 cell lines were completely methylated in 
the 13 CpG sites examined, and subsequent 5-aza-dC treatment resulted in the up-
regulation of ABCG2 mRNA expression. Moreover, the cell line results were reflected 
in the patient samples where the percentage of methylated sites within the ABCG2 
promoter was inversely correlated to the ABCG2 mRNA expression (Turner et al., 
2006). Bram et al confirmed these findings when examining ABCG2 promoter 
methylation patterns in breast, ovarian, and T-cell leukaemia cell lines (Bram et al., 
2009). Furthermore, the increase in ABCG2 mRNA levels observed after 
chemotherapy was due to site-specific demethylation, rather than global demethylation 
of CpG sites within the ABCG2 promoter.  
 
The above studies have examined the methylation status of BCRP promoter regions 
and found that the degree of methylation was inversely correlated to ABCG2 mRNA 
expression levels. However, this has not been examined in detail in breast cancer cell 
lines or in clinical breast cancer samples. Furthermore, the above studies have not 
examined whether BCRP protein expression is influenced by the methylation status of 
BCRP promoter regions.  
 
Regulation of BCRP in NAET 
In the clinical setting, some patients are treated with NAET, which modulates oestrogen 
levels or its function (see Section 1.4). This provides an ideal setting for examining 
143 
 
BCRP expression levels before and after manipulation of oestrogen function and for 
investigating the regulatory mechanisms involved in defining these levels. When 
endocrine therapy is given in the adjuvant setting, patients who require chemotherapy 
are given this treatment first, followed by endocrine therapy. However, in NAET a 
subset of patients will subsequently receive adjuvant chemotherapy. Therefore, the 
impact of NAET on BCRP expression has potential therapeutic implications. For 
example, if NAET causes up-regulation of BCRP expression, this may potentially 
reduce the efficacy of adjuvant chemotherapy. Conversely, if NAET causes down-
regulation of BCRP expression, this may support the use of concurrent chemotherapy 
and endocrine therapy. The latter is not currently recommended in clinical practice, 
although a phase II clinical trial has shown a marginal benefit in breast cancer patients 
randomised to letrozole plus cyclophosphamide, compared to letrozole alone (Bottini et 
al., 2006).  
 
In this chapter, my aim was to investigate the effect of modulating oestrogen level or 
function on BCRP expression using clinical samples from patients treated with NAET. I 
then investigated whether BCRP promoter methylation was involved in defining BCRP 
expression in breast cancers. Initially, I used breast cancer cell lines for assay 
development, but I then applied assays to the same NAET clinical samples. This 
approach allowed examination of the relationship between methylation levels and 
protein expression in clinical samples. I also examined whether NAET influenced 
BCRP promoter methylation.     
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6.3 Results 
6.3.1 BCRP expression was significantly up-regulated after NAET  
I aimed to determine expression levels of BCRP both pre- and post-treatment in the 
tumours of a cohort of breast cancer patients treated with NAET. A cohort of 51 
patients was assembled who had matching pre-NAET core biopsy tissues and post-
NAET resection tissues (Table 3.2). Immunohistochemistry for BCRP was performed 
and quantified with the protocols used previously (Section 3.6), and I examined 
whether NAET modulates BCRP expression, and if expression levels have any 
significance in terms of response to NAET or subsequent survival. Detectable BCRP 
expression was mainly in epithelial cells, with localisation that was mainly cytoplasmic 
or membrane-associated with some accentuation of cell nuclei. This was similar to the 
staining patterns observed in the NAC cohort. Protein expression was successfully 
quantified in all 51 matched pairs of core and resection tissues; these data are shown 
in Appendix Section 1: Table S5. The following representative images demonstrate the 
changes in protein expression after exposure to NAET (Fig 6.1); BCRP expression was 
up-regulated post-NAET in majority of the cases; 48/51 cases (94%) (Fig 6.2), and this 
up-regulation was statistically significant (Wilcoxon signed-rank tests: p<0.0001) (Fig 
6.2).  
 
 
 
 
 
 
 
145 
 
 
 
 
 
 
 
 
Figure 6.1: Immunohistochemistry for BCRP in the NAET cohort (x20 magnification). 
The representative matched pair of images show very little/no staining in the core 
tissues (pre-NAET), as opposed to stronger staining in the resection tissues (post-
NAET). These images represent the significant up-regulation in BCRP expression.  
 
 
 
            Pre-NAET            Post-NAET 
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 Figure 6.2: BCRP expression is up-regulated after exposure to NAET (red: up-
regulation, blue: down-regulation; left). Matched pre-NAET and post-NAET breast 
cancer samples were stained using immunohistochemistry for BCRP. Expression 
within tumour cells was quantified as a histoscores of 0 – 300. Expression levels in 
matched samples are linked by lines coloured red or blue so as to indicate an increase 
or decrease in expression respectively. BCRP up-regulation was seen in 48/51 cases 
(94%). The right panel shows median histoscore values with interquartile range (n=51) 
and demonstrates a significant overall increase in BCRP expression after NAET 
exposure (Wilcoxon signed-rank tests: p<0.0001). 
                      
6.3.2. Correlation of BCRP expression with clinico-pathological parameters 
My next aim was to analyse potential correlations between pre- and post-NAET BCRP 
expression levels, as well as the change in expression levels, against various clinico-
pathological parameters (outlined in Table 3.2) using Spearman’s rho analyses (Table 
6.1). Change in BCRP expression level was determined by subtracting matched pre-
NAET BCRP histoscores from post-NAET BCRP histoscores, with positive values 
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designated as up-regulation, and negative values designated as down-regulation. As 
stated in section 4.3.5, a more strict threshold of p<0.01 was used to indicate statistical 
significance. No significant correlations were observed for BCRP expression with the 
clinico-pathological parameters. The expression levels and the change in expression 
levels were then examined against the response to NAET. The latter was defined as 
the categorical changes in tumour stage (TNM staging) after NAET, or as the 
quantitative changes in tumour size derived from comparison of resection pathology 
tumour sizes to pre-NAET ultrasound tumour sizes (Table 6.1). No significant 
correlations were observed. NAET regimen and duration were also not significantly 
correlated to BCRP expression level pre- or post-NAET or the change in expression 
levels. 
 BCRP 
pre 
 
BCRP 
post  
BCRP ∆  
 
Age at diagnosis 0.16 
(0.27) 
0.1 
(0.49) 
0.06 
(0.7) 
Tumour factors determined pre-NAET    
Grade 0.12 
(0.39) 
-0.06 
(0.68) 
-0.05 
(0.76) 
T Stage    0.02 
  (0.87) 
-0.21 
(0.14) 
-0.2 
(0.16) 
PR status -0.17 
(0.26) 
-0.06 
(0.68) 
-0.03 
(0.83) 
Histological type 0.1  
(0.5) 
0.15 
(0.3) 
0.1 
(0.5) 
Tumour factors determined post-NAET    
T stage 0.07 
(0.65) 
-0.12 
(0.39) 
-0.08 
(0.58) 
Lymphovascular invasion -0.04 
(0.78) 
 -0.17 
(0.24) 
-0.12 
(0.4) 
Axillary metastasis -0.05 
(0.72) 
-0.36 
(0.011) 
-0.3 
(0.04) 
Duration of NAET -0.02 
(0.89) 
0.05 
(0.71) 
0.13 
(0.35) 
NAET regimen -0.2 
(0.17) 
-0.09 
(0.55) 
-0.002 
(0.99) 
Tumour response    
∆ T stage -0.09 
(0.54) 
0.05 
(0.74) 
0.14 
(0.33) 
∆ in tumour size  0.03 
(0.84) 
0.24 
(0.11) 
0.33 
(0.02) 
 
Table 6.1: Spearman’s correlation coefficients demonstrating relationships between 
expressions pre- or post-NAET, or change in expression (∆) for BCRP with clinico-
pathological parameters and tumour response (p values are denoted in brackets). 
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6.3.3 Pre-NAET BCRP expression predicts disease free survival 
Pre- and post-NAET BCRP expression levels as well as the change in expression 
levels were then analysed for correlations with DFS. For pre- and post-NAET 
expression levels, ROC curve analysis was performed to dichotomise expression into 
high and low expression groups. The cut-offs providing the highest combined sensitivity 
and specificity for prediction of DFS were selected; the respective cut-offs for 
histoscores were 13.6 for pre-NAET and 112.9 for post-NAET. For change in 
expression level, values were dichotomised into up-regulation or down-regulation. 
Kaplan-Meier Survival analyses were performed (Figure 6.3). There were no significant 
relationships between DFS and post-NAET BCRP expression levels or change in 
BCRP expression levels.  However, pre-NAET BCRP expression levels significantly 
correlated with DFS (Log rank: p=0.027); patients with high BCRP expression had a 
relatively poor 5-year survival of 63.6%, compared to those with low BCRP expression 
for whom 5-year survival was an excellent 93.3% (Fig 6.3). Multivariate Cox regression 
analysis was performed taking into account the pathological factors typically regarded 
as having prognostic impact, including tumour grade, histological subtype, receptor 
status, axillary metastasis, tumour stage, receipt of adjuvant chemotherapy or 
radiotherapy and lymphovascular invasion. This showed that high BCRP expression 
pre-NAET independently predicted DFS, with a hazard ratio of 19.1 (95% confidence 
interval, 1.05-348.2; p=0.046).  
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Figure 6.3: Kaplan-Meier survival analyses for BCRP expression levels and its change 
versus disease free survival. No significant correlation was detected for the change in 
expression levels or post-NAET expression level. However, high BCRP expression pre-
NAET significantly predicted for poorer disease free survival.  
 
6.3.4 Investigation of the role of BCRP promoter methylation in defining BCRP 
expression levels in breast cancers 
My eventual aim was to investigate whether methylation status of ABCG2 promoter 
region influenced BCRP protein expression observed in my cohorts of both NAC (see 
Section 4.3.1) and NAET (see Section 6.3.1) treated breast cancers and whether 
changes in methylation related to the changes in expression seen after treatment. In 
order to achieve this aim, in vitro experiments using cell lines were carried out initially 
to develop assays to assess BCRP promoter methylation. The cells lines used were 
the luminal breast cancer line MCF7, the non-neoplastic breast epithelial cell line HB2 
and two multiple myeloma cell lines (H929 and HL60), for which BCRP promoter 
methylation levels have previously been reported (Turner et al., 2006). DNA was 
extracted from these cell lines and bisulphite treated before amplification of a 257bp 
BCRP promoter region that reportedly undergoes methylation that regulates BCRP 
expression (Chen et al., 2012a). Amplified DNA was cloned and individual clones were 
sequenced; this enabled examination of the methylation of 27 CpG sites for each 
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individual clone (see Section 3.11 to 3.14). Chen et al showed that the ABCG2 
promoter region was globally unmethylated in pancreatic cancer cell line SW1990 
(Chen et al., 2012a). Turner et al showed that H929 cell line demonstrated infrequent 
methylation, while methylation was prevalent in HL60 cells (Turner et al., 2006). In 
accordance with published data (Chen et al., 2012a, Turner et al., 2006) both breast 
cell lines and H929 cell line demonstrated only infrequent methylation, while 
methylation was prevalent in HL60 cells (Fig 6.4).  
 
 
Figure 6.4: Examination of methylation status in the 27 CpG sites within the Chen et al 
amplicon. Black lollipops show methylated CpG sites, white lollipops show 
unmethylated CpG sites and yellow lollipops show data that were not interpretable. 
Each row represents individual clones. The majority of CpG sites were unmethylated in 
MCF7, HB2, and H929 cell lines. In contrast, CpG sites were globally methylated in 
HL60 cells. The red rectangles encompass the 4 CpG sites to be examined by 
pyrosequencing (see below).  
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Next, I examined whether BCRP protein expression correlated with these methylation 
levels. Western blots were performed using cell lysates from the four cell lines (see 
Section 3.10). Western blots showed that the level of BCRP expression was 
considerable in MCF7, HB2, and H929 cells, reflecting their unmethylated status. 
However, BCRP expression was attenuated in the HL60 cells, reflecting the methylated 
status (Fig 6.5). This demonstrates a potential inverse correlation between protein 
expression and methylation status of the BCRP promoter region, and implicated 
methylation as a key regulatory event.  
 
                       
Figure 6.5: Western blot examining differential expression of BCRP in MCF7, HB2, 
H929, and HL60 cells.  
 
Finally, I aimed to use pyrosequencing assays to determine methylation of specific 
CpG sites. This was because it was unlikely to be possible to amplify the relatively 
large amplicon described above from small, clinical FFPE samples, such as the breast 
biopsies I aimed to analyse ultimately. FFPE tissues have fragmented DNA, and for 
bisulphite modification and analysis the amplicon length should ideally be less than 150 
base pairs (Patterson et al., 2011). Therefore, this limits the number of CpG sites that 
can be examined. Given these constraints, two pyrosequencing assays were designed 
    75 kDa 
Beta actin 
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within the Chen et al amplicon resulting in 4 representative CpG sites to be examined 
with pyrosequencing. The 4 CpG sites are highlighted within the red boxes on Figure 
6.4; these were compatible with the criteria required for pyrosequencing and their 
methylation status appeared to be representative of the entire region for each cell line. 
Pyrosequencing analysis was performed for the 4 CpG sites in the 4 cell lines to 
confirm that pyrosequencing analyses reproduced the results obtained using bisulphite-
treatment and molecular cloning (Table 6.2). This showed that both assays showed the 
same pattern of methylation between the cell lines and hence validated the use of the 
pyrosequencing assays.   
 
CpG sites and degree of 
methylation 
Position 165  
       (%) 
Position 172   
        (%) 
Position 236   
        (%) 
Position 250     
       (%) 
MCF7         0        2.95        1.77       8.63 
HL60        60         59         58        63 
HB2         0          0        1.72       6.51 
H929         0          0        2.1       7.45 
 
Table 6.2: Pyrosequencing analysis of the designated 4 CpG sites (see Fig 6.4) to be 
used for methylation analysis of clinical samples. As per molecular cloning analysis, 
high degree of methylation is seen in the HL60 cell line with barely detectable degree 
of methylation observed in the MCF7, HB2, and H929 cell lines. Therefore, this 
validated the use of pyrosequencing analysis for the clinical samples. 
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6.3.5 Pyrosequencing analysis of BCRP promoter methylation using clinical 
samples from patients treated with NAET 
Having developed successful pyrosequencing assays that apparently provided insights 
into functionally-relevant BCRP promoter methylation, my next aim was to apply these 
assays to examine the methylation status of the BCRP promoter region in clinical 
samples from my neoadjuvant cohorts to determine if methylation status of BCRP 
promoter region influenced protein expression, and whether neoadjuvant therapy 
influenced the methylation status of the BCRP promoter region. Only the NAET cohort 
was available for this analysis, since I was unable to regain access to the clinical 
blocks for the NAC cohort. 46 core tissues and 51 resection tissues within the NAET 
cohort had sufficient tissue to attempt DNA extraction, bisulphite treatment, and 
pyrosequencing (see Section 3.11.2, 3.12, and 3.15). Data for the selected 4 CpG sites 
within the BCRP promoter region are shown in Appendix Section 1, Table S6. The 
analyses were successful for at least two CpG sites in only 36/46 pre-NAET core 
tissues, and for all four CpG sites in only 17/46 tissues. For the post-NAET resection 
tissues, pyrosequencing analysis was successful for at least two CpG sites in 48/51 
cases and for all four sites in 33/51 cases.  
 
The level of methylation varied from 0-40.7% in the pre-NAET samples, as opposed to 
0-33.9% in the post-NAET samples. The medians and ranges of methylation for each 
CpG sites are shown in Table 6.3. This showed that methylation was barely detectable 
for the CpG sites at position 165, 172, and 236 pre- or post-NAET. The degree of 
methylation was more pronounced on position 250 however. Figure 6.6 shows that 
methylation levels did not change significantly after exposure to NAET. Although the 
change in methylation level in position 236 was statistically significant, the median 
change in methylation level was minimal (from 0 to 2.9%). 
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CpG sites and 
degree of 
methylation; 
median with 
range in brackets 
Position 165  
       (%) 
Position 172   
        (%) 
Position 236   
        (%) 
Position 250     
       (%) 
Pre-NAET 2.5 (0-22) 0 (0-10.4) 0 (0-17.8) 10.1 (0-47.4) 
Post-NAET 0 (0-12.3) 0 (0-7.8) 2.9 (0-16.9) 11.6 (0-33.9) 
 
Table 6.3: Pyrosequencing analyses showing the degrees of methylation of 4 specific 
CpG sites. The degree of methylation is displayed for each site both pre- and post-
NAET as percentages with mean and range. 
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Figure 6.6: Analysis of pyrosequencing assay for the 4 CpG sites. Each CpG site is 
denoted in a different colour. The degree of methylation is displayed showing median 
with range. Apart from position 250, the remaining 3 CpG sites showed low degrees of 
methylation pre- or post-NAET. NAET did not result in change in methylation status of 
CpG sites shown by the p values (Mann-Whitney unpaired t-test) apart from position 
236. However, the degree in change of median was minimal (from 0 to 2.9%) in 
position 236. 
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Examination of the change in methylation level after exposure to NAET for individual 
cases were possible in 32 cases for position 165 and 172, and for 13 cases for position 
236 and 250. Increases in methylation were observed after NAET in 11/32 cases for 
position 165, 12/32 cases for position 172, 8/13 cases for position 236, and 7/13 cases 
for position 250 (Fig 6.7).  
 
Figure 6.7: Matched comparison of methylation level after exposure to NAET. Each 
graph shows change in methylation level after NAET exposure for each CpG positions 
as determined by pyrosequencing; CpG positions 165 and 172 (n=32), and CpG 
positions 236 and 250 (n=13). Red lines denote increases in methylation level, and 
blue lines denote decreases in methylation level. Increases in methylation levels were 
observed in 34.3% and 37.5% for CpG positions 165 and 172. Increase in methylation 
levels were more frequently observed for CpG positions 236 and 250 (61.5% and 
53.8% respectively).  
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6.3.6 Correlation of methylation levels in BCRP promoter region with protein 
expression 
Using the data from the pyrosequencing analysis, I then examined whether methylation 
level of the CpG sites in the clinical samples correlated with the matching protein 
expression as determined in Section 6.3.1 by immunohistochemistry. This was 
performed using Spearman’s rho analysis by comparing the degree of methylation as 
determined by pyrosequencing analysis with histoscore assessments of protein 
expression. Pre- and post-NAET histoscores were compared to pre- and post-NAET 
methylation levels respectively for the 4 CpG sites examined. The change in protein 
expression was determined by subtracting pre-NAET histoscore from the matching 
post-NAET histoscore. Similarly change in methylation level was determined by 
subtracting pre-NAET methylation level from the matching post-NAET methylation 
level. This enabled comparison of the change in methylation level with change in 
protein expression after exposure to NAET (Table 6.4). Pre- or post-NAET BCRP 
protein expression was not correlated with methylation level of the BCRP promoter 
region pre- or post-NAET respectively. Change in BCRP protein expression was 
subsequently compared to change in methylation levels. Again, no significant 
relationships were seen.   
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 Pre-NAET BCRP protein 
expression (n=51) 
Post-NAET BCRP protein 
expression (n=51) 
∆ BCRP protein 
expression (n=51) 
Pos 165 pre 
n=36 
0.17 (0.33)   
Pos 165 post 
n=48 
 -0.14 (0.35)  
Pos 165 ∆ 
n=32 
  0.1 (0.6) 
Pos 172 pre 
n=36 
0.08 (0.66)   
Pos 172 post 
n=48 
 -0.18 (0.22)  
Pos 172 ∆ 
n=32 
  -0.1 (0.59) 
Pos 236 pre 
n=18 
-0.04 (0.87)   
Pos 236 post 
n=36 
 0.32 (0.06)  
Pos 236 ∆ 
n=13 
  -0.03 (0.91) 
Pos 250 pre 
n=18 
0.05 (0.83)   
Pos 250 post 
n=36 
 0.11 (0.51)  
Pos 250 ∆ 
n=13 
  -0.35 (0.24) 
 
Table 6.4: Spearman’s correlation coefficients demonstrating relationships between 
protein expression pre- or post-NAET, or change in expression (∆) for BCRP versus 
methylation levels of 4 CpG sites pre- or post-NAET, or change in methylation (∆) of 
BCRP promoter region as determined by pyrosequencing (p values are denoted in 
brackets). 
158 
 
Finally, data concerning pre- and post-NAET samples were combined to determine 
whether methylation levels at each of the four CpG sites correlated with expression in 
up to 82 samples (Table 6.5). This analysis, surprisingly, showed that the degree of 
methylation on CpG position 236 was positively correlated with protein expression 
(rho=0.39; p=0.003). The methylation levels of the remaining 3 CpG sites did not show 
significant correlations with protein expression.  
 
                Pre- and post-NAET combined methylation level 
       Pos 165 
        (n=82) 
       Pos 172 
         (n=82) 
      Pos 236 
       (n=54) 
     Pos 250 
       (n=54) 
Pre- and post-
NAET combined 
protein expression 
         -0.08     
          (0.5) 
         -0.02    
         (0.88) 
         0.39   
      (0.003) 
         0.18   
         (0.2) 
 
Table 6.5: Combined analysis of protein expression versus methylation level. For each 
of the 4 CpG sites, the methylation levels pre- and post-NAET were combined and then 
compared against combined pre- and post-NAET protein expression using Spearman’s 
rho analysis (p values are denoted in brackets). Methylation level of position 236 was 
positively correlated with protein expression (rho=0.39; p=0.003). No significant 
correlation was observed for the remaining 3 CpG sites however. 
 
6.3.7 Comparison of BCRP promoter region methylation with clinico-pathological 
parameters 
My next aim was to analyse potential correlations between pre- and post-NAET 
methylation levels of the 4 CpG sites within the BCRP promoter region as well as the 
change in methylation levels, and the clinico-pathological parameters (outlined in Table 
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3.2) using Spearman’s rho analyses (Table 6.6). As stated in Section 4.3.5, a more 
strict threshold of p<0.01 was used to indicate statistical significance. The presence of 
axillary metastasis was positively correlated with the change in methylation of CpG site 
250 (rho=0.83; p=0.001). Therefore, axillary metastasis was more likely to be detected 
in patients where the methylation level of CpG site 250 was increased after exposure to 
NAET. Multivariate linear regression analysis was performed to determine if change in 
methylation of CpG site 250 predicted the presence of axillary metastasis. The 
following clinico-pathological parameters were included in the analysis; tumour grade, 
pre- and post-NAET tumour stage, lymphovascular invasion, histological subtype, 
duration of NAET, and NAET regimen. The change in methylation of CpG site 250 still 
remained significant upon multivariate analysis in predicting the presence of axillary 
metastasis (p=0.013).  
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Table 6.6: Spearman’s correlation coefficients demonstrating relationships between 
methylation level pre- or post-NAET, or change in methylation level (∆) with clinico-
pathological parameters (p values are denoted in brackets). 
 
Methylation levels and the change in methylation levels were then examined against 
the response to NAET. The latter was defined in two separate ways: the change in 
tumour stage after NAET (TNM staging), and as a quantitative change in tumour size 
derived from comparison of resection pathology to pre-NAET USS (Table 6.7). This 
analysis showed no significant correlation between pre- or post-NAET methylation 
levels and the change in methylation levels of the 4 CpGs sites with tumour response 
to NAET. 
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 Pos 
250 
pre 
 
Pos 
250 
post  
Pos 
250 
∆  
 
Pos 
236 
pre 
Pos 
236 
post  
Pos 
236 
∆  
 
Pos 
172 
pre  
Pos 
172 
post  
Pos 
172 
∆  
 
Pos 
165 
pre 
Pos 
165 
post 
Post 
165 
∆ 
∆ T 
Stage 
-0.07 
(0.8) 
0.08 
(0.68) 
0.32 
(0.3) 
0 
(1) 
0.19 
(0.29) 
0.39 
(0.21) 
0.26 
(0.15) 
0.01 
(0.98) 
-0.16 
(0.39) 
0.21 
(0.24) 
-0.06 
(0.72) 
-0.21 
(0.27) 
∆ in 
tumour 
size 
-0.08 
(0.77) 
-0.13 
(0.46) 
0.1 
(0.76) 
0.04 
(0.88) 
-0.01 
(0.95) 
0.06 
(0.86) 
-0.11 
(0.56) 
-0.05 
(0.77) 
0.07 
(0.73) 
-0.03 
(0.86) 
-0.09 
(0.58) 
0.06 
(0.76) 
 
Table 6.7: Spearman’s correlation coefficients demonstrating relationships between 
methylation levels pre- or post-NAET, or change in methylation levels (∆) with tumour 
response (p values are denoted in brackets). 
 
6.3.8 Comparison of methylation level of BCRP promoter region with disease free 
survival 
Pre- and post-NAET methylation levels as well as the change in methylation levels 
were then compared against DFS using Kaplan-Meier Survival analyses, after 
dichotomisation as previously using ROC curve analysis (for pre-NAET and post-NAET 
levels; see selected cut-offs in Table 6.8) or simply into increased or decreased groups 
(for change in methylation).  
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 Pos 165 Pos 172 Pos 236 Pos 250 
Cut-off 
methylation 
level pre-
NAET 
5.8 4.7 6.8 41.7 
Cut-off 
methylation 
level post-
NAET 
1.8 
 
12.4 11.9 28.9 
 
Table 6.8: Cut-off values for methylation levels based on ROC curve analysis. Pre- and 
post-NAET methylation level cut-off were determined for the 4 CpG sites based on the 
highest point of combined sensitivity and specificity. 
 
Subsequent Kaplan-Meier survival analyses showed that change in methylation levels 
after exposure to NAET did not predict DFS. High pre-NAET methylation levels in CpG 
positions 165 and 172 predicted for poor DFS (Log rank: p=0.009 and p<0.01 
respectively). High post-NAET methylation levels in CpG positions 165, 172, and 250 
also predicted for poor DFS (Log rank: p=0.018, p=0.03, and p=0.003 respectively (Fig 
6.8). Multivariate Cox regression analysis was performed taking into account the 
pathological factors typically regarded as having prognostic impact, including tumour 
grade, histological subtype, receptor status, axillary metastasis, tumour stage, receipt 
of adjuvant chemotherapy or radiotherapy, and lymphovascular invasion. This showed 
that methylation levels pre or post-NAET did not predict DFS independently (Table 
6.9).  
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Figure 6.8: Kaplan-Meier survival analyses for BCRP methylation levels and its 
change versus disease free survival. Each row denotes each of the four CpG positions 
examined. For CpG position 165, high pre- and post-NAET methylation level predicted 
poor DFS (p=0.009 and p=0.018 respectively). For CpG position 172, high pre- and 
post-NAET methylation level predicted poor DFS (p<0.01 and p=0.03 respectively). For 
CpG position 250, high post-NAET methylation level predicted poor DFS (p=0.003).  
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CpG positions Log rank p value P value after multivariate Cox 
regression analysis 
165 pre-NAET 0.009 0.21 
172 pre-NAET <0.01 0.22 
165 post-NAET 0.018 0.24 
172 post-NAET 0.03 0.26 
250 post-NAET 0.003 0.93 
 
Table 6.9: Results of multivariate Cox regression analysis on disease free survival 
versus methylation levels of the CpG sites examined. Although Kaplan-Meier analysis 
showed that the above methylation levels predicted for DFS on the Log rank p values, 
subsequent multivariate Cox regression showed that methylation levels of the 
examined CpG sites did not independently predict DFS. 
 
6.3 Discussion 
 
Impact of NAET on BCRP expression and its significance 
In this chapter I first established that BCRP protein expression was up-regulated after 
exposure to NAET using immunohistochemistry performed on clinical FFPE samples. 
This has several significances. Firstly, this study clarifies the previous conflicting in vitro 
findings regarding the role of oestrogen in regulation of BCRP expression. Ee et al 
showed that ABCG2 mRNA expression was enhanced by the addition of 17β-
oestradiol, and this effect was reversed by the use of anti-oestrogen ICI 182,780. (Ee 
et al., 2004). In contrast, Imai et al used western blot experiment to show that BCRP 
expression was down-regulated in response to oestrogen, and this effect was reversed 
by tamoxifen (Imai et al., 2005). The results from immunohistochemistry in this study 
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concur with the latter study findings. This effect was irrespective of duration of NAET or 
the NAET regimen in this study. Secondly, given that BCRP expression is up-regulated 
after NAET, this raises the question regarding the efficacy of chemotherapy after 
NAET. It might be expected that administration of adjuvant chemotherapy would have 
reduced efficacy given the high BCRP expression post-NAET, although it remains 
unknown how long the raised BCRP levels would be maintained post-NAET. In the 
current study cohort, only 6/51 patients received adjuvant chemotherapy after 
completion of NAET, and no further tissues were available after adjuvant 
chemotherapy to further study BCRP expression. This question requires examination in 
a larger cohort to determine the role of sequential chemotherapy following NAET. 
Another key finding was that high BCRP expression pre-NAET independently predicted 
poorer disease free survival in patients. This has potential clinical significance in 
predicting which subset of patients may have poor disease free survival following 
NAET. These patients may benefit from adjuvant chemotherapy to potentially improve 
disease free survival, bearing in mind the potential question regarding the efficacy of 
chemotherapy post-NAET. It is difficult to envisage how the pre-NAET BCRP levels in 
tumour cells could have a direct functional link with response to therapy in these cases 
as these levels invariably change after NAET (and these changed levels were not 
associated with survival), and the main target for the aromatase inhibitors used in most 
of these patients is not even in the breast cancer cells themselves. It may be that 
BCRP levels are simply a marker of a more aggressive tumour. In support of this, high 
BCRP expression “side population” cells are known to be resistant to chemotherapy 
and radiotherapy, and have potential for colony formation and proliferation. These cells 
are enriched for cancer stem cells, characterised by their low accumulation of Hoechst 
dye, which is mediated by functional BCRP. They are also characterised by CD44 
expression, and no or low CD24 expression (CD44+CD24-/low) (Nguyen et al., 2010). 
Therefore, high BCRP expression observed in this study may be a marker of cancer 
stem cell activity in breast cancer, and hence associated with higher rates of disease 
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recurrence. In any event, this finding requires further validation in an independent 
cohort. The semi-automated method of protein expression quantification in this study 
lends itself well for this purpose due to its reproducibility. It is worth noting that this 
study is the first to examine BCRP expression in an NAET cohort. Guidelines suggest 
NAET duration of 3 to 4 months (Chia et al., 2010) although this is variable in clinical 
practice, as reflected by my study cohort. In any event, my study showed that NAET 
treatment duration did not have any impact on the degree of change in BCRP 
expression (see Table 6.1). 
 
Investigation of methylation levels in BCRP promoter region in vitro and in clinical 
samples 
An inverse relationship between BCRP promoter region methylation level and ABCG2 
mRNA and/or protein expression has been well established in vitro. Nakano et al 
treated human small lung cancer cell line, PC-6, with 5-aZa-dC to induce demethylation 
of the BCRP promoter region. This treatment resulted in increased expression at the 
mRNA and protein levels (Nakano et al., 2008). Similarly, our in vitro experiment 
results showed that hypomethylation seen in the MCF7 cell line was reflected in 
substantial BCRP protein expression seen on immunoblotting. However, no difference 
in the degree of methylation was observed between the MCF7 breast cancer cell line 
and the non-cancerous HB2 breast cell line. Similarly, Wu et al showed that ABCG2 
promoter region was hypomethylated in lactating mouse mammary gland (Wu et al., 
2014a), supporting the cell line findings in this study that hypomethylation of ABCG2 
promoter region is not specific to cancer cells. The low levels of methylation in the four 
CpG sites examined in the clinical samples pre- and post-NAET mirror the low levels of 
methylation seen in the breast cell lines. Moreover, NAET exposure did not significantly 
change methylation levels in the matched FFPE tissue samples. This is a novel 
approach to examine the potential effect of endocrine therapy on methylation level of 
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BCRP promoter region. Other previous studies have examined the effect of DNA 
methyltransferase inhibitors on BCRP expression (Nakano et al., 2008, Turner et al., 
2006), but not of therapeutic drugs. It is also worth bearing in mind that successful 
pyrosequencing analyses of all 4 CpG sites were possible in only 17 pre-NAET core 
tissues and 33 post-NAET resection tissues respectively out of total of 51 cases. This 
is due to the relative lack of core tissue availability compared to resection tissue. 
Although frozen tissue is superior in terms of DNA integrity, patients treated at LTHT do 
not routinely have frozen tissues available for research purposes. DNA extracted from 
FFPE breast tissue blocks has undergone formalin fixation, which cause degradation 
and cross-linking between proteins and protein/DNA bases, resulting in a lower DNA 
yield. In addition, bisulphite conversion also further degrades DNA. 
  
Comparison of protein expression and methylation levels in the clinical samples did not 
result in the significant negative correlation that was expected. Although previous 
studies report an inverse relationship between ABCG2 mRNA expression and level of 
methylation in the BCRP promoter region (Bram et al., 2009, Turner et al., 2006), no 
such direct correlation could be detected when protein expression was compared to 
methylation levels in the clinical samples. Therefore, other mechanisms stated on 
section 6.1 such as gene amplification, transcriptional regulation unrelated to DNA 
methylation, and post-transcriptional regulation by miRNAs amongst other mechanisms 
are likely to have further influences on BCRP protein expression (Nakanishi and Ross, 
2012).  
 
Comparison of methylation levels and their change showed that axillary metastasis was 
more likely to be detected in patients where the methylation level of CpG site 250 was 
increased after NAET exposure. This proved significant on multivariate analysis. A 
decrease in BCRP protein level might have been expected in cases where promoter 
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methylation levels increased after NAET. However, no such inverse correlation was 
detected between methylation level and protein expression in this study, and it may be 
that this correlation between BCRP promoter dynamics and breast cancer behaviour is 
not directly related to BCRP function, but is a marker of a different aspect of the biology 
of the cells. However, in practical terms, examining methylation levels at CpG sites 
within the BCRP promoter region offers potential prognostic insights. Pre- and post-
NAET methylation levels in multiple CpG sites correlated with disease free survival on 
Log-rank univariate analysis, with higher methylation levels predicting poorer disease 
free survival. However, on multivariate analysis none of the methylation levels 
independently predicted disease free survival, demonstrating that these methylation 
levels mark aspects of cancer biology that are already encompassed within the routine 
clinico-pathological assessments. 
 
Given that BCRP expression was shown to have prognostic significance in the NAC 
cohort, the same approach of promoter methylation analysis could have been 
performed – and indeed this was my intention although I was unable to access the 
samples for further analysis. This would have been of interest to study the potential 
effect of chemotherapy on methylation levels of BCRP promoter region, and whether 
methylation was involved in determining the post-NAC BCRP levels that were 
associated with survival. 
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7.0 Discussion 
My work has focused on the analysis of xenobiotic transporter expression in the 
context of neoadjuvant systemic therapy (NST) in breast cancer. Pgp, MRP1, and 
BCRP, have been implicated in resistance to chemotherapy given their ability to efflux 
chemotherapeutics from cancer cells. The translational research carried out in this 
study aimed to identify potential molecular markers that predict tumour response or 
patient survival, and also examined potential underlying molecular mechanisms 
responsible for resistance to NST.  
 
BCRP as a prognostic marker 
This research strategy identified BCRP protein expression as having significance in 
independently predicting disease free survival in both NAC and NAET cohort. This has 
potential importance in the clinical setting since further adjuvant therapeutic strategies 
could be required to improve DFS in patients with high BCRP expression pre-NAET or 
post-NAC. It is interesting that BCRP expression has prognostic significance in both 
cohorts despite their considerable differences. In the NAET cohort, the majority of 
patients were post-menopausal with lower stage and lower grade breast cancers. All 
have high ER expression. In the NAC cohort, the majority of patients were pre-
menopausal with higher stage and higher grade breast cancers. Exposure to NAET 
resulted in overall up-regulation of BCRP expression with up-regulation seen in 48/51 
cases. In contrast, after exposure to NAC, no overall up-regulation of BCRP expression 
occurred with up-regulation seen in 23/39 cases. Despite these differences, BCRP 
expression remains a potential prognostic marker of disease free survival. This finding 
is further supported by other studies where BCRP expression was examined using 
immunohistochemistry in lung (Kim et al., 2009) and pancreatic cancer (Lee et al., 
2012). Both studies have shown BCRP expression to be associated with poor DFS, 
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although this was not in the context of any neoadjuvant therapy. Tumour response to 
NST is categorised using the RESIST criteria which defines tumour response into four 
categories (Table 1.3). In our study BCRP expression in both cohorts did not correlate 
with tumour response, despite the significant correlations observed with DFS. This may 
have been due to the categorical nature of the RECIST criteria giving a non-continuous 
representation of response; therefore, actual change in tumour size was also compared 
to BCRP expression but this again did not detect any significant correlation. This raises 
the question about whether clinical tumour response to NST is representative of 
changes in subsequent DFS. So far studies have shown that only pCR is a marker of 
improved DFS (Cortazar et al., 2014).  
 
Gene regulation of xenobiotic transporters: therapeutic implications 
Two hypotheses concerning gene regulatory pathways were generated by examining 
the changes in xenobiotic transporter expression after NST. A key reason for 
attempting to understand these gene regulatory pathways better is to assess whether 
therapeutic strategies can be designed to manipulate the gene expression of key 
molecules, rather than their function as with traditional small molecule inhibitors. This is 
particularly relevant to the first hypothesis below. A second reason is to understand 
whether and how therapies already in clinic impact on expression of key molecules, 
and therefore whether therapy induced changes in expression should be taken into 
account when planning treatment. 
   
Firstly, significant correlations between MRP1 and Notch1 NICD expressions observed 
after NAC, as well as the relevant study findings by Cho et al and Gonzalez-Angulo et 
al, resulted in the development of hypothesis that Notch1 NICD inhibition would result 
in abrogation of MRP1 activity and thereby enhance the efficacy of chemotherapeutics 
171 
 
(Cho et al., 2011, Gonzalez-Angulo et al., 2012). Chemoresistance continues to remain 
a challenge and alternative strategies are in clinical practice such as tailoring of NAC 
regime according to tumour response, but pCR rates remain low and mastectomy rates 
remain high (13.3% and 62.2% respectively in my study cohort). Therefore, 
manipulation of molecular pathways involved in chemoresistance is likely to have 
impact on improving patient outcome. My own data suggested that Notch1 inhibition 
did not synergise with chemotherapy in terms of reducing cell survival/proliferation – 
however, I also demonstrated poor efficacy of the Notch1 inhibitor used, DAPT. Further 
research in my supervisor’s group shows potential clinical relevance as they showed 
that Notch1 NICD inhibition does indeed enhance chemotherapy efficacy in vitro. A 
further promising study has been reported by Schott et al. They conducted a pre-
clinical and a phase I clinical trial evaluating the use of the GSI MK-0752 in 
combination with docetaxel. For the pre-clinical study, human breast tumour biopsies 
were transplanted into the mammary gland fat-pad of immune deficient mice. 
Treatment with MK-0752 achieved reduction in the breast cancer stem cell population 
in this context. Furthermore, compared to each therapy alone, a combination therapy of 
docetaxel and MK-0752 resulted in enhanced reduction of tumour size in mice. In the 
clinical trial, 30 breast cancer patients received MK-0752 with docetaxel and a 
favourable safety profile was reported (Schott et al., 2013). 
 
In my study, Notch1 NICD expression was significantly up-regulated in breast cancer 
patients treated with NAC. Whilst I did not establish that MRP1 is an important down-
stream target of Notch1 NICD activation, Notch is an oncogene and aberrant Notch 
signalling plays an important role in breast cancer. Its multiple roles in breast cancer 
include tumour proliferation, protection of tumour cells from apoptosis, breast cancer 
stem cell self-renewal, and angiogenesis of the surrounding stroma (Brennan and 
Clarke, 2013). Therefore, Notch inhibition remains an attractive target, and further pre-
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clinical studies are required before Notch inhibitors are to be established for potential 
clinical use.   
 
Secondly, the hypothesis that oestrogen is involved in defining BCRP levels, potentially 
via DNA methylation was examined in clinical samples using immunohistochemistry 
and pyrosequencing assays. While, it was clear that oestrogen activity may impact on 
BCRP expression, there was no evidence that promoter methylation was involved in 
this – and indeed I did not find an inverse correlation between protein expression and 
promoter methylation in the clinical samples. The key clinical implication of these 
findings relate to the up-regulation of BCRP by NAET and whether this impacts on 
response to subsequent therapies (see Section 6.3). 
 
BCRP as a drug target 
In this study, high BCRP expression post-NAC predicted poor DFS. At present, 
patients treated with NAC do not receive further systemic treatment unless they are ER 
positive, and subsequent management is simply clinical surveillance. The group of ER 
negative patients include patients with triple negative breast cancer who have the worst 
prognosis due to lack of alternative systemic treatment apart from chemotherapy. 
Instead of clinical surveillance, patients identified as high risk of recurrence due to high 
BCRP expression post-NAC may in theory benefit from drugs that target BCRP itself, 
such as BCRP inhibitors, immediately after surgery. Similarly, patients with high BCRP 
expression pre-NAET should perhaps be treated with BCRP inhibitors prior to NAET. 
Such anticipatory approaches are likely to be more successful since the level of 
potential systemic tumour burden is likely to be significantly lower than at the time of 
symptomatic disease recurrence where cure becomes unlikely due to the high level of 
systemic tumour burden (Arteaga, 2013). The following studies highlight the 
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development of BCRP inhibitors. Kruijtzer et al treated patients with range of solid 
tumour, including ovarian and colon cancer, with chemotherapeutic topotecan and 
GF120918, a BCRP inhibitor also known as Elacridar, as opposed to topotecan alone. 
It is worth noting that GF120918 is a dual inhibitor which also inhibits Pgp. The 
combination treatment resulted in increased bioavailability of topotecan to 97.1%, 
compared to 40% in topotecan alone group. The addition of GF120918 to topotecan 
did not result in significant additional toxic side-effects (Kruijtzer et al., 2002). However, 
the study cohort included only 16 patients and did not include patients with breast 
cancer. Rabindran et al transfected the MCF-7 cell line to over-express BCRP. They 
examined the effect of Fumitremorgin C (FTC) on accumulation of mitoxantrone, 
doxorubicin, topotecan, and paclitaxel in the BCRP overexpressing MCF-7 cells. Unlike 
GF120918, FTC is a specific inhibitor of BCRP. Treatment with FTC resulted in 
potentiation of toxicity of all the aforementioned chemotherapeutic drugs apart from 
paclitaxel (Rabindran et al., 2000). However, FTC is not currently used in vivo due to its 
significant neurotoxic side effects in mice and other animals (Allen et al., 2002). Allen et 
al showed that an analogue of FTC, Ko143, achieved potent inhibition of BCRP in 
human ovarian carcinoma cell line and mouse fibroblast cell line, demonstrated by 
increased cellular mitoxantrone accumulation. Furthermore, Ko143 was well tolerated 
in mice with no evidence of tissue pathology in major organs under histological analysis 
(Allen et al., 2002). Therefore, Ko143 could potentially be used in future clinical trials to 
investigate whether BCRP inhibition results in improved patient outcome. Interestingly, 
tyrosine kinase inhibitors (TKIs) such as imatinib (Gleevac) and gefitinib (Iressa) have 
also been implicated in BCRP inhibition. The former is used for treatment of chronic 
myeloid leukaemia. A study by Ozvegy-Laczka et al showed that TKIs caused inhibition 
of the ATPase activity of BCRP. TKIs also inhibited BCRP-dependent active 
fluorescent Hoechst dye extrusion in a BCRP-over-expressing HL60 cell line. This 
shows that functional efflux activity of BCRP protein is attenuated by TKIs without 
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affecting expression. Furthermore, treatment with TKIs increased the cytotoxicity of 
mitoxantrone in these cell lines (Ozvegy-Laczka et al., 2004).  
      
Prognostic markers: are single markers enough? 
Given the complexity of breast cancer biology, information gained from panels of 
molecular markers is likely to be more informative than individual markers in the clinical 
setting. Such a panel of molecular markers that provides prognostic information is 
already in current clinical use in the form of MammaPrint (Agendia) and OncotypeDx 
(Genomic health) to aid treatment decisions regarding the use of adjuvant 
chemotherapy (DeMichele et al., 2013). The former is a 70-gene signature test in which 
the genes were identified from a case-control study of young, node negative breast 
cancer patients with more than 10 years of follow-up. Gene expression profiles of 
patients who suffered from disease relapse were distinct from patients who remained 
disease free. The latter examines the expression of 16 outcome-related genes and 5 
reference genes, as measured by RT-PCR. These expressions are combined using a 
mathematical algorithm to calculate the risk of recurrence in patients with ER positive, 
lymph node negative breast cancer (Dowsett and Dunbier, 2008). These clinical tools 
provide objectivity in difficult clinical circumstances where the potential survival gain in 
treating patients with chemotherapy has to be balanced against its potential significant 
side-effects and costs. As yet, MammaPrint or OncotypeDx have not been validated in 
the neoadjuvant setting. Future research in breast cancer patients treated with NAC will 
hopefully identify similar panel of molecular markers, which could be utilised to 
accurately predict response to NAC and survival in individual patients. No panel of 
molecular markers exist for patients who are treated with endocrine therapy, perhaps 
reflecting the fact that patients who are ER positive have an already relatively good 
prognosis. For patients who are treated with NAET, Ellis et al developed pre-operative 
endocrine prognostic index (PEPI) which consists of pathological tumour size and 
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nodal status, Ki67 level, and ER status to predict the risk of disease relapse. Those 
patients who had high PEPI score have higher likelihood of disease relapse and should 
be recommended adjuvant chemotherapy (Ellis et al., 2008). This has particular 
relevance in our study since BCRP expression was up-regulated by NAET and hence 
the efficacy of adjuvant chemotherapy has to be in question. My study cohort of 51 
patients treated with NAET lacks power to answer this question clearly. However, such 
question could potentially be answered by the utilisation of clinical samples from trials 
such as the Perioperative Endocrine Therapy- Individualising Care (POETIC) study 
(Dowsett et al., 2011). In this national multi-centre randomised trial, post-menopausal 
ER positive breast cancer patients received four weeks of aromatase inhibitors peri-
operatively or received no peri-operative treatment with subsets of patients going onto 
receive adjuvant chemotherapy based on criteria such as PEPI. Examination of BCRP 
expression in such cohorts has feasibility as change in BCRP expression in the NAET 
cohort was not influenced by the length of therapy or regime, although unfortunately 
the samples are currently available only for the trial protocol.       
 
NST has shown to be a valuable treatment modality in aiding identification of predictive 
markers and in looking at molecular pathways and changes involved in resistance to 
NST. Its use is currently limited to patients with locally advanced breast cancer who 
would be obligate candidate for mastectomy at the time of diagnosis. It achieves down-
staging of locally advanced breast cancer to enable breast conservation surgery in a 
subset of patients. In patients where tumour to breast volume ratio is small enough to 
enable breast conservation surgery at the time of diagnosis, NST is not routinely 
offered as there is no perceived advantages. In contrast, due to equivalent DFS and 
OS between NST and adjuvant systemic therapy, international expert consensus by 
Berruti et al argue that NST should be used in routine management of operable breast 
cancer (Berruti et al., 2011). There is a rationale behind this approach, but this has to 
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be balanced against the likelihood that surgical management of breast cancer will not 
alter at the end of NST as all patients will receive at least breast conservation surgery 
at present. More patients will require treatment monitoring in the form of MRI with 
added costs, and patients will have to live with tumours in situ during therapy, which 
can result in raised anxiety and psychological morbidity. However, if high proportions of 
patients treated with NST achieved complete pathological response this would extend 
the role of NST in a greater number of patients, especially if these patients could be 
spared surgery. At present, all patients undergo surgery even if MRI monitoring 
indicates complete radiological response, and this is a pragmatic approach given that 
MRI is not sensitive enough to determine complete pathological response. Questions 
about the need for surgery in patients who achieve complete pathological responses 
have been raised by Rea et al, who proposed future trials to investigate the area (Rea 
et al., 2013). However, with the current available regime of NST, the proportion of 
patients who achieve complete pathological response remains low, especially in the 
NAET cohort. Hence, the current approach of limiting NST only to patients who are 
obligate candidates for mastectomy may be appropriate. However, it is hoped that with 
future molecular research and targeted drug development, the efficacy of NST may 
improve to such an extent that NST can be extended to a wider cohort of patients.  
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9.0 Appendix  
9.1 Recipe list 
 
TBS     60ml 2.5M NaCl 
     20ml 1M Tris Hcl 
     Make up to 1L 
 
TBST   As above with the addition of 1.25ml of 10%v/v  
Tween-20 
 
10mM Citric acid buffer (pH 6.0) Add 2.1g citric acid monohydrate to 800ml of 
distilled water. Add 13ml 2M NaOH solution 
dropwise until pH of 6.0 is reached. Make up to a 
final volume of 1L using distilled water. 
 
2M Sodium hydroxide Add 8g of sodium hydroxide to 100ml of distilled  
water 
 
0.3% Hydrogen peroxide Add 1ml of 30% hydrogen peroxide to 99ml of 
100% methanol  
 
Scott’s tap water Add 20g of magnesium sulphate and 3.5g of 
sodium bicarbonate to 1L of distilled water 
 
 
 
 
192 
 
 
RIPA buffer     Tris-HCL 10mM 
EDTA 1mM 
EGTA 0.5mM 
NaCl 140mM 
SDS 0.1% 
Triton x100 1% 
Na Deoxycholate 0.1% 
H2O 
1mM PMSF 
1mM DTT 
1xPIC (P8340; Sigma-Aldrich) 
 
DNA buffer     1M Tris-HCL, 1M. pH 8.0 100ml 
 0.5M EDTA    100ml 
 dH20 water    300ml 
 
TAE buffer    Glacial acetic acid 
     Tris base 
     0.5M EDTA  
 
1% agarose gel Add 2g agarose to 200ml 1x Tris Acetate EDTA 
(TAE) buffer (pH 8.0) and heat in 900W 
microwave for 2 minutes. Once cool, 6ul of 
ethidium bromide was added. 
 
LB solution Add a sachet of LB broth EZMix™ powder 
(L7658; Sigma-Aldrich) to 500ml of distilled water, 
and autoclave for 1 hour. 
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LB agar plate As above with the addition of 7.5g agar and 500ul 
of ampicillin. 25ml of the resulting solution was 
poured onto each Petri dish to set. 
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9.2 Supplementary tables 
         Total automated histoscore         Total histoscore BK           Total histoscore BW  
24.2 37.6 52 
47.7 41.6 49.4 
0.7 0 0 
38.6 106.1 84.6 
82.3 43.2 125.1 
84.5 45 112.5 
65.7 100.8 65.5 
84.2 138.2 136.2 
129 209.7 173.6 
35.2 5.3 40.6 
9.6 0 91.9 
34.3 12.8 51.3 
28.6 36.3 95.2 
67.3 180.5 115.1 
1.2 0 0 
11.1 0 0 
15.7 9.3 25.7 
27.5 4.8 28.9 
0.8 0 0 
153.8 220.4 197.5 
30.6 8 31.9 
6.2 0 0 
3.4 0 0 
13.3 0 0 
10.3 13.3 33.1 
0.4 0 0 
50.1 15.9 27.2 
6.2 0 0 
1 0 0 
60.4 43.1 90.4 
1.8 0 0 
1.4 0 0 
12.2 0 9.9 
61 117.3 104 
172.4 263.1 275 
0.3 0 0 
107 164.4 102.3 
30.4 46.1 78.9 
170.1 133.7 96.6 
8.1 4.7 3.6 
31.5 2.5 9.5 
20.2 1.8 8.8 
20.1 10.9 0 
34.2 43.7 18 
4 0 0 
81.1 134.3 83.3 
17.4 0 6 
32.3 34.4 45 
5.4 4.5 6.3 
64 78.1 141.6 
1 0 3.1 
162.6 170.3 208.2 
61.7 33.3 126.9 
89.2 115.4 130.5 
 
Table S1: Comparison of manual versus automated histoscores 
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SLIDE no 
Pre-NAC 
score BK Pre-NAC score BW 
 
Post-NAC score BK 
 
Post-NAC 
score BW 
1 0 0 
 
3 
 
3 
2 3 3 
 
5 
 
5 
3 3 2 
 
6 
 
4 
4 3 4 
 
0 
 
0 
5 0 0 
 
0 
 
0 
6 3 3 
 
5 
 
4 
7 0 0 
 
2 
 
3 
8 0 0 
 
0 
 
0 
9 0 0 
 
4 
 
4 
10 3 3 
 
7 
 
6 
11 2 3 
 
3 
 
3 
12 0 0 
 
0 
 
0 
13 0 0 
 
8 
 
8 
14 4 4 
 
5 
 
5 
15 2 2 
 
7 
 
6 
16 0 3 
 
8 
 
8 
17 0 0 
 
7 
 
7 
18 0 0 
 
4 
 
4 
19 2 2 
 
7 
 
7 
20 2 2 
 
3 
 
4 
21 3 3 
 
4 
 
4 
22 0 0 
 
3 
 
3 
23 0 0 
 
5 
 
5 
24 4 3 
 
3 
 
3 
25 4 3 
 
0 
 
0 
26 0 0 
 
6 
 
6 
27 0 0 
 
2 
 
2 
28 0 0 
 
7 
 
7 
29 0 0 
 
3 
 
3 
 
Table S2: Allred scores for Notch1 expression 
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         Patient 
number     DNA concentration pre-NAET (ng/ul)    DNA concentration post-NAET (ng/ul) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
62.2 
38.5 
22 
53.5 
12.7 
48.9 
81.8 
139.1 
9.2 
6.1 
94.8 
29 
 
46 
8 
27.1 
47.4 
48.5 
16.1 
45.3 
16.8 
65.1 
41.5 
108.3 
76.1 
48.4 
9.1 
17.4 
44.7 
10.8 
91.8 
12 
 
 
24.7 
13.7 
56.3 
63 
83.7 
 
15 
18.8 
40.8 
10.2 
36.3 
114.8 
14.7 
26.3 
30.3 
43.1 
 
50.2 
295.9 
97 
156.1 
958.1 
60.4 
77.8 
174.9 
454.9 
98.8 
24.6 
299.2 
635.2 
122.8 
138.8 
161.4 
129.3 
135.8 
124.3 
47 
907.9 
400 
68.1 
453.5 
212.4 
452.7 
280.2 
277.7 
25.2 
9 
17.9 
17.9 
253.8 
34.3 
259.2 
581 
127.7 
169.2 
60.9 
338.4 
68.2 
711.3 
48.9 
454.8 
68.9 
386.1 
112.3 
143 
291 
370.3 
58.1 
   
 
Table S3: Concentration of DNA extracted from FFPE tissues 
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Patient 
     Pre-NAC   
          Pgp  
 
 
Post-
NAC 
Pgp  
 
 
Pre-
NAC  
MRP1  
 
 
Post-
NAC 
MRP1  
Pre-NAC  
BCRP  
 
 
Post-
NAC    
      BCRP 
1 0.2 
 
0.3 
 
0.3 
 
64.8 86.3 
 
84.8 
2 0.2 
 
45.3 
 
0.03 
 
59.7 1.6 
 
65 
3 7.8 
 
26.8 
 
5.5 
 
24.6 64.5 
 
89.7 
4 0.6 
 
8.5 
 
0.2 
 
108.5 7.9 
 
88.3 
5 44.6 
 
95.1 
 
1.3 
 
28.6 1.8 
 
11.1 
6 0.2 
 
7 
 
0.1 
 
1 13.8 
 
65 
7 0.2 
 
10.1 
 
0.3 
 
94.4 5.9 
 
72.5 
8 0.05 
 
12 
 
0.02 
 
37.1 19.5 
 
30.2 
9 56 
 
12.1 
 
0.01 
 
75.3 31 
 
50 
10 8.8 
 
100.5 
 
0.02 
 
35.7 58.6 
 
4.3 
11 6.5 
 
32.5 
 
0.5 
 
76.6 22.2 
 
13.5 
12 0.9 
 
35.4 
 
0.1 
 
80.1 20.5 
 
34 
13 8.3 
 
87.8 
 
0.2 
 
84.8 2 
 
39 
14 1.7 
 
34 
 
1.3 
 
84.1 66.8 
 
4.8 
15 31.2 
 
48.8 
 
35.4 
 
18.2 46.3 
 
24.7 
16 79.8 
 
168.7 
 
1.1 
 
39.1 20.8 
 
119.9 
17 5.5 
 
13.2 
 
1.6 
 
0.9 15.3 
 
8.4 
18 12.7 
 
56 
 
0.5 
 
1.8 85.8 
 
40.6 
19 0.4 
 
0.3 
 
0.1 
 
117.5 12.8 
 
29.8 
20 3.7 
 
1.4 
 
1 
 
69.2 5.2 
 
55.4 
21 8 
 
42.1 
 
0.1 
 
30 98.5 
 
22.3 
22 0.1 
 
106.3 
 
0.01 
 
0.5 0.9 
 
161.3 
23 0.04 
 
17.2 
 
0.2 
 
82 0.2 
 
82.8 
24 8.8 
 
16.3 
 
8.1 
 
14.5 13.8 
 
33 
25 9.9 
 
25 
 
6.1 
 
36.7 28.2 
 
25.9 
26 16.2 
 
2.9 
 
0.5 
 
161.6 53.8 
 
18.9 
27 104 
 
107.9 
 
0.8 
 
9.7 7.8 
 
9.4 
28 15.8 
 
58.3 
 
0.4 
 
27.3 2.2 
 
12 
29 0.2 
 
1.4 
 
1.5 
 
0.2 1.5 
 
20.4 
30 86.7 
 
13.1 
 
0.5 
 
197.5 62.3 
 
11.8 
31 48.9 
 
171.4 
 
3.2 
 
55 131.8 
 
133.2 
32 0.6 
 
0.2 
 
0.2 
 
202.9 1.6 
 
115.8 
33 10.6 
 
117.9 
 
1.8 
 
88.4 9.4 
 
13.9 
34 40.1 
 
21.4 
 
0.8 
 
31.7 143.5 
 
73.2 
35 61.1 
 
34.5 
 
0.009 
 
28.9 107 
 
44 
36 30.8 
 
101.3 
 
0.4 
 
25.7 54.9 
 
5 
37 51.2 
 
40.4 
 
0.02 
 
91.5 34.3 
 
23.9 
38 1.8 
 
65.3 
 
0.04 
 
57.7 1.6 
 
82.7 
39 161.7 
 
32.4 
 
0.2 
 
7.4 13.7 
 
11.6 
40 36.8 
 
 
 
0.02 
 
 5 
 
 
41 77.1 
 
 
 
0.05 
 
 1.7 
 
 
42 32 
 
 
 
1.3 
 
 72.7 
 
 
43 34.5 
 
 
 
0.7 
 
 77.9 
 
 
44 97 
 
 
 
0.1 
 
 7.7 
 
 
45 54.5 
 
 
 
0.1 
 
 0.5 
 
 
 
Table S4: Semi-automated histoscores for Pgp, MRP1, and BCRP 
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         Patient    
         number 
    BCRP expression pre-NAET     
            (histoscores: 0-300)   
 BCRP expression post-NAET  
            (histoscores: 0-300) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
0.6 
5.9 
6.9 
2.0 
19.4 
0.6 
1.9 
3.1 
0.8 
10.4 
2.5 
7.4 
1.7 
0.7 
2.1 
33.7 
0.6 
7.0 
1.9 
2.0 
1.4 
4.5 
1.6 
1.7 
16.3 
1.3 
1.3 
2.9 
1.1 
33.7 
14.0 
16.7 
80.6 
13.3 
17.0 
1.2 
26.7 
1.8 
4.0 
5.1 
82.0 
27.8 
8.7 
27.7 
71.2 
2.8 
13.9 
31.6 
2.4 
1.8 
0.9 
40.9 
105.0 
33.8 
38.3 
6.0 
20.7 
50.6 
75.2 
5.5 
31.1 
23.6 
7.5 
87.2 
7.2 
80.0 
105.2 
13.0 
23.6 
45.5 
59.5 
80.7 
33.6 
16.4 
21.9 
19.5 
7.8 
63.5 
34.1 
31.4 
41.2 
16.2 
33.8 
101.5 
33.2 
50.2 
27.1 
120.5 
31.9 
53.4 
58.0 
139.6 
9.0 
42.1 
19.5 
133.4 
48.2 
25.5 
124.5 
28.7 
15.7 
68.8 
   
 
Table S5: Semi-automated histoscores for BCRP expression in the NAET cohort 
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 Pre-NAET methylation %   Post-NAET methylation %   
Patient 
number 
pos 
165 
pos 
172 
pos 
236 
pos 250 BCRP 
expression 
pre-NAET 
pos 
165 
pos 
172 
pos 
236 
pos  
250 
BCRP 
expression 
post-NAET 
1 0 0 0 9.51 0.6 5.79 3.31     40.9 
2 2.96 0 2.57 15.72 5.9 0 0 0 13.3 105.0 
3         6.9 5.59 1.99 7.13 16.35 33.8 
4 0 0     2.0 0 0 9.24 14.31 38.3 
5         19.4 4.17 2 2.23 7.96 6.0 
6 6.54 2.9 0 0 0.6 0 0 0 0 20.7 
7 0 0 0 0 1.9 3.41 0 3.54 10.74 50.6 
8 0 0 17.84 40.74 3.1 6.23 0 6.84 18.44 75.2 
9 2.8 0 0 8.94 0.8     0 23.84 5.5 
10         10.4 0 0 0 16.6 31.1 
11 0 0     2.5 0 0     23.6 
12 1.93 2.18 0 11.41 7.4 0 7 3 14 7.5 
13  NA NA  NA  NA  1.7 0 0 5 20 87.2 
14     0 12.85 0.7 0 0 3.82 11.8 7.2 
15 0 0     2.1 0 0 0 10.8 80.0 
16 0 0     33.7 0 0     105.2 
17 2.47 0 3.47 7.35 0.6 0 0 4.85 14.43 13.0 
18         7.0 0 0 0 11.36 23.6 
19 0 0     1.9 0 7.75 4.1 12.56 45.5 
20 0 0     2.0 1.39 0 1.94 8.12 59.5 
21 0 0     1.4 0 4 4 13 80.7 
22 0 10.06     4.5 0 4.88     33.6 
23         1.6 8.25 0     16.4 
24 3.31 2.78     1.7 12.34 7.61 0 0 21.9 
25 21.97 10.39 10.19 11.39 16.3 6.4 6     19.5 
26 6.45 5.92               7.8 
27         1.3 2.16 6.39 14.52 33.89 63.5 
28         2.9 0 0 5 11 34.1 
29         1.1         31.4 
30 3.61 0 0 10.73 33.7 0 0     41.2 
31 0 0     14.0 4.79 2.56     16.2 
32         16.7 0 0 0 0 33.8 
33  NA NA  NA  NA  80.6 0 0     101.5 
34  NA NA  NA  NA  13.3 0 0 2.99 17.03 33.2 
35 2.96 0 0 14.39 17.0 0 0 7 11 50.2 
36 2.75 0 0 18.83 1.2 0 6.3 8.54 14.99 27.1 
37 0 5.02 0 0 26.7 3.77 6.21     120.5 
38         1.8 0 0 0 8.45 31.9 
39 8.26 3.17 0 12.02 4.0     16.9 18.32 53.4 
40 NA NA  NA  NA  5.1 0 0     58.0 
41 2.89 0     82.0 3.68 2.41 2.65 9.67 139.6 
42 0 0     27.8 5.84 0 0 0 9.0 
43 7.08 4.33     8.7 0 0 3.43 8.53 42.1 
44 4.9 0     27.7         19.5 
45 3.72 3.22     71.2 3.52 0 2.33 11.07 133.4 
46 0 0     2.8 0.00 0 2.79 13.69 48.2 
47 6.73 0 0 5.48 13.9 0 0 0 14.02 25.5 
48 2.81 0 0 6.47 31.6 0 0 4.17 11.04 124.5 
49 5.04 0 0 0 2.4 2.59 2.32     28.7 
50 0 0     1.8 2.96 1.55 2.75 10.77 15.7 
51 NA NA  NA  NA  0.9 7.22 0     68.8 
 
Table S6: Pyrosequencing analysis to examine methylation level of BCRP promoter 
region in the NAET cohort. The table shows degree of methylation for each of the 4 
CpG sites pre- and post-NAET. The matching protein expression is also shown in the 
form of histoscores from immunohistochemistry. The blank columns are where the 
pyrosequencing assay was unsuccessful despite repeated assays. The 5 NA columns 
for the pre-NAET methylation analysis are where there were insufficient remaining 
FFPE tissue to perform macrodissection and subsequent DNA extraction. 
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9.3 Supplementary figures 
 
 
Figure S1: Step-sectioning of pCR blocks resulted in detection of residual tumour cells 
(anti-cytokeratin AE1/3 antibody; Dako)  
 
 
Figure S2a: Optimised TMA staining for Pgp (UIC2), x20 magnification  
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Figure S2b: Optimised TMA staining for MRP1 (QCRL1), x20 magnification 
 
 
Figure S2c: Optimised TMA staining for BCRP (BXP21), x20 magnification 
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Figure S2d: Optimised TMA staining for Notch1 (anti-activated Notch1), x20 
magnification 
 
 
 
Figure S2e: Pgp expression in axillary lymph nodes 
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Figure S2f: MRP1 expression in axillary lymph nodes 
 
 
 
Figure S2g: BCRP expression in axillary lymph nodes 
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Figure S3: 3 and 5 day MCF7 cell titration curve showing the optical density reading 
on the y-axis and the initial cell number plated per well on the x-axis. Each point on the 
graph shows triplicate results. 10,000 cells (3 days) and 7500 cells (5 days) were 
chosen for the combination assay to allow for log phase growth.   
          
c e ll n u m b e r
0 2 0 0 0 0 4 0 0 0 0 6 0 0 0 0 8 0 0 0 0 1 0 0 0 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
3  d a y s
5  d a y s
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Figure S4: 5 day T47D cell titration curve showing the optical density reading on the y-
axis and the initial cell number plated per well on the x-axis. Each point on the graph 
shows triplicate results. 10,000 cells were chosen for the combination assay to allow 
for log phase growth.   
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Figure S5: Gradient PCR for bisulphite-modified DNA extracted from H929 cell lines 
using Turner et al primers. This showed an appropriately sized PCR product of around 
500 base pairs. The optimal annealing temperature was determined at 56oC.  
 
 
 
 
Figure S6: Gradient PCR for bisulphite-modified DNA extracted from H929 cell lines 
using Chen et al primers. This showed an appropriately sized PCR product of around 
250 base pairs. The optimal annealing temperature was determined at 55oC.  
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Figure S7: PCR of bisulphite-converted DNA from cell lines using Turner et al and 
Chen et al primers. For all cell lines, using Turner et al primers resulted in a PCR 
product of around 500 base pairs, and Chen et al primers a product of around 250 
base pairs. Negative controls included a lane with nuclease free water instead of 
bisulphite-converted DNA and DNA from HL60 cell line that was not bisulphite-
converted. For MCF7 cell line, an independent bisulphite-converted DNA sample from 
Dr James Thorne was used.  
 
 
 
 
Figure S8: Gel electrophoresis using products from colony PCR of cloned HB2 Chen 
et al amplicon. 23 colonies were randomly selected, and 9 successfully cloned plasmid 
DNA mini-preps were available for sequencing. 
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Figure S9: Gel electrophoresis using products from colony PCR of cloned H929 Chen 
et al amplicon. 23 colonies were randomly selected, and 9 successfully cloned plasmid 
DNA mini-preps were available for sequencing. 
 
 
 
 
 
Figure S10: Gel electrophoresis using products from colony PCR of cloned HL60 Chen 
et al amplicon. 23 colonies were randomly selected, and 12 successfully cloned 
plasmid DNA mini-preps were available for sequencing. 
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Figure S11: Gel electrophoresis using products from colony PCR of cloned MCF7 
Chen et al amplicon. 23 colonies were randomly selected, and 12 successfully cloned 
plasmid DNA mini-preps were available for sequencing. 
 
 
 
 
 
Figure S12: Gel electrophoresis using PCR products of the pyromark assay examining 
5 CpG sites. The bands are seen just below the 300 base pair ladder, but were only 
present for the cell line samples but not for the FFPE samples.   
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Figure S13: Pyrosequencing analysis for the 4 cell lines examining the 5 CpG sites 
assigned by the pyromark assay. The 5 CpG sites in H929, MCF7, and HB2 cell lines 
are unmethylated. However, the equivalent CpG sites in HL60 cell line shows high 
degree of methylation.  
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Figure S14: Dose-response curve for doxorubicin (MCF7 and T47D cell lines) showing 
optical density reading on the y-axis (normalised to untreated) and log 10 of 
doxorubicin concentration added to the wells at 24 hours on the x-axis (0 to 1μM). This 
allowed determination of approximate range of IC values after 2 and 4 days of 
treatment with doxorubicin for MCF7 cells, and after 4 days of treatment for T47D cells. 
Each co-ordinates represent triplicate values and optical density readings from wells 
containing medium only was subtracted. 
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Figure S15: DAPT 2 and 4 days titration curve (MCF7 cell line) showing optical density 
reading on the y-axis (normalised to untreated) and Log 10 of DAPT concentration 
added to the wells at 24 hours on the x-axis (0 to 10μM). Increasing concentration of 
DAPT on its own did not have any effect on cell growth/survival. Each co-ordinates 
represent triplicate values and optical density readings from wells containing medium 
only was subtracted.  
 
 
 
213 
 
 
 
Figure S16a: 2 and 4 day combination assay in MCF7 cell lines for the lower DAPT 
concentrations (1nM to 1uM). Y-axis shows optical density reading.  The first black bar 
denotes the controls (-), with increasing DAPT. The first red bar denotes the IC10 
values without DAPT (-), with the remainder showing IC10 doxorubicin with increasing 
DAPT. The first blue bar denotes the IC50 values without DAPT (-), with the remainder 
showing IC50 doxorubicin with increasing DAPT.  
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Figure S16b: 2 and 4 day combination assay for the MCF7 cell lines for the higher 
DAPT concentrations (1uM to 100μM). Y-axis shows optical density reading. The first 
black bar denotes the controls (-), with increasing DAPT. The first red bar denotes the 
IC10 values without DAPT (-), with the remainder showing IC10 doxorubicin with 
increasing DAPT. The first blue bar denotes the IC50 values without DAPT (-), with the 
remainder showing IC50 doxorubicin with increasing DAPT.  
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Figure S17: 4 day combination assay using T47D cell lines (DAPT concentrations of 
1nM to 100uM). Y-axis shows optical density reading. The first black bar denotes the 
controls (-), with increasing DAPT. The first red bar denotes the IC10 values without 
DAPT (-), with the remainder showing IC10 doxorubicin with increasing DAPT. The first 
blue bar denotes the IC50 values without DAPT (-), with the remainder showing IC50 
doxorubicin with increasing DAPT.  
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Figure S18: Western blot to examine MRP1 expression using MCF7 another 
independent cell lysates treated with doxorubicin +/- DAPT. Increasing doses of 
doxorubicin treatment led to a dose-dependent up-regulation of MRP1 expression. 
DAPT treatment did not result in down-regulation of MRP1 expression however. 
Combination therapy of doxorubicin and DAPT did not cause significant down-
regulation of MRP1 expression in general.  
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Figure S19: Western blot to examine Notch1 NICD expression using an independent 
MCF7 cell lysates treated with doxorubicin +/- DAPT. Increasing doses of doxorubicin 
resulted in the down-regulation of Notch1 NICD expression. Treating the cells with 
DAPT did not result in down-regulation of Notch1 NICD expression. However, the 
combination of doxorubicin and DAPT led to down-regulation of Notch1 NICD 
expression. 
 
218 
 
 
Figure S20: Western blot to examine Notch1 NICD expression using another 
independent MCF7 cell lysates treated with doxorubicin +/- DAPT. Increasing doses of 
doxorubicin resulted again resulted in the down-regulation of Notch1 NICD expression. 
DAPT treatment did not result in down-regulation of Notch1 NICD expression. 
However, the combination of doxorubicin and DAPT led to down-regulation of Notch1 
NICD expression.   
 
 
 
 
 
 
